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X I 
INTRODUCTION 
The kidney is concerned with many homeostatic mechanisms. It maintains the 
overall chemical composition of the intracellular environment by regulating the quantity 
of water, sodium chloride, potassium, phosphate (Pi) and numerous other substances in 
the body. Due to its absorptive property the kidney maintains a positive balance of 
required elements especially that of Pi; this plays an important role in health, disease 
and in development and growth. Animals have two kidneys and each kidney is made up 
of millions of functional units known as "nephron". The structure of mammalian kidney 
apparently looks very homogenous, however, it can be viewed as a composite of several 
organs/segments geometrically, functionally and metabolically (Schmidt and Guder, 
1976). 
The kidneys are reddish brown, paired structures that lie on either side of the 
vertebral column in the lumbar region of the body. Each kidney is 10-13 cm long and 
2.5- 4 cm wide. The outer surface is convex and inner surface is concave. The inner 
surface has a deep notch called hilus. The, renal artery, renal veins and nerves enter the 
kidney through the hilus. In a section of kidney, the peripheral dark reddish brown 
portion is called the cortex and the central light red portion is the medulla. Each human 
kidney contains millions of nephrons which form the conical region and fiUer the blood 
to form urine. One end of the nephron i.e. the proximal end towards the outer surface of 
kidney (the cortex) is formed of the malphigian capsule composed of double walled 
Bowman's capsule, enclosing a network of capillaries called the glomerulus. The 
glomerulus receives blood through a small arteriole called afferent arteriole. After 
supplying blood to glomerulus, the blood leaves through a vessel called efferent 
arteriole. It divides immediately into a second capillary network that surrounds the 
remaining tubular portion of the nephron. The capsular space of Bowman's capsule is 
continuous with the lumen of the tubule. The proximal convoluted tubule that arises 
from the capsule is coiled and leads to a "U" shaped part, the loop of Henle. The 
Henle's loop has a descending limb, a thin middle limb and an ascending limb (Fig 1). 
The ascending limb leads to another coiled part, the distal convoluted tubule which 
opens into common tubule called the collecting duct (Schmidt and Guder, 1976). 
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Fig 1: Structure of kidney 
(a) Structure of Kidney showing cortical and medullary regions 
(b) Schematic drawing of a nephron 
(c) Anatomical parts of the Kidney- A longitudinal view 
The luminal membrane of the proximal tubule is characterized by numerous 
extensions called microvilli. The major function of the microvilli is to increase the total 
surface available for contact with tubular fluid from which many components are 
absorbed at high rates; it also serves as an actively moving organelle. The motility of 
brush border may be important in transcellular transport of renal proximal tubule. Each 
concentric tissue plane from cortex to inner medulla also possesses individual 
characteristics with respect to their ionic content and characteristics of metabolism 
(metabolic rates) among the above tissue zone (Schmidt and Guder, 1976). 
Nephrons, which consist of various subsegments, show distinct structural and 
functional differences. Thus, nephron heterogeneity also adds to the variation in the 
function of the kidney as a whole. Both inter- and intra-nephronal heterogeneity exists 
in the mammalian kidney that depends on the origin and location of the nephrons in 
cortical region of the kidney (Morel and Chabardes, 1985; Bankir et a/., 1987). The 
nephrons which originate from the glomeruli located in the superficial cortex are known 
as "superficial nephrons" while the nephrons originating from the deep cortical region 
are known as "deep" or "juxtamedullary nephrons". These populations of nephrons 
have been found to be structurally and functionally distinct (Bankir ei a/., 1987). 
Structural and functional differences between proximal convoluted tubules 
(PCT) of superficial cortex and juxtamedullary cortex represent inter-nephron 
heterogeneity whereas differences between early segment and late segment of proximal 
tubule of a single nephron represent intra-nephron or axial heterogeneity. Nephrons 
have been classified into three groups: superficial cortical nephrons have glomeruli 
located approximately 0.5-1 mm below the capsular surface, mid cortical nephrons have 
glomeruli situated in the mid cortex deep to the superficial nephron but above the 
juxtamedullary nephrons and juxtamedullary nephrons have glomeruli located 
immediately above the corticomedullary junction (Figl) (Jacobson and Berry, 1982; 
JacobsOn and Kokko, 1985). Generally, the most superficial nephrons have short loops 
(or even cortical loops) and deep nephrons have long loops. Besides this the differences 
in glomerular diameters, proximal tubular length, filtration rate, epithelial permeability 
and transport characteristics, transepithelial vohage differences and distribution of 
various enzyme activities are other factors that contribute to distinguish different 
nephron populations (Jacobson and Berry, 1982; Jacobson and Kokko, 1985). 
In intra-nephron or axial heterogeneity, the proximal tubules have been divided 
into three distinct morphological subsegments namely, SI, S2 and S3. The early PCT 
both in superficial and juxtamedullary nephrons is defined as S1 subsegment and can be 
identified by it's attachment with glomeruli on one side (Woodhall et al., 1978; 
Kaissling and Kriz, 1979). S2 is defined as the late superficial proximal convoluted 
tubule and includes the rest of convolutions and entire pars recta (straight portion) in 
cortical portion of the kidney (Woodhall et cr/.,1978; Kaissling and Kriz., 1979). S3 is 
located principally in the outer stripe of outer medulla and terminal superficial proximal 
straight tubule. S3 is identified by its medullary location and by its connection with thin 
limbs on distal part. Superficial pars recta is long and contains S2 and S3 cell types 
where as juxtamedullary pars recta is short and made predominantly of S3 subsegment 
(Woodhall et a/. 1978). All S2 subsegments (pars recta), as they descend from cortex 
into the outer stripe of outer medulla, change from the S2 to S3 cell type. 
There is also a functional difference, beside the morphological difference, in the 
inter- and intra-nephron of proximal tubule. The proximal tubule (mainly in the cortex) 
is the major site for the reabsorpfion of solutes including amino acids, sugars, several 
other nutrients, inorganic phosphate (Pi) and certain ions such as sodium (Na"^ ). This 
absoption occurs at the luminal or brush border membrane (BBM) site of proximal 
tubules (Blond and Whittam, 1964). In the SI subsegment of early PCT Na*-K^ ATPase 
activity, oxidative metabolism and active transport is relatively high, resulting in very 
efficient Na^-coupled net reabsorption of glucose, amino acids, phosphate and net 
secretion of hydrogen ions (Morel and Chabardes, 1985). It is well established that the 
majority of fihered solutes in the adult kidney are mainly reabsorbed in early proximal 
segment with only a small fraction being reabsorbed in more distal segments. Transport 
capacities of glucose. Pi and H^ by S2 segment decrease progressively along the 
proximal convolutions (Morel and Chabardes, 1985). Finally, in S3 segment transport 
of organic acids and bases mainly takes place; however, Na^-K^ ATPase activity and 
Na* transport are found to be relatively low. The retention of Na^ ions and Pi in body by 
the kidney is required for proper growth and development. 
In the proximal tubule, the apical cell border is well developed and closely 
packed microvilli form the brush border. The luminal membrane contains a number of 
specific carrier systems for the reabsorption or transport of ions and solutes (Kinne and 
Schwartz, 1978). It is well known that in the proximal tubule, brush border membrane 
(BBM) is the major site at which most of the fluid (upto 65%), Na^ ions (65%) and 
most of the solutes are reabsorbed (Dousa and Kempson, 1982; Murer and Burckhardt, 
1983; Kempson and Dousa, 1986; Gmaj and Murer, 1986). It is also the site for the 
regulation of the reabsorptive properties by the adaptive changes and by various stimuli 
(Kempson and Dousa, 1986). 
The transport of Na* appears to be a major function in the mammalian kidney 
since it is coupled with the transport of various other substances. Thus, in the absence of 
Na"^  transport the transport of other solutes such as hexoses, amino acids and Pi 
approaches zero (Ullrich et al., 1974). It has been reported that one third of the net 
trans-epithelial sodium flux is transported actively (Fromter et al., 1973). At least 80% 
of the active transport in the kidney depends on the availability of adenosine 5'-
triphosphate (ATP) (Gyory and Kinne, 1971), indicating a linkage between transport 
process and energy producing metabolic reactions (Cohen and Barae-Nieto 1973; 
Cohen and Kamm 1981; Stoff et al., 1976; Kinne, 1979). The active transport 
performed by the kidney has also been shown to be associated with the consumption of 
oxygen and the rate of oxygen consumption in turn has been related to the production of 
cellular ATP. Earlier studies have shown a linear relationship between sodium transport 
and oxygen consumption (Thurau, 1961; Torelli et al., 1966) though a direct 
relationship with energy production or utilization could not be confirmed. Fatty acids, 
glucose and their metabolites are known to contribute to the energy supply of the kidney 
in various mammals including man (Lee et al., 1962). The rate of metabolism of the 
above substrates by one or the other pathways (e.g. TCA cycle, glycolysis, HMP shunt 
pathway) seems to be dependent on the availability of oxygen in any particular zone of 
the kidney (Kean et al, 1961; Lee et al, 1962; Weidermann and Kerbs, 1969; Cohen 
and Barae-Nieto, 1973; Cohen and Kamm, 1976). Moreover, the energy generated by 
the metabolism of the above substrates was found to support the transport work of the 
kidney (Aperia and Liebow, 1964). The transport of Na^ and the oxygen tension have 
been found to be different in the cortex and the outer and inner medulla (Akuland and 
Krog, 1960, 1961; Akuland, 1962). Similarly, the metabolic activity of the cell in these 
three kidney zones was also found to be different and was related very well with the 
oxygen tension of that cell/tissue (Kean e/ a/., 1961; Lee et ai, 1962; Weidermann and 
Kerbs, 1969; Cohen and Kamm, 1976; Schmidt and Guder 1976). Thus, the transport 
properties appear to be directly or indirectly dependent on the energy producing 
metabolic activity of the cells. 
ACUTE RENAL FAILURE (ARF) 
Regulation of normal volume and composition of body fluids by the kidney and 
the process of urine formation begins with the uhrafiltration of the blood delivered to 
the kidney, proceeds through intra renal processing of the ultrafihrate by tubular 
reabsorption and secretion and ends by elimination of urine thus formed. ARF is 
defined as an abrupt decrease in renal function sufficient to result in retention of 
nitrogenous waste, i.e. blood urea nitrogen (BUN) and creatinine, in the body (Bidani 
and Churchill, 1989; Shibouta et ai, 1990). It is a process rather than a state. ARF 
caused due to toxic insult or ischemia results in depressed metabolic activity because of 
limited O2 supply through the blood, curtailing energy production and leading to the 
loss of active reabsorption and secretion processes in the kidney (Vogt and Fraber, 
1968; Molitoris and Kinne, 1987; Molitoris et a/., 1989) 
In ARF both the kidneys stop their function in a very short period of time. ARF 
is often due to acute tubular necrosis caused either by ischemia or toxic insult to the 
kidney (Venkatachalam et al, 1978; Porter and Bennett, 1981; Paddock et al., 1981, 
1985; Molitoris and Kinne 1987; Molitoris et al, 1989; Humes and Liu, 1994). ARF 
begins with cellular damage initiated by primary toxic insult or ischemia and continues 
until renal function and structure have essentially recovered due to reperfusion of blood 
or by administrafion of various drugs, hormones or anti-oxidants (Seigel et al, 1980, 
1984; Schaudies and Johnson, 1993, Friedlaender et al., 1995; Girardi and Elias, 1995, 
Price et al, 1995; Appenroth et al, 1997). Although the time course of injury and 
recovery overlap are variable depending upon the degree of damage, nevertheless, ARF 
can be grossly divided into three phases, pathogenic phase, manifestation phase and 
recovery phase. In the first phase, a progressive disintegration and necrosis, especially 
of tubular epithelial cells, has been observed leading to the functional loss of the kidney 
which is manifestated by the reduction in inulin clearance (Olbricht et al, 1977) In the 
second phase, long lasting effects are observed that severely effect the clearance of both 
creatinine and inulin and which can continue for several days after recovery begins, 
depending on the degree of renal damage. Other additional adverse effects are not 
observed and the recovery processes are not initiated in this phase In the recovery 
phase, there is an increase in the concentrating ability of the kidney with eventual 
normalization of kidney function 
A variety of experimental models have been used to study ARF In experimental 
animals, toxic ARF can be induced by various agents such as heavy metals (Wedeen 
and Qian, 1991; Natochin et al, 1994), chemicals (Yagil, 1990, Koechel et al, 1991, 
Shah and Walker, 1992) and drugs (Porter and Bennett, 1981, Rosen et al, 1994) Most 
common cause of ARF in cancer patients at present is the nephrotoxic effect of 
antineoplastic agents (Choie et al, 1981, Schrier, 2002) 
Pathophysiology of Acute Renal Failure 
Various chemicals and antineoplastic agents cause acute and chronic renal 
failure leading to the partial or total loss of normal excretory function of the kidney 
(Safirstein et al, 1986; Yagil, 1990, Shah and Walker, 1992) This is reflected by 
oligouria and a steady rise in the concentrations of urea and creatinine in plasma 
(Shibouta etal, 1990). ARF induced by administration of toxic agents is characterized 
by a progression of well-defined events. Initially, the epithelial cells lining the proximal 
tubule (the principal site of damage along the nephron) exhibit varying degrees of 
sublethal cell injury that can uhimately culminate in cellular necrosis which finally 
leads to ARF 
Physiologic and morphologic studies suggest that there are four major possible 
pathogenic mechanisms of ARF, which includes renal vasoconstriction, glomerular 
permeability, tubular obstruction and tubular leakage (Nissenson, 1998). Classical 
concept regarding the cause of the loss of renal flinctions in ARF include tubular 
leakage across the damaged epithelium, tubular obstruction by cast formation or 
interestitial compression, a decrease in renal blood flow and glomerular membrane 
permeability (Vanholder et ai, 1987). However, due to lack of support for a satisfactory 
explanation for the loss of renal function following toxic insult some of the other factors 
were considered as not the only basis for initiating the damage caused by toxic insult or 
ischemia. A reduction in glomerular permeability was able to explain only depressions 
in filtration rate but not the decrease in tubular function (Savin et ai, 1983). Thus the 
extensive research of the past 40 years using morphology, clearance and micropuncture 
techniques were unable to provide a universal view regarding the mechanism for the 
pathogenesis of ARF. The other reason for not reaching a consensus could be due to the 
fact that most of the evidences are based on structural alterations rather than on 
functional ones. 
CISPLATIN INDUCED NEPHROTOXICITY 
Cisplatin is a heavy metal platinum co-ordination complex containing a centra! 
atom of platinum surrounded by two chloride ions and two ammonia molecules in cis 
geometry. Chemically it is a cis isomer of diamminedichloroplatinum (II) (CDDP). The 
empirical formula of the active compound is PtCl2H6N2. CDDP, a lower molecular 
weight compound, distributes readily into almost all tissues and intracellular organelles 
when administered intraperitonially. Administration of CDDP results in the highest 
initial and persistent drug level in the kidney (Stewart et al., 1982). 
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Fig.2: Structure of cisplatin 
Cisplatin (CDDP) is widely used as an antineoplastic agent for the treatment of 
various malignancies. It is used alone or in combination with other approved 
chemotherapeutic agents for the treatment of metastatic testicular cancer (de Graaf et 
al., 1997), advanced ovarian carcinoma (Lorusso ei al., 1998), advanced bladder 
carcinoma and squamous cell carcinoma of head and neck (Nakashima et al., 1990). 
CDDP exhibits side effects including pronounced nausea and vomiting, hearing loss 
(Dehne ei al., 2001) and bone marrow depression (Rocco et al., 1990). The chief limit 
to its greater efficacy, however, is its dose dependent nephrotoxicity that leads to acute 
renal failure. The alterations induced by CDDP in the kidney functions are 
characterized by change in urine volume, increase in BUN and serum creatinine levels 
(Babu et al., 1999). Some biolochemical changes due to CDDP treatment include 
generation of free radicals, lipid peroxidation (Matsushima et al., 1998), loss of renal 
sulfhydryl groups, damage to mitochondria (Zhang and Lindup, 1994) and inhibition of 
DNA synthesis (Gomeva, 1993). However despite these observations the exact 
molecular mechanism by which CDDP causes nephrotoxicity remains unclear at 
present. 
Renal uptake, excretion, and metabolism of cisplatin 
In rats, 50% of injected CDDP is excreted in the urine 24 hr after it's administration 
(Litterst et al., 1979) with most of the excreted platinum appearing in the urine within 
the first hour (Safirstein et al., 1981). Platinum is extensively bound to plasma proteins. 
Free CDDP in the plasma, by virtue of its low molecular weight and uncharged 
character, is freely filtered at the glomerulus (Safirstein et al., 1984). The concentration 
of platinum in the kidney is several fold above plasma levels and higher than in other 
organs (Litterst et al., 1979). The harmful effect of CDDP is thought to be mediated by 
transport of its metabolites from the tubular lumen into the tubular cells. Platinum levels 
in the kidney cortex and medulla and the cytosol reach maximal levels within 1 hr of 
CDDP administration (Mistry et al., 1989). The process by which the kidney 
accumulates CDDP is dependent upon normal oxygen utilization and is inhibited by 
drugs that compete for the transport of organic bases in a dose dependent manner 
(Safirstein et al., 1987). Studies on renal conical slices and membrane vesicles showed 
that the uptake of CDDP by kidney is associated with active renal secretion, particularly 
the organic cation transport systems (Williams and Hottendorf, 1985, Miura et al., 
1987). A recent study reported that the organic cation drugs, diisopyramide and 
verapamil, inhibited the renal accumulation of CDDP and this inhibition resulted in the 
amelioration of nephrotoxicity whereas plasma pharmacokinetics of CDDP were only 
slightly effected (Handa et al., 1999). All this suggests that the renal uptake of CDDP 
involves some specific interaction of the drug with the kidney, perhaps involving 
transport or binding to components of the base transport system. 
CDDP is excreted largely unchanged in the urine. However, CDDP that enters 
the cell undergoes biotransformation. Earlier studies suggested that cell platinum binds 
to macromolecules but a large portion (30-50%) of total cell platinum is in a form 
whose molecular weight is below 500 Daltons and whose chromatographic behaviour is 
different from CDDP (Safirtein et al, 1987). Platinum metabolites formed are not 
biologically active as mutagens whereas excreted platinum is mutagenic (Lecointe el 
al., 1979). CDDP undergoes ligand binding reactions which are virtually irreversible 
(Daley-Yates and McBrien, 1984; Nagai et al., 1996). In biological fluids CDDP is 
transformed immediately to aquated CDDP as a resuU of the release of chloride ions 
and their replacement by H2O and OH" and equilibrium between CDDP and its aquated 
form is maintained. Both aquated and unchanged CDDP react readily with nucleophiles 
(Farris et al, 1985; Dedon and Borch, 1987). CDDP is biotransformed through binding 
to lower molecular mass substances such as glutathione, methionine, cysteine and to 
high molecular mass substances such as albumin and nucleic acids and the resulting 
metabolites are known as mobile and fixed metabolites respectively (Farris et al., 1985, 
1988). Earlier, it was determined by the fractional clearances of several platinum 
species bound to lower molecular mass substances that these platinum species undergo 
renal secretion or reabsorption (or both). 
CDDP distributes rapidly into both kidney and liver with peak tissue levels 
being reached within 1-3 min of intravenous administration. It is eliminated from these 
tissues in parallel to plasma elimination indicating that CDDP equilibrium between 
plasma and both tissues was attained instantly. Both CDDP and mobile metabolites 
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were distributed extensively in the kidney and some specific mechanisms may exist to 
maintain the difference between the plasma and renal concentrations (Handa et al., 
2000). 
CDDP in the kidney, as well as in plasma, was transformed to both metabolites. 
Mobile metabolites were partially transformed to fixed metabolites after CDDP and 
mobile metabolites in plasma were taken up by the kidney (Handa et a!., 2000). Mobile 
metabolites in plasma were found to be less toxic than CDDP when they were 
administered to rats. This suggests that intact CDDP in plasma was the major species 
responsible for nephrotoxicity after CDDP administration. Only CDDP and mobile 
metabolites could be taken up into the kidney and these platinum species were 
transformed into further metabolites. The pharmacokinetics of CDDP and mobile 
metabolites was dose dependent. 
Morphological pattern of cisplatin nephrotoxocity 
The administration of CDDP resulted in morphological alterations in the S3 
segment (pars recta) of the proximal tubule situated in the outer stripe of the medulla 
(Dobyan et al, 1980; Kuhlmann et al., 1997). The outer stripe is defined as the region 
of the kidney which extends from corticomedullary junction to the region where the 
pars recta of the proximal tubule changes to the thin descending limb of Henle. 
Pathological changes were rarely observed in the S1 and S2 segments of pars convoluta 
of the proximal tubule. 
Very few changes were noted 1 to 2 days after the injection of drug, although a 
focal loss in brush border, increased cytoplasmic vesicles and a necrotic cell were seen 
occasionally in the proximal tubules in the outer stripe region. More severe lesions 
became evident after 3 days; the S3 segment of the proximal tubule in the outer stripe of 
the medulla showed a spectrum of morphologic alterations. A focal loss or thinning of 
microvillus brush border was evident at all levels of microscopy. In some cells, the 
brush border was almost completely obliterated with only a few microvilli remaining. 
The cytoplasm of many cells appeared condensed. Clumping of nuclear chromatin and 
increased number of cytoplasmic vesicles could be seen in many of the injured cells 
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Other cells appeared to round up and lose their normal orientation and often protruded 
into the tubular lumen. Completely necrotic cells were evident and could be seen 
sloughing into tubular lumen. In some areas only a bare basal lamina remained, the cells 
adjacent to these areas appeared to flatten out and send long, thin cytoplasmic processes 
out to reline the bare basal lamina (Dobyan et al., 1980; Jones et al., 1985). After 5 
days, the predominant pattern of injury was a widespread tubular necrosis of the S3 
segment of the proximal tubule in the outer stripe region. Desquamation of necrotic 
epithelial cells resulted in patches of denuded basement membrane. Necrotic cells were 
characterized by having swollen mitochondria with flocculent densities and cell 
membrane rupture with subsequent vesicle formation. Necrotic debris could be seen 
filling in the tubular lumen. However, the epithelial cells lining the S3 segment of 
proximal tubule appeared to be undergoing extensive regeneration 7 days after CDDP 
administration. Most tubules lying in the region of the outer stripe were widely dilated 
and were lined by low-lying epithelial cells of varying height. The microvillus brush 
border lining the luminal surface of these regenerating cells exhibited quite different 
patterns. Some epithelial cells were completely devoid of microvilli whereas others 
possessed some microvilli of variable heights. The cytoplasm of these cells contained 
abundant ribosomes and long cistemae of rough surfaced endoplasmic reticulum. The 
nuclei showed prominent nucleoli and the nuclear chromatin was well dispersed. Some 
tubules showed complete regeneration. Despite this massive regeneration necrotic cells 
were still present and could be seen in many tubular lumens suggesting that the 
regeneration was not complete. (Dobyan et al., 1980; Offermann et al., 1984) 
Like other heavy metals CDDP also reduces renal blood flow (Offermann et al., 
1984) and this resuhs in an early fall in glomerular fihration rate. The outer stripe of the 
outer medulla might be expected to be more sensitive to these changes because of its 
relatively poor vascularization. 
Cellular mechanism of cisplatin nephrotoxicity-
CDDP is a neutral square-planar coordination complex with two labile chloride 
groups and two relatively inert ammine ligands in the cis confirmation. The chloride 
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ions can be lost and replaced by H2O. An additional driving force for substitution of 
chloride by water is loss of proton from aqua-species to form various hydroxyl species. 
Hydroxy-bridged dimer, trimer and higher oligomers are formed in dilute solutions 
(Faggiani et al., 1977). 
PtCI,(NH3), <^Pt(NH3)3CI(H,0)^ <^Pt(NH3),(0H,) /^ 
+cr *cr 
Pt(NH3)2Cl(OH) Pt(NH3)2(OH2)(OH)" 
Hydrolysis reactions of CDDP. 
The concentration of chloride ions in plasma (103 mM) is sufficiently high to 
maintain CDDP in the neutral, dichloride form. After passive diffusion across the lipid 
membrane the chloride ion concentration decreases sharply (to 4 mM), promoting the 
release of labile chloride ligands in the cis position and their replacement by water 
molecules. From thermodynamic data on [(en)PtCl2], it has been estimated that the 
relative concentration of the various aquated species in the plasma is 2% of the total 
platinum and that this value increases to 42% once the drug enters the cytoplasm (Lim 
and Martin, 1976). These aquated forms are highly reactive with nucleophiles and can 
lose hydrogen ions to from cytotoxic hydroxyl radicals. At equilibrium, the proportion 
between these diversely cytotoxic complexes depends on chloride concentration and, to 
a lesser extent, on pH and total platinum concentration (Earhart et al., 1983). The 
aquated species subsequently react with various intracellular components including 
DNA. There is convincing evidence that the primary biochemical lesion induced by 
CDDP in cancer cells is inhibition of DNA synthesis (Howel and Gale 1970, Gomeva et 
al, 1993). The inhibition of DNA synthesis is persistent and occurs at much lower 
doses than necessary to inhibit RNA and protein synthesis (Harder and Rosenberg 
1970). The cytotoxicity of CDDP is believed to be due to the formation of DNA adducts 
which includes DNA-protein cross-links, DNA monoadducts and interstand and 
intrastand cross-links (Ingber, 1993). Such bidentate binding is responsible for 
inhibition of DNA template replication in mammalian cells (De Martinis and Bianchi, 
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2001). Several studies suggest that CDDP exerts its activity in a manner similar to 
alkylating agents by drug interaction with the nucleophilic sites of pyrimidines in DNA 
(Zwelling and Kohn, 1979). These intrastand DNA cross links occur after physiological 
activation of drug when CDDP passes from a chloride-rich plasma milieu (103 mM) to 
low-chloride intra cytoplasmic milieu (4 mM). 
Toxic effect of CDDP may also be related to damage caused by reactive oxygen 
species such as superoxide anion and hydroxyl radicals and inhibition of the activity of 
anti-oxidant enzymes in renal tissues. Abnormal levels of reactive oxygen species react 
with polyunsaturated fatty acids and causes an increase in lipid peroxidation. An 
increase in peroxidation of polyunsaturated fatty acids in plasma membrane and 
subcellular membrane can cause cellular disturbances such as changes of membrane 
lipids and protein and transport activity and this may cause cell damage or death. 
Several studies have shown that administration of anti-oxidants modifies the parameters 
that change during CDDP induced nephrotoxicity such as serum creatinine, BUN, lipid 
peroxidation etc. CDDP is found to elevate urinary activities of enzymes, N-acetyl-(3-
glucoseaminidase (Hayashi et al., 1997) which is rich in lysosomes and alanine 
aminopeptidase (Verplanke ei al., 1994), y-glutamyl transferase (Gordon et al., 1986) 
located in brush border membranes of renal cells. The possibility that membrane lipid 
peroxidation has a role as primary event in the toxicity of chemicals has been suggested 
in recent years. The peroxidation of membrane lipids in lysosomes and brush borders 
probably results in enzyme leakage in tubules. 
CDDP exert its effect mainly on S3 segment of the proximal tubule (Racusen 
and Solez, 1986). This region has large number of mitochondria as compared to other 
parts of the kidney (Tisher, 1982). Biochemical, morphological and flmctional 
alterations induced by CDDP in renal mitochondria support the idea that mitochondria 
could be the primary target for toxicity. Subcellular accumulation of CDDP in 
mitochondria supports this hypothesis (Sharma and Edwards, 1983). CDDP 
significantly decreases concentration of mitochondrial protein sulfhydryl groups, 
inhibits Ca"^ ^ uptake by mitochondria and collapses the mitochondrial potential (Zhang 
and Lindup, 1994). As renal function declined and reached its peak, mitochondrial 
14 
respiration was impaired and calcium accumulation developed. The presence of 
necrosis characterized by swelling of mitochondria and other cellular organelles has 
been clearly demonstrated in tissue sections of kidneys from patients with CDDP 
nephrotoxicity. This hypothesis is further supported by experiments in isolated renal 
tubules that have shown significant inhibition of Na*-K^ ATPase and Ca^-Mg^ ATPase 
activities thus effecting the mitochondrial synthesis of ATP and the Na^-K^ and Ca^ ^ 
pumps (Dobyan et al, 1980). As mentioned before, there is considerable evidence that 
DNA is the principal intracellular target of CDDP. There are two distinct genomes in 
the cell, mitochondrial and nuclear and Singh et al. (1989) have postulated that 
mitochondrial DNA damage induced by CDDP causes nephrotoxicity. The reasons for 
postulating that mitochondrial DNA could be the major target for CDDP are: i) 
mitochondrial DNA is less closely associated with proteins than nuclear DNA (Salazar 
et al., 1982) and theoretically would be more accessible to attack by aquated species of 
CDDP ii) DNA repair mechanisms are abundant in the nucleus but sparse in 
mitochondria (Clayton, 1982) and iii) CDDP accumulates in higher concentration in 
mitochondria compared to nucleus (Sharma and Edwards, 1983). If mitochondrial DNA 
is damaged then de novo synthesis of mitochondrial proteins would not occur and thus 
degeneration of organelles would result. However, further investigations are necessary 
to demonstrate whether mitochondrial DNA is indeed the ultimate target for CDDP 
leading to nephrotoxicity. 
One of the most important intracellular anti-oxidant systems is the glutathione 
redox cycle. Glutathione is one of the essential compounds responsible for maintaining 
cell integrity because of its reducing properties and participation in cell metabolism 
(Theresa etal., 1996). The depletion of renal glutathione level has been observed in rats 
in response to oxidative stress caused by CDDP (Nakano and Gemba, 1989; Sadzuka et 
al., 1992) The exact mechanism of CDDP induced changes in renal glutathione 
concentration has not been completely elucidated. The interaction of CDDP with 
enzymes which contain sulfhydryl group(s) is fairly well known. In terms of 
biotransformation, platinum complexes have been shown to react with with plasma 
protein sulfhydryl groups (Gonias and Pizzo, 1983). Perturbation of intracellular thiols 
is also involved in Ca^ homeostasis (Moore et al., 1988, Nicotera et al., 1992). The 
15 
homeostasis of Ca^ in the mitochondria is believed to be closely linked either directly or 
through the pyrimidine nucleotides and so an imbalance in one could affect the status of 
the other and diminish the cell viability (Reed, 1990). 
A recent study suggests that apoptosis may also play an important role in 
development of CDDP induced acute renal failure (Lee at al, 2001). Apoptosis is a 
form of cell death with morphological features quite distinct from necrosis 
(Schwatzman and Cidlowski, 1993, Majno and Joris, 1995). In contrast to necrosis, 
apoptosis is characterized by both cytosolic and nuclear shrinkage. The nuclear 
chromatin in the apoptotic cell undergoes condensation whereas the plasma membrane 
and mitochondria remain morphologically intact. Recently apoptosis was recognized as 
an important mechanism of cell death mediating the antitumour effect of CDDP as well 
as other chemotherapeutic agents (Dive and Hickmann, 1991). CDDP has been reported 
to induce apoptosis in renal epithelial cells (Lieberthal et al., 1996, Zhan et al., 1999). 
Exposure to high concentrations of toxins or severe depletion of ATP leads to rapid 
metabolic collapse and necrosis. In contrast, lower concentration of the same agents has 
been shown to cause apoptosis (Dive and Hickmann, 1991, Martin and Green, 1995). In 
renal epithelial cells high concentration of CDDP led to necrotic cell death within few 
hours whereas low concentration led to apoptosis over several days (Lieberthal el al., 
1996). The final pathway by which CDDP cause tubular cell necrosis remains to be 
established, but different studies demonstrated that the cytotoxicity of CDDP is 
probably due to combination of insults, including peroxidation of cell membrane, 
mitochondrial dysfunction, inhibition of protein synthesis and DNA damage 
Physiological Aspects of Cisplatin-induced Nephrotoxicity 
1. Cisplatin induced polyuria and renal heamodynamics-
CDDP administration causes polyuria which occurs in two distinct phases. Early 
polyuric phase was seen after 24 hrs of CDDP administration, this phase improves 
spontaneously. Urine osmolality initially falls over the first 24-48 hrs, but glomerular 
filtration rate (GFR) in this phase is normal. A second phase of increased volume and 
reduced osmolality occurs between 72 and 96 hrs, this phase is accompanied by reduced 
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GFR and is persistent (Safirstein et al., 1987). The early phase of polyuria responds to 
large doses of vasopressin (Clifton et al., 1982). Blood levels of vasopressin are low 
during this phase and CDDP reduces release or synthesis of vasopressin from isolated 
pituitary cells (Clifton et al, 1982). The most prominent abnormality of solute transport 
during this phase of polyuria is the lack of addition of urea to fluid in loop of Henle. It 
was observed that there was diminished fluid reabsorption either in deeper nephrons or 
collecting ducts of CDDP treated animals. Inulin clearance initially falls 48-72 hrs after 
CDDP administration. Abnormal inulin permeability occurs at severely necrotic S3 
segment of proximal convoluted tubules. Thus, the decline in inulin clearance after 3 
days of treatment is due to both renal decline in ultra filtration rate and abnormal inulin 
permeability. Renal plasma flow, whole kidney GFR and single nephron GFR are 
reduced due to CDDP treatment. The changes in the renal blood flow indicate elevated 
renal vascular resistance (Offermann et ah, 1984). 
2. Cisplatin induced Hypomagnesaemia-
Hypomagnesia is a common complication of CDDP administration in humans 
(Evans et al., 1995) and this persists due to renal defect in magnesium reabsorption 
(Wong et al., 1988). In vivo perfiision studies indicate that the thick ascending limb of 
Henle's loop in S3 segment has a remarkable capacity to increase the absolute 
reabsorption of magnesium with an increase in delivered load (Quamme and Dirks, 
1980). Recent studies in rat model suggest that abnormal magnesium excretion is due to 
defect in either magnesium transport in juxtamedullary nephrons or collecting ducts 
(Mavichak e/a/., 1985). 
CHROMIUM TOXICITY 
Chromium is an essential trace element involved in glucose and lipid metabolism 
(Borel and Anderson, 1984). It is often used for industrial purposes such as leather 
tanning process. Chromium is also widely used in industrial chemicals with use in steel, 
alloy cast irons, paints etc (Richard et al., 1979). The toxicological effects of industrial 
exposure to chromium compounds are well known and include allergic dermatitis, skin 
ulcers, perforation of nasal septum and increased incidences of bronchogenic carcinoma 
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(Gibb et ai, 2000). Renal necrosis, hepatic damage and respiratory cancer have been 
reported in chromium (VI) exposed humans (Enterline, 1974; Wedeen and Qian 1991; 
Acharya, 2001,). Most of these health hazards have been ascribed to exposure to 
hexavalent chromium compounds, such as potassium dichromate and sodium chromate, 
because they are more rapidly absorbed and are more corrosive and irritating than other 
valance states. Some studies indicate that serum and urine chromium levels were high in 
workers exposed to chromium in leather tanning industries (Randall and Gibson, 1989; 
Stuper et ai, 1999). The chrome ulcer generally occurred on exposed area of the 
workers body in contact with vapors, fumes and/or dust containing hexavalent 
chromium. 
Pathophysiology of Potassium Dichromate Induced Acute Renal Failure 
Acute renal failure induced by hexavalent chromium compounds such as 
potassium dichromate (K2Cr207) and sodium chromate (Na2Cr04), best approximates 
the basic criterion for an acceptable experimental nephrotoxic model. These criteria are: 
ease of induction of acute renal failure, reproducible alterations in renal functions which 
were predicted at any given time point in the course of acute renal failure and parallels 
in the pathophysiologic manifestations of the model of experimental acute renal failure 
with those observed in clinical acute renal failure (Ryan et al, 1978; Picauda et ai, 
1991). 
Administration of K2Cr207 is toxic to kidney and results in acute renal failure. 
The initial toxic signs of ingesting hexavalent chromium compounds by humans are 
abdominal pain, vomiting, diarrhoea and intestinal bleeding (Sanz et ai, 1991). These 
are followed by renal failure resuUing from tubular necrosis (Michie et ai, 1991). In 
animal toxicology the evaluation of enzymeuria has been widely used in the assessment 
of renal tissue integrity (Price, 1982); the release of tissue enzyme in urine is considered 
to be an early and sensitive indicator of nephrotoxic damage. The release of enzyme is 
due to greater cell loss from the basement membrane or increased cellular permeability, 
possibly due to increased exocytosis. It is observed that 4-24 hr after administration of 
K2Cr207 urinary excretion rate of brush border enzymes y-glutamyl transferase, alkaline 
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phosphatase and leucine aminopeptidase, cytosoHc enzyme lactate dehydrogenase and 
the lysosomal enzyme N-acetyl-P-glucoseaminidase were all significantly elevated 
(Gumbleton and Nicholls, 1988). Further effects consisted of increased levels of urea 
and creatinine in blood plasma, decreased urinary pH, increased urinary excretion of 
proteins and glucose and decreased sodium excretion in urine (Jonker et al., 1993). 
Smith (1988) have shown that K2Cr207 reduces gluconeogenesis, total glutathione 
(reduced and oxidized) concentration and increases lipid peroxidation in kidney 
homogenates. Aggressive dialysis appears to be the best therapy for K2Cr207 ingestion 
(Saryn and Reedy, 1988) and the administration of ascorbic acid has been 
recommended to reduce the high nephrotoxicity of hexavalent chromium (Ellis, 1982; 
Koralluse^a/., 1984) 
Nephrotoxic doses of K2Cr207 have led to the development of reversible acute 
tubular necrosis located largely in the proximal tubule. The morphological damage was 
restricted mostly to the pars convoluta i.e. the SI and S2 segments of proximal tubule 
(Dewitt-Bains, 1965; Biber et al., 1968) with minimal necrosis of the inner cortex. After 
4-24 hr following a single K2Cr207 injection morphological changes in the kidney with 
proximal tubular necrosis in the outer cortex were observed, more extensive necrosis 
occurred between 2-3 days. However, between 5-8 days after dosing, recovery from 
toxic damage was evident. Histochemical experiments to study enzyme loss showed a 
similar pattern. The kidneys of rabbits injected with K2Cr207 showed marked congestion 
in addition to thickening of the walls of small blood vessels. Glomerular tufts were 
shrunken in some places while proliferation of endothelial cells obliterating the Bowman 
space was seen. There was necrosis and epithelial desquamation of the convoluted 
tubule, at each place eosinophilic hyaline material was seen lying in the lumen and the 
interstitial tissue was seen infiltrated with mononuclear cells and lymphocytes. At some 
places plenty of red blood cells were seen lying in between intertubular spaces (Mathur 
etai, 1977;Kirschbaume^a/., 1981). 
Several studies have shown that chromate ions can penetrate the cell membrane 
quite readily and act as a strong oxidizing agent. The cellular and subcellular membrane 
integrity is, therefore, disturbed resuhing in the leakage of lysosomal enzymes in urine 
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(Gumbleton and Nicholls, 1988). Lysosomes are particularly prominent in the early 
parts of proximal tubule, the SI and S2 segments, which demonstrate extensive 
endocytic activity, processing materials reabsorbed from the glomerular filtrate 
(Maunsbach, 1969). They are the major site of intracellular toxin deposition and in this 
manner reduce the susceptibility of other intracellular organelles to injury. However, at 
the same time, lysosomes may be structurally and functionally impaired as a result of 
toxin accumulation and can potentially serve as an intracellular source of toxin when 
they release accumulated toxin at some stage of injury. Heavy metals accumulate to 
some degree within lysosomes and it has been well documented that such accumulation 
results in inhibition of normal degradative processes for endocytosed macromolecules 
(Madsen and Christensen, 1978; Mego and Cain, 1978). Despite the potential for cell 
damage to result from abnormal release of intralysosomal enzymes and the occurrence 
of lysosomal disruption after lethal cell injury is established, it has been difficult to 
document that substantial release of lysosomal enzymes occurs at sufficiently early 
stages in the development of injury for the process to play a primary pathogenetic role, 
ahhough a few reports providing some evidences for early lysosomal release have been 
reported (Wildenthal et al., 1978). Furthermore, the acidic pH optima of most 
intralysosomal enzymes likely limits their activity when released, even into injured 
cells. Despite all these studies the role of lysosomes in the overall pathogenesis of cell 
injury remains a topic of continued investigation. 
A method widely used to evaluate the nephrotoxicity of various compounds is 
the technique using kidney slices. The kidney slice technique can be used to determine 
the effect of prior drug treatment of laboratory animals on renal organic acid (p-
aminohippurate) or organic base (N-methylnicotinamide) transport, on glucose 
synthesis and on oxygen consumption by renal cortical slices. The nephrotoxic agents 
uranyl nitrate and K2Cr207 exert inhibitory effects on renal function, although both 
agents enhance organic base transport at low dose and K2Cr207 enhances organic acid 
transport at moderate doses (Hirsch, 1976). Segment specific localization of p-
aminohippuric acid and glutathione synthetase activity along the proximal tubule was 
also investigated in kidneys of rats treated with K2Cr207. Significant dose dependent 
decrease of p-aminohippuric acid uptake in the renal cortical slices and loss of kidney 
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protein content after 24 and 48 hr of K2Cr207 treatment was observed (Trevisan et ai, 
2001). Hojo and Santomi (1991) observed that decreased renal GSH and glutathione 
reductase (GSSG-R) levels accompanied K2Cr207 nephrotoxicity. Pre-treatment with 
buthionine sulfoximine, an inhibitor of GSH biosynthesis, enhanced Cr(VI) 
nephrotoxicity and remarkably diminished kidney GSH and GSSG-R levels. In contrast, 
pre-treatment with glutathione methyl ester, a GSH-supplying agent, prevented Cr(VI) 
from exerting harmftil effect on mouse kidney and restored kidney GSH levels (Hojo 
and Santomi, 1991). 
Excretion of chromium 
Chromium is excreted in urine and feces. Urinary excretion is the major route, 
accounting for at least 80% of injected chromium, but elimination via intestine also 
plays a role although the site of chromium excretion from the intestine is unknown. 
Hopkins (1965) found 0.5-1.7% of an intravenous chromium dose in the feces of rats 
killed 8 hr after the injection. Collins ef a/. (1961) studied urinary excretion after 
intravenous load and found that the portion of chromium, which is in dialyzable form in 
the blood (probably coordinated to small molecular ligands) is filtered at the 
glomerulus, but upto 63% is reabsorbed from the filtrate in tubuli. Protein bound 
chromate is excreted only to a very small degree; nearly all the chromium in the urine is 
in the dialyzable form (Collins et al., 1961). Tubular reabsorption may account for the 
relatively high chromium concentration in kidney. Hopkins (1965) reported a biphasic 
urinary elimination pattern of ''Cr administered to rats as a single dose of hexavalent 
chromium compound and reported its excretion half life to be 22-24 days. Bragt and 
Van Dura (1983) also reported that the clearance of ' 'Cr from the blood was biphasic, 
the half time for the fast phase of blood clearance was 4.6 days. The biphasic blood 
clearance pattern and the bi or multiphasic urinary excretion patterns for chromium 
suggest the existence of several slow releasing storage compartments. Nearly 50 years 
ago. Gray and Steriing (1950) described the affinities of hexavalent chromium for red 
blood cells and plasma protein. Others have subsequently investigated the nature of 
chromium-protein interactions (Zacharais, 1959; Borguet et al., 1990). Chromium 
appears to bind mainly to transferrin, and to a lesser extent to albumin. It is quite clear 
21 
that some of the compartments to which chromium is distributed include kidney, liver, 
spleen and bone, but the proposed pathways and kinetic models require additional 
refinement (Lim etal., 1983; Gregus and Klaassen, 1986; Salem and Katz, 1989)). 
Celluar mechanism of toxicity of Cr (VI) compounds 
Chromium (Cr) is found primarily in two valance forms, Cr(VI) and Cr(ni) (De 
Flora et al., 1990). Cr(VI) coumpounds are more toxic and carcinogenic than Cr(III) 
(Bianchi et al, 1983) because Cr(VI) can readily cross cellular membrane via 
nonspecific anion carriers (Lu and Yang, 1995). However, once inside the cells Cr(VI) 
is reduced through reactive chromium intermediates Cr(V) and Cr(IV) to the ultimate 
kinetically stable Cr(III) by cellular reductants including glutathione, cysteine, ascorbic 
acid, riboflavin and NADPH-dependent flavoenzymes such as microsomal cytochrome 
P450 reductase (De Flora et al, 1990, 1989; Sugiyama, 1992; Yuann et a/., 1999). 
Therefore, formation of paramagnetic species such as Cr(V) plays an important role in 
the induction of the toxic properties of Cr(VI). Initially, Cr(III) was thought to be 
relatively nontoxic but was later found to cause genotoxicity in a cell-free system (De 
Flora et al., 1990). Cr(III) interacts with DNA to induce DNA strand breaks, DNA-
protein cross-links and oxidative DNA base modification such as the formation of 8-
hydroxydeoxyguanosine (8-OH-dG) (Snow 1991; Tsou etal., 1996). 8-OH-dG is a key 
biomarker relevant to carcinogenesis because its formation in DNA causes 
misincorporation during replication and subsequently leads to G->T transversions 
(Shibutani et al., 1991; Cheng et al., 1992). The carcinogenic mechanism of Cr(III) 
relates to its ability to generate hydroxyl radicals (*0H) from H2O2 via a Fenton type 
reaction (Tsou etal., 1996; Lloyd et al., 1998). The highly toxic 'OH then targets DNA 
resulting in oxidative DNA base adducts such as 8-OH-dG. Previous studies 
demonstrated the important role of Cr(V) in the induction of DNA strand breaks by 
Cr(VI) in cultured mammalian cells (Sugiyama, 1994). 
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PROTECTION AND PREVENTION OF ARF 
Numerous attempts have been undertaken to protect or enhance the recovery from 
experimentally induced acute renal failure. However, the usefulness of these studies is 
not merely in the amount of protection they might bring but also in the insight into the 
pathophysiology of ARF that they may offer. Different drugs, hormones and anti-
oxidants have been used in recent years which induce a partial recovery from toxic 
insult or ischemia (Appenroth etal, 1997; Saad etai, 2000). Some attempts have been 
made in the past to reverse the drug or ischemia induced alterations by using glucose, 
essential and non essential amino acids and their a-keto derivatives which could 
increase the survival rate after an ARF episode (Toback, 1984). In studies performed to 
prevent ARF, if was found that prostaglandin E, bradykinin, furosemide and mannitol 
attenuate the functional defect in some models of ARF. Recently, calcium channel 
blockers like verapamil have been included in the above group (Goldfarb et ai, 1983; 
Burke etal.. 1984). 
Several other agents have been shown to control renal failure induced due to 
ischemia or toxic insult. These include epidermal growth factors (Schaudies and 
Johnson, 1993; Price e/a/., 1995), endothelin (Shiboutae/a/., 1990; Stacy eta/., 1990), 
atrial natriuretic factors (Lieberthal et al., 1990; Awazu and Ischikawa, 1993), 
defibrotide (Berti et al, 1991), glycine (Li et al, 1995), insulin like growth factor 1 
(Miller et al., 1992; Friedlaender et al., 1995), platelet activating factor (Rodriguez-
Barbero et al, 1997), platelet-activating factor antogonist BN52021 (Hanslik et al., 
1994), fasting (LeBrun et al, 1999) and fish oil (Ali and Bashir, 1994) Various 
hydroxyl radical scavengers like superoxide dismutase (Matsushima et al, 1998), 
vitamin C and E (Durak et al, 2002), or iron chelator (Ozdemir et al, 2002), when 
administered just prior to the ischemic events or toxic insult, have been reported to 
ameliorate renal toxicity. 
The above mentioned attempts, which were made to ameliorate the function of 
ARF induced kidney, generally resulted in an improvement of glomerular filtration rate, 
renal blood flow, decreased serum creatinine and BUN levels with increased inulin as 
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well as creatinine clearance and in the enhancement of cellular regeneration (Ullrich et 
ai, 1977; Shibouta et al., 1990; Humes and Liu, 1994; Schaudies and Johnson, 1993; 
Awazu and Ischikawa, 1993; Girardi and Elias, 1995). The above efforts, however, 
failed to provide any generalized mechanism for the damage or repair of the ARF 
kidney in particular. 
Protection and Prevention Against CDDP Nephrotoxicity 
Nephrotoxicity is the most serious side effect associated with CDDP therapy. The 
wide therapeutic application of CDDP depends not only on its clinical efficacy but also 
on the development of strategies that diminish the severity of the ARF it produces. In 
the past five years, a numbers of laboratories have elucidated various agents which may 
be useful in preventing or attenuating the development of ARF. The most commonly 
used protective measure is to establish a solute diuresis (Dana and Kachhwaha, 1996) 
Pre- and post hydration with saline or mannitol has been found to prevent CDDP 
induced nephrotoxicity (Nagai and Ogata, 1996). In animals, furosemide or mannitol-
induced diuresis concurrent with CDDP administration has been reported to decrease 
renal toxicity of CDDP in some studies. A commonly applied protocol is administration 
of CDDP in isotonic saline, followed by infusion of isotonic saline or mannitol for 24 
hours before and after the drug is infused. The exact mechanism of diuretic induced 
reduction of nephrotoxicity is not known, although the reduction of platinum 
concentration in the tubular fluid caused by diuretics is assumed to account for the 
protection. Although the concentration of CDDP is lower in the urine, neither the tissue 
concentration of the drug nor the toxicity is altered by such maneuver protection (Pera 
et ai, 1979). Alternatively, the high chloride content of the urine might reduce its 
speciation into toxic metabolites, but mannitol is equally effective in diminishing the 
degree of renal failure. Moreover, chloride concentration in urine is reduced during 
mannitol induced diuresis, so this explanation seems inadequate as well. Some studies 
show protective effect of acetazolamide, a carbonic anhydrase inhibitor, against changes 
in gross indicators of general toxicity (e g. body weight loss) and renal damage (e g 
BUN elevation). These protective effects were similar to those observed with mannitol 
Acetazolamide pre-treated animals were found to exhibit less tubular necrosis and rapid 
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recovery from renal damage than animals pre-treated with mannitol (Osman et a\., 
1984). In addition to its action as a diuretic, acetazolamide is an organic acid which may 
competitively decrease tubular reabsorption of CDDP. Also, acetazolamide is a sulfur 
containing drug and several sulfur containing compounds have been shown to be 
effective in blocking or reducing CDDP toxicity (Borch and pleasants, 1979; Howell 
and Taetle, 1980). Acetazolamide probably reduces CDDP nephrotoxicity by a 
chemical interaction with reactive sites on CDDP molecule (Osman et al., 1984). 
Additional maneuvers have also been attempted to reduce CDDP nephrotoxicity. 
Dimethyldithiocarbamate, which has been shown to compete for platinum binding to 
DNA (Bodenner eial., 1986), reduces CDDP induced nephrotoxicity in animals but has 
been much less successful in human trials due to its toxicity and failure to reduce CDDP 
ototoxicity (Berry e/or/., 1990). 
Several authors have reported that streptozotocin induced diabetes in rats 
protected them against CDDP induced nephrotoxicity in comparison with normal 
animals (Scott et al., 1989; Sarangarajan and Cacini, 1996). This protective effect was 
attributed to several mechanisms such as increased level of endogenous atrial natriuretic 
peptide, increased renal uptake and/or retention of CDDP and marked elevation of renal 
metallothionine (Cacini and Singh, 1991; Ormond et al., 1992). Najjar and Saad (2001) 
showed that pharmakinetics of CDDP remain unchanged in diabetic and normal rabbits. 
Hill et al. (1975) found that in patients treated with CDDP there was a fast and slow 
phase of Pt loss from plasma depending on the time after administration. Results 
revealed that streptozotocin-induced hyperglycemia did not significantly alter the 
plasma pharmacokinetics of either the free ultrafilterable or total plasma Pt, although 
the total plasma Pt levels of diabetic groups 4 hr after CDDP administration were found 
to be significantly lower than those of the nondiabetic group. 
There are several evidences indicating that the administration of cytostatic 
agents from various categories leads to the generation of free radicals, elevated amount 
of lipid peroxidative products (Subramaniam et al., 1993; Look and Musch, 1994; Faure 
et al., 1996) and a decrease in the vitamin E concentrations (Faber et al., 1995) in the 
plasma after the treatment. The total radical trapping capacity of the anti-oxidants was 
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found to be decreased in the plasma of the lung cancer patients after the first infusion of 
doxorubicin (Wayner et ai, 1987; Erhola et ai, 1996). This decrease was due to the 
reduction of vitamin C and uric acid concentrations. In vitro studies have shown that 
CDDP generates free radicals through various mechanisms. In cell free systems, CDDP 
generates "Oi" and "OH" by interaction with DNA (Masuda et ai, 1994) and inhibited the 
activity of thiotransferase, an enzyme that generates the active (reduced) form of 
vitamin C (ascorbate) from oxidized vitamin C (dehydroascorbate) in response to 
oxidative stress (Wella et ai, 1991). Furthermore, nmnne macrophages released 
significantly increased amounts of H2O2 and *02", after treatment with CDDP (Sodhi 
and Gupta, 1986). Generation of reactive oxygen species induces DNA damage due to 
attack at C-8 of guanine. This DNA damage is usually repaired by enzymes and one of 
the repair products 8-OH-dG is excreted in urine without fiirther metabolism (Gentile et 
al., 1998). The formation of free radicals is thought to be crucial in the development of 
nephrotoxicity and other organ damage. 
Anti-oxidant enzymes protect cellular components from endogenously derived 
oxidants. For example leakage of electrons from the electron transport chain gives rise 
to superoxide anion. The presence of superoxide dismutase in mitochondria prevents 
their escape and results in peroxide formation, which can diffuse into cytosol where it 
may influence signal transduction pathway. CDDP generates reactive oxygen species 
such as superoxide anion and hydroxyl radicals (Masuda et ai, 1994; Kruidering et ai, 
1997) and also inhibits the activity of anti-oxidant enzymes in renal tissue. 
Administration of superoxide dismutase, an antioxidant enzyme, before administration 
of CDDP results in significant reduction of CDDP-induced nephrotoxicity (McGinness 
et ai, 1978). Furthermore CDDP induced nephrotoxicty is associated with the depletion 
of cellular thiols such as metallothionine (MT) and glutathione (GSH). MT and GSH 
can act as free radical scavangers and prevent progression of lipid peroxidation (Sato 
and Bremmer, 1993; Anderson 1998). Since platinum can be bound to the thiols in 
cysteine, GSH and MT molecules, MT and GSH may prevent CDDP induced renal 
toxicity by trapping platinum and scavanging free radicals produced by CDDP. 
Catalytic iron also plays an important role in the pathogenesis of CDDP induced renal 
injury. One of the important mechanisms by which iron mediates tissue injury is the 
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generation of highly toxic hydroxyl radicals via the iron catalyzed Haber-Weiss 
reaction. Deferoxamine, an iron chelator, protects rats from the nephrotoxicity induced 
by CDDP (Baliga et ai, 1998; Ozdemir et al., 2002) and also completely inhibits the 
liberation of free radicals (Hannemann and Baumann, 1988). 
CDDP chemotherapy induces a fall in plasma anti-oxidant enzyme levels which 
may reflect a failure of the anti-oxidant defense mechanism against oxidative damage 
induced by commonly used anti tumour drugs (Gruber and Anuszewska, 2000). Much 
attention has been given to the possible role that dietary anti-oxidants play in protection 
against CDDP induced nephrotoxicity (Appenroth et al., 1997). Previous reports have 
shown the protective effects of several anti-oxidants like vitamin C, curcumin and 
selenium against the nephrotoxicity and lipid peroxidation induced by CDDP (Baldew 
et al., 1989; Bogin et al., 1994; Appenroth et al., 1997). Other anti-oxidants such as 
eugenol, silibinin and cysteine also showed protection against CDDP-induced toxicity 
in vitro. A recent study used bixin, a natural carotenoid, for overcoming CDDP induced 
toxicity. Bixin is one of the most effective biological singlet molecular oxygen 
quenchers and may contribute to the protection of cell and tissues against deleterious 
effects of free radicals (Silva et ai, 2001). Pre-treatment with bixin reduced the total 
number of chromosomal aberrations, inhibited the increase in lipid peroxidation and 
renal glutathione depletion induced by CDDP (Silva et al., 2001). 
Vitamin C is an essential nutrient and active reducing agent and is involved in 
many biological processes (Padh, 1990; Antunes and Takahashi, 1998); it prevents the 
generation of reactive oxygen species by cascade of reactions. Vitamin C has been 
shown to protect against various kinds of injuries and neoplasms involving oxidative 
stress. It is possible that treatment of animals with vitamin C may attenuate CDDP 
induced lipid peroxidation, glutathione depletion and increase in serum creatinine and 
BUN levels. 
Protection Against K2Cr207-Induced Nephrotoxicity 
Investigations into thyroid induced nephrotoxic effects have lately acquired 
growing interest owing to the demonstration of a positive influence of thyroid hormone 
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upon various renal functions. These occurr not only in normal or hypothyroid 
individuals but also in individuals suffering from kidney disease (Schulte-Wissermann 
et al, 1977). It has been proposed that there is a thyroxin mediated effect on tubular 
cells resulting in an increase in Na* reabsorption in proximal tubule and loop of Henle, 
increase in renal blood flow and GFR, stimulation of gluconeogenesis (Bradley et al, 
1974) and Na"'-K'^  ATPase activity in the renal cortex (Somjen et al., 1981) and 
promotion of glucose and amino acid uptake (Siegal and Ingbar, 1979) by epithelial 
cells. The beneficial effect of thyroxin on K2Cr207 treated rats was sustained and led to 
more prompt recovery of glomerular function. GFR and cellular morphology were 
better preserved by thyroxin. The studies indicate that treatment with thyroxin results in 
enhanced recovery from acute toxic renal insult caused by K2Cr207 and that this 
beneficial effect is unlikely to be related to nonspecific systemic effects of the hormone 
(Siegal et al., 1984). Nephrotoxins and ischemia cause depletion of tissue level of ATP 
with concomitant increase in the levels of ADP and AMP (Zhang and Lindup, 1997). It 
has been proposed that restoration of AMP synthesis by the damaged kidney can have a 
beneficial effect. Seigel et al. (1980,1984) showed that administration of adenine 
nucleotides (ATP, ADP, AMP), together with magnesium chloride, ameliorated the 
renal function after the initiation of acute renal failure. One of the reasons for the 
decrease of ATP in renal tissue can be due to depleted Pi level due to reduced Pi 
reabsorption across the apical membrane, the primary site of action for most 
nephrotoxins. The Na-Pi co-transport across luminal brush border membrane is the rate-
limiting step in Pi reabsorption by proximal tubule (Dousa and Kempson, 1982). Thus 
the studies of Na-Pi co-transport and its modulation by various stimuli are considered to 
be useful for the protection against ARF. 
Several studies indicate that K2Cr207 administration causes genotoxicity and the 
generation of reactive oxygen species (Qi et al., 2000; Ueno et al., 2001). Previous 
studies demonstrated the important role of Cr(V) in the induction of DNA strand breaks 
by Cr(VI) in cultured mammalian cells (Sugiyama, 1994). Pre-treatment of cultured V-
79 cells with riboflavin increased Cr(VI) induced DNA strand breaks while similar pre-
treatment with oc-tocopherol, succinate or ascorbic acid resulted in less total Cr(V) and 
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simultaneously fewer DNA strand breaks caused by Cr(VI) (Sugiyama et al., 1989; 
Sugiyama, 1991, 1992). Pre-treatment with deferoxamine, an iron chelator, also 
inhibited the formation of Cr(VI) induced DNA strand breaks and suppressed Cr(V) 
formation in the liver and kidney (Ueno et al., 2001). 
Melatonin, as an anti-oxidant, is effective in protecting membrane lipids, nuclear 
DNA and proteins from oxidative damage induced by a variety of free radical 
generating agents and processes both in in vivo and in vitro (Reiter et al, 1995, 1997; 
Romero et al, 1999). Susa et al (1997) found that melatonin markedly reduced nuclear 
DNA strand breaks induced by K2Cr207. They speculated that melatonin protected cells 
from free radical toxicity by one of several means, including melatonin's ability to 
preserve intracellular levels of vitamins E and C, stimulation of catalase activity, and/or 
by directly scavenging the *0H. 
Vitamin C and E are strong anti-oxidants that act as potent free radical scavangers in 
biological systems. Vitamin E is a potent peroxyl radical scavanger and specially 
protects polyunsaturated fatty acids within phospholipids of biological membranes and 
in plasma lipoproteins (Burton et al, 1983). The phenolic hydroxyl group of tocopherol 
reacts with an organic peroxyl radical to form the corresponding organic hydroperoxide 
and the tocopherol radical (Vit E-0*) (Burton et al, 1985). Vitamin C oxidizes vitamin 
E and restores it in biological systems This anti-oxidant network depends upon the 
supply of aqueous anti-oxidants and the metabolic activity of the cells. 
Vitamin E has protective effects against the carcinogenic and mutagenic activity of 
chemical agents and ionizing radiations (Sugiyama, 1992). Qi et al (2000) showed that 
Trolox, a water soluble vitamin E analogue, successfiiUy inhibited the Cr(III)-induced 
formation of 8-OH-dG in isolated DNA in a concentration dependent manner. Vitamin 
C, a water soluble physiologic anti-oxidant has antiviral, anticancer and antimutagenic 
activity (Sugiyama et al, 1992) although under certain conditions vitamin C can also 
act as a pro-oxidant generating free radicals (Shamberger, 1984). In a number of 
studies, ascorbate potentiates the production of reactive oxygen species, DNA strand 
breaks and 8-OH-dG formation induced by Cr(VI) plus H2O2 (Steams et al, 1994, 
1995, Shi e^  a/., 1999). 
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SCOPE 
Cis-diamminedichloroplatinum (II) (CDDP), commonly known as cisplatin, is 
an antineoplastic agent having a remarkably wide spectrum of clinical activity in solid 
tumor therapy. Its use has significantly improved the response rate in patients treated for 
metastatic testicular (de Graaf e/ al, 1997) and ovarian carcinoma (Lorusso et al, 1998). 
CDDP has also become an important component of present treatment programs for the 
management of bladder carcinoma, squamous cell carcinoma of head and neck 
(Nakashima et al., 1990) and bronchogenic carcinoma of lungs (Bedini et al., 1991), 
The major dose limiting toxicity of CDDP is its effect on the kidney. This toxicity is 
thought to be mediated by the effects of CDDP on renal perfusion, tubular function or 
both and is characterized by destruction of proximal tubular cells situated in the 
corticomedullary section of the kidney (Dobyan etal., 1980; Kuhlmann et al., 1997). 
After administration, CDDP undergoes rapid distribution to nearly all the 
organs. Platinum tissue concentration was found to be high in the kidney (nearly 3-4 
times the plasma concentration) after drug administration in dogs and rats (Litterst et 
al., 1979). Studies on rats have shown that 50% of the injected CDDP is excreted 
unchanged in the urine 24 hr after administration. Several authors have reviewed the 
problem of CDDP nephrotoxicity, its pharmacokinetics and pharmacodynamics. 
Amelioration of CDDP induced toxicity remains of particular interest since renal 
damage is one of its most critical and serious side effects and frequently constitutes a 
dose limiting factor. 
Exposure to several chemicals used in industries can also cause nephrotoxicity. 
This includes chromium compounds that are widely used in leather tanning, dye and 
chemical industries; exposure to them results in acute renal failure (ARF). The ARF 
induced by CDDP and other nephrotoxins in experimental animals causes structural 
tubular damage. Toxic or ischemic insuh is mainly responsible for the reversible and 
irreversible loss of excretory functions of kidney in which the renal proximal tubular 
cells are severely affected and undergo dynamic transformation (Venkatachalam et al., 
1978). It has been shown that the proximal tubular brush border membrane is badly 
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damaged by toxic or ischemic insult. The effect of nephrotoxins has been manifested in 
rats mainly by the disappearance of brush border microvilli or by occasional 
internalization of microvilli and subsequent loss into lumen leading to cellular necrosis 
in ARF (Poddock et al, 1985). Some studies have demonstrated that the loss of 
activities of brush border membrane (BBM) enzymes, AP, GGTase and LAP correlates 
with enzymeuria. The experimental ARF induced by ischemia (Khundmiri et al., 1997) 
or by drugs / chemicals like mercuric chloride, gentamicin and several other antibiotics 
(Weiner and Jacobs, 1983; Sundin, 1997) resuhs in loss of microvilli, increased apical 
vascularization, mitochondrial swelling and eventual cell necrosis at specific site within 
the proximal tubule. The morphology associated with each of these models of ARF has 
been studied in detail, while the changes associated with the sublethal cell injury by 
chromium (VI) compounds are unknown. This is despite the fact that chromium 
induced ARF is one of the major side effects in workers exposed to chromium 
compounds in chemical and dye industries (Weeden and Qian, 1991). 
Administration of a single dose of CDDP and K2Cr207 in rats results in 
profound alterations in the function, metabolism and structural integrity of renal tubular 
cells. Both CDDP and K2Cr207 show site specific effects within the proximal tubular 
segments. The SI subsegment (pars convoluta) showed susceptibility to K2Cr207 while 
the S3 subsegment (pars recta) was severely damaged by CDDP. Studies of transport 
function showed reduction in the Na* dependent glucose (Molitoris and Kinne, 1987; 
Molitoris etai, 1989) and organic cation (Maeda et al., 1993) transport in nephrotoxin 
or ischemia induced ARF. The transport of Pi, which is involved in the maintenance of 
energy for many renal functions (Vogt and Farber, 1968; Yusufi and Dousa, 1987), has 
not been studied so far in K2Cr207 induced ARF. The transport of Pi in renal proximal 
tubule is regulated at BBM site (Dousa and Kempson, 1982). CDDP and K2Cr207 
induced nephrotoxicity also results in lipid peroxidation, depletion of sulfhydryl groups, 
generation of free radicals and suppressed activity of free radical scavanging enzymes 
Despite all these observations the exact biochemical mechanism of CDDP and K2Cr207 
induced toxicity is not clear. 
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The study of nephrotoxins like K2Cr207 and clinically relevant drugs such as 
CDDP in the laboratory can provide clues to the pathogenesis of toxic nephropathy as 
well as to renal injuries produced by other etiological agents. Several studies have 
shown that \atamin C ameliorates the nephrotoxic effects of both CDDP and K2Cr207 
In view of this, the present work was carefiilly designed and undertaken to study the 
damage caused by nephrotoxins to the structure and functions of the renal tubules. For 
better understanding of the mechanism of pathogenesis of CDDP and K2Cr207 induced 
ARF, and its possible reversal, the following studies were performed. 
1. The food intake and body weights of rats were determined at different times after 
administration of a single dose of CDDP or K2Cr207. The serum and urine 
parameters viz. creatinine, BUN, phospholipids, cholesterol along with proteinuria 
and glucosuria were carefially monitored after administration of CDDP and 
K2Cr207. 
2. The activities of some marker enzymes considered to be of structural and functional 
importance to the proximal tubular BBM e.g. alkaline phosphatase, y-glutamyl 
transferase, maltase and leucine aminopeptidase were determined in BBMVs 
isolated from whole cortex and homogenates of cortex and medulla of CDDP and 
K2Cr207 treated and control rats. The activities of enzymes belonging to other 
organelles were also determined after CDDP and K2Cr207 administration. 
3. The activities of various enzymes of metabolic importance, especially those related 
to glucose metabolism, were determined in different tissue zones of the kidney, e.g. 
whole cortex and medulla, from CDDP and K2Cr207 treated rats. 
4. Transport of inorganic phosphate (Pi) was determined in the BBMVs isolated from 
CDDP and K2Cr207 treated rats. 
5. The protective and preventive effect of vitamin C pre-treatment was studied on 
K2Cr207 or CDDP induced changes in several parameters e.g. BUN, serum 
creatinine, BBM marker enzymes. Pi transport, lipid peroxidation, SH groups and 
on free radical scavanging enzymes catalase and superoxide dismutase. 
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These studies show that administration of CDDP and K2Cr207 resulted in 
specific alterations in the above mentioned parameters. Pre-treatment with vitamin C 
significantly reduced the changes produced by CDDP or K2Cr207 administration. These 
studies would be helpful in further understanding the pathogenesis of CDDP and 
K2Cr207 induced toxic ARP and its possible prevention and protection. 
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MATERIALS AND METHODS 
Animals: 
Adult male Albino rats (Wistar strain) were purchased from Experimental Animal 
Facility Centre, AIIMS, New Delhi and Jamia Hamdard University, New Delhi, India 
Enzyme substi'ates: 
D-glucose-6-phosphate, sodium pyruvate, oxaloacetate, L-malic acid, fructose 1,6 
diphosphate, p-nitrophenyl phosphate, ATP, y-glutamyl p-mtroanilide, and L-leucine-
p-nitroanihde were purchased from Sigma Chemical Co , USA 
Radio Chemicals: 
Radioactive inorganic phosphate ( Ti) was purchased from Bhaba Atomic 
Research Centre, India 
Miscellaneous: 
All other chemicals used were of the finest quality commercially available and their 
sources are indicated against them Glass double distilled water was used in all 
experiments 
CHEMICAL SOURCE 
Acetic acid 
Ammonium molybdate 
Bovine serum albumin 
1 -Chloro 2,4-dinitrobenzene 
Calcium carbonate 
Cholesterol 
Choline chloride 
E Merck, India 
Glaxo, India 
SRL, hidia 
Sigma Chemical Co , USA 
Qualigens, India 
SRL, India 
Loba Chem Co , India 
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Cisplatin 
Copper sulphate 
Creatinine 
Cysteine hydrochloride 
5,5'-Dithiobis 2-nitrobenzoic acid 
Di-potassium hydrogen orthophosphate 
Di-sodium hydrogen orthophosphate 
Ferrous sulphate 
Ferric chloride 
Folin's Phenol reagent 
Glucose 
Glucose oxidase 
Glutathione 
Glycine 
HEPES 
Hydrochloric acid 
Magnesium chloride 
Magnesium sulphate 
Nicotinamide Adenine Dinucleotide Phosphate (NADP 
Nicotinamide Adenine Dinucleotide Reduced (NADH) 
Ouabain 
p-Nitroaniline 
p-Nitrophenol 
Perchloric acid 
SigmaChem Co ,USA 
BDH, India 
BDH, India 
Sigma Chem. Co , USA 
SRL, India 
Qualigens, India 
Quahgens, India 
Ranbaxy Lab , India 
SRL, India 
Loba Chem Co , India 
Sigma Chem C o , USA 
Sigma Chem Co , USA 
SRL, hidia 
E Merck, India 
Sigma Chem Co , USA 
E Merck, India 
Qualigens, India 
Sarabhai Chem, India 
) SRL, India 
SRL, hidia 
Sigma Chem Co , USA 
Sigma Chem Co , USA 
Loba Chem Co , India 
Qualigens, India 
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Horse radish peroxidase 
Picric acid 
Potassium dihydrogen orthophosphate 
Potassium dichromate 
Pyrogallol 
Sodium chloride 
Sodium dihydrogen orthophosphate 
Sodium hydroxide 
Sodium potassium tartarate 
Succinic acid 
Sucrose 
Sulphuric acid 
Thiobarbitunc acid 
Trichloroacetic acid 
Sigma Chem Co , USA 
Quahgens, India 
Qualigens, India 
BDH, India 
Qualigens, India 
E Merck, India 
Qualigens, India 
Qualigens, India 
Qualigens, India 
BDH, India 
CDH, India 
Qualigens, India 
E Merck, India 
Loba Chem Co , India 
Tris SRL, India 
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1 Animal Protocol 
Adult male Wistar rats weighing 180-200 g were used in all the studies Animals 
were stabilized for 10 days prior to the experiment on standard pellet rat diet 
(Amrut Laboratones, Pune, India) with free access to water Cisplatin, in normal 
saline, was injected intraperitonially (i p ) as a single dose (6mg/kg body weight) 
in a volume adjusted to 1 ml with normal saline (0 9% NaCl) Control rats were 
injected with appropnate volume of saline in the same manner Animals were 
sacrificed 2, 4, 8 and 16 days after CDDP administration after being 
anesthetized with anesthetic ether Control animals were similarly sacrificed In 
another series of experiments, K2Cr207 was injected i p as a single dose of 15 
mg/kg body weight in a volume of 2 ml Control rats were given an equivalent 
volume of normal saline The animals were sacrificed 1, 2, 4 and 8 days after 
administration of K^CriO? or normal saline The rats were weighed, blood and 
24 hr unne specimens were collected before the treatment and sacrifice After 
the rats were sacrificed their kidneys were removed and tissue was used for 
preparation of BBMV and cortical and medullary homogenates 
2. Analysis of Serum Parameters 
The blood was allowed to clot, centrifuged at 2000 rpm and serum collected 
The serum samples were deproteinated with 3% TCA in a ratio of 1 3 After 
incubation for 10 min at room temperature, the samples were centrifuged at 
4000 rpm (Remi Centrifuge, India) for 10 min The protein free supernatant was 
used to quantitate serum creatinine (Scr) and inorganic phosphate (Pi) and the 
precipitate was used for quantitation of total phospholipids Cholesterol was 
determined directly in the serum samples Absorbance of samples was measured 
in a DU 40 spectrophotometer (Beckman, USA) 
(i) Creatinine: The serum creatinine was determined by the method of Levinson 
and MacFate (1969) To 0 5 ml of the deproteinated serum supernatant, 250 1^ 
of 10% NaOH and 0 5 ml of saturated picric acid were added and incubated for 
exactly 20 min at room temperature A calibration curve was simultaneously 
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prepared using known concentration of creatinine solutions containing 2-5 \xg 
creatinine. Absorbance of the samples and the standards was read at 520 nm 
(iii) Inorganic phosphate: The inorganic phosphate (Pi) was measured m the 
deproteinated serum supematants by the method of Tausky and Shorr (1953) 
The serum supernatant (1ml) was diluted to 3 ml with glass distilled water and 2 
ml of FeS04 reagent (5 g FeS04 was dissolved in 10 ml of 10% w/v ammonium 
molybdate in 10 N H2SO4 and diluted to 100 ml with glass distilled water) was 
added. A calibration curve containing known amounts of KH2PO4 (0 018-0 28 
|j,moles) was prepared simultaneously with the test samples. After incubation at 
room temperature for 20 min, the blue colour obtained was read at 620 nm 
against a reagent blank 
(iv) Phospholipids: Total phospholipids were determined in the serum TCA-
precipitates by the method of Bartlett (1959) as modified by Marinetti (1962) 
The precipitates were digested with 1 ml of 70% perchloric acid on an electric 
digestion unit After cooling to room temperature 3 ml of glass distilled water 
was added. The inorganic phosphate released was estimated by adding 2 ml of 
FeS04 reagent by the method of Tausky and Shorr (1953) as described above in 
Pi estimation. The phospholipid values were obtained after multiplying the 
phospholipid phosphorus by a factor of 25. 
(v) Cholesterol: Cholesterol was determined directly in serum samples by the 
method of Zlatkis et al. (1953). To 3 ml acetic acid, 30 \i\ serum sample was 
added and then 2 ml FeClj reagent (1 ml of 10% FeCl,^  w/v in glacial acetic acid 
diluted to 100 ml with concentrated H2SO4) was added carefully from the side to 
allow the formation of a brown ring The samples were mixed thoroughly, 
cooled and the colour intensity was read at 560 nm against a reagent blank A 
calibration curve was simultaneously prepared using known solutions containing 
0.02- 0.2 mg cholesterol 
(vi) Urea nitrogen and glucose: Levels of urea and glucose were assayed by 
standard colorimetric procedures, urea by reaction with diacetyl monoxime and 
38 
glucose by reaction with glucose oxidase, using kits from Sigma Chem Co , 
USA 
3. Preparation of Kidney Homogenates for Determination of Metabolic 
Enzymes 
The kidneys from treated (CDDP or K2Cr207) and control animals were 
removed, decapsulated and kept m ice-cold buffered saline (154 mM NaCl, 5 
mM Tns-HEPES, pH 7 5) The cortical and medullary regions were carefully 
separated (Yusufi et al, 1994), and homogenized at 4 V in 50 mM mannitol, 2 
mM Tris-HCl, pH 7, using a glass-teflon homogenizer to make a 15% (w/v) 
homogenate The homogenates were centnfuged at 800xg at 4 "C for 10 min in a 
Beckman J2-M1 high-speed refrigerated centrifuge to remove the cell debris 
The supematants were used for enzyme analysis 
4. Preparation of Brush Border Membrane (BBM) 
The kidneys from treated (CDDP or K^Cr^ Ov) and control animals were 
removed, decapsulated and kept in ice-cold buffered saline (154 mM NaCl, 5 
mM Tns-HEPES, pH 7 5) The whole cortex (WC) was carefully separated from 
medulla for BBM preparation as described by Yusufi e/ al. (1994) The BBM 
vesicles (BBMV) were prepared from whole cortical homogenates by the MgCl2 
precipitation method of Schmitz et al (1973) as described by Yusufi and Dousa 
(1987) and as outlined in the schematic diagram (Fig 3) In each experiment, 
tissues from three to six animals (control and treated) were pooled to obtain a 
sufficient amount of starting material All the steps involved were strictly carried 
out at 0-4 V unless otherwise specified 
a) The homogenate (10% w/v) was diluted with 2 mM Tris-HCl, 50 mM mannitol, 
pH 7, buffer (20ml/g tissue) followed by high speed homogenization (Ultra-
Turrex T25, KA-Laportechnik) with three pulses of 30 sec each with 30 sec 
interval between each pulse Aliquots of cortical homogenates were saved and 
quickly frozen for further analysis 
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RAT RENAL CORTEX 
PELLET 
DISCARDED 
CORTICAL 
HOMOGENATE 
50 mM MANNITOL 5 mm 
TRIS-HEPES, pH 7.0 
HIGH SPEED HOMOGENIZATION (UL-
TRA-TURREX) 
BBMV IN 
HOMOGENATE 
MG^ 2 PRECIPITATION AND CENTRIFUGA-
TION AT 2000 Xg FOR 10 MIN. 
BBMV IN 
SUPERNATANT 
c 
BBMV PURIFICATION 
BY CENTRIFUCATION 
AT 35000XG FOR 
30 MIN. 
BBMV 
SUSPENDED IN 300 
MM MANNITOL 5 MM 
TRIS-HEPES, PH 7.4 
Fig 3 : Schematic representation of BBMV preparation from rat renal cortex 
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b) 1 M MgCla was added to the homogenate to a final concentration of 10 mM 
and kept on ice for 20 min with intermittent shaking 
c) The homogenate was then centnfuged at 2000xg (4000 rpm) for 10 min in a 
Beckman J2-M1 refrigerated centrifuge using JA-17 rotor 
d) The pellet was discarded and the supernatant was recentnfuged at 35,000xg 
(17,000 rpm) for 30 mm 
e) The white outer portion of the fluffy pellet was carefully resuspended in a small 
volume of 300 mM mannitol, 5 mM Tns-HEPES, pH 7 4, leaving the dark 
brown centre of the pellet undisturbed (mitochondrial contamination) 
f) The steps (d) and (e) were repeated twice and the final pellet was resuspended in 
300 mM mannitol, 5mM Tris-HEPES, pH 7 4, buffer 
The suspension thus obtained was homogenized by hand held Douncer or passed 
through a 21 gauge needle This BBM suspension was quickly frozen in small 
aliquots and used for enzyme analysis while aliquots of freshly prepared 
membranes were used for transport studies 
5. Enzyme Assays 
All enzymes were assayed at zero order kinetics unless otherwise specified The 
activity of each enzyme from various groups was determined simultaneousK 
under similar conditions by using same solutions to avoid day to day 
experimental variations One unit of enzyme activity is defined as the amount of 
enzyme required to catalyze the formation of 1 jimole of product per min or hr 
under the specified experimental conditions Specific activity is defined as the 
enzyme unit per mg protein Absorbance was read in a DU 40 
spectrophotometer (Beckman, USA) or a Calbiometer (Calbiochem, USA) 
(a) Carbohydrate metabolism enzymes: The assays for dehydrogenases were 
earned out at room temperature (28-30 "C) by measuring the extinction changes 
m a Calbiometer fixed at 340 nm The net reaction rate was measured b\ 
difference of the extinction values obtained from addition of the substrate oni\ 
and for actual enzymatic reaction following the addition of substrate The molar 
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extinction coefficient of NADH and NADPH used in calculation of reaction rate 
was 6.22 mivr'cm"* at 340 nm. G6Pase and FBPase were assayed at 37 C. 
(i) Lactate dehydrogenase (L-Lactate : NAD oxidoreductase; LDH; E.C. 
1.1.1.27): The activity of LDH was measured by the method of Kornberg 
(1955). The reaction mixture, in a total volume of 3 ml, contained 50 mM Tris-
HCl, pH 7.4, 10 i^ moles MgCb, 5 nmoles sodium pyruvate, 0.24 nmoles NADH 
and 4.0-6.0 |ig protein. The activity was measured as pyruvate dependent 
oxidation of NADH to NAD^ for 5 min at 340 nm. 
(ii) Malate dehydrogenase (L-Malate : NAD oxidoreductase; MDH; E.C. 
1.1.1.37): The activity of MDH was measured by the method of Meyer el al. 
(1948). The reaction mixture, in a total volume of 3 ml, contained 33 mM Tris-
HCl, pH 7.4, 2.5 nmoles oxaloacetate (OAA, pH neutralized to 7.4), 0.24 
|j,moles NADH and 2-3 fxg protein. The activity was measured as OAA 
dependent oxidation of NADH to NAD^ for 5 min at 340 nm. 
(Hi) Glucose-6-phosphate dehydrogenase (D-Glucose-6-phosphate NAD? 
oxidoreductase; G6PDH; E.C. 1.1.1.49): G6PDH was assayed by the 
method of Shonk and Boxer (1964). The reaction mixture, in a total volume of 
3 ml, contained 50 mM Tris-HCl, pH 7.4, 10 i^ moles MgCb, 5 )imoles glucose-
6-phosphate, 0.24 fimoles NADP^, and 0.6-1.2 mg protein. The activity was 
measured by monitoring the glucose-6-phosphate dependent reduction of 
NADP^ to NADPH for 5 min. at 340 nm. 
(iv) Malic enzyme (L-Malate : NAD? oxidoreductase; ME; E.C. 1.1.1.40): ME 
was assayed by the method of Ochoe et al. (1948). The reaction mixture, in a 
total volume of 3 ml, contained 33 mM Tris-HCl, pH 7.4, 10 jiimoles MnCb, 5 
Hmoles L-malic acid (pH adjusted to 7.4), 0.24 |imoles NADP' and 0.6-1.2 mg 
protein. The activity was measured by monitoring the malic acid dependent 
reduction of NADP"^  to NADPH for 5 min at 340 nm, 
(v) Giucose-6-phosphatase (D-glucose-6-phosphate phosphohydrolase; G6Pase; 
E.C. 3.1.3.9): G6Pase was assayed according to the method of Shull ei al. 
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(1956). The reaction mixture, in a total volume of 1.5 ml, contained 33 mM 
Tris-HCl, pH 7.4, 10 nmoles MgCb, 10 [amoles glucose-6-phosphate and 1-2 
0 
mg protein. The reaction was carried out for 60 min at 37 C and stopped with 1 
ml of 10% TCA after 60 min. The samples were centrifuged at 4000 rpm (Remi 
Centrifuge, India) and inorganic phosphate liberated was determined in the 
protein free supematant by the method of Tausky and Shorr (1953) 
(vi) Fructose-l,6-bisphosphatase(D-fructose-l-6-diphosphate-l-
phosphohydrolase; FBPase; E.C. 3.1.3.11); It was assayed by the method of 
Freedland and Harper (1959). The reaction mixture, in a total volume of 1 5 ml, 
contained 33 mM Tris-HCl, pH 7.4, 10 fimoles MgCb, 12 fjmoles cysteine-HCl, 
10 [imoles fructose 1,6-diphosphate and 0.6-0.8 mg protein The reaction was 
carried out for 60 mm at 37 C and then stopped by addition of 1.0 ml of 10% 
TCA. The samples were centrifuged at 4000 rpm (Remi Centrifuge, India) and 
the inorganic phosphate released was determined in protein free supernatant by 
the method of Tausky and Shorr (1953). 
(b) Basolateral membrane (BLM) and lysosomal marker enzymes: 
(i) Na*-K* ATPase (E.C. 3.6.U): The activity of Na -^K^ ATPase was assayed as 
described by Konkel et al. (1986) in cortical and medullary homogenates 
Enzyme preparation (35-45 \ig protein) was incubated for 15 min at 37 "C in 
1.5 ml solution containing 4.8 mM ATP, 120 mM NaCl, 24 mM KCl, 7 2 mM 
MgSOa and 48 mM Tris-HCl, pH 7.6. The reaction was terminated by addition 
of 0.3 ml of 30% TCA and the Pi released was determined by the method of 
Tausky and Shorr (1953). The assay was then done in presence of 1 2 mM 
ouabain. The difference in ATPase activity without or with 1.2 mM ouabain is 
taken as a measure of Na -^K^ ATPase (Dousa, 1970). 
(ii) Acid phosphatase (AcidPase, E.C. 3.1.3.2): The activity of acid phosphatase 
was determined in cortical and medullary homogenates by the method of Verjee 
(1969). The reaction mixture of contained 2.4 ml of 0 05 M sodium acetate, pH 
4.5, and 100 ^l homogenate (35-40 ^g protein) The reaction was started by the 
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addition of 0 5 ml of 4 8 mM p-nitrophenyl phosphate (final concentration 0 8 
mM), incubated for 15 min at 30 "^C and then stopped by adding 2 ml of 2 N 
NaOH A calibration curve of p-nitrophenol (0 05-0 4 ^moles) was prepared 
simultaneously The yellow colour developed was read at 405 nm against a 
reagent blank 
(c) Marker enzymes of bi*ush border membrane: These enzymes were assayed in 
cortical and medullary homogenates and BBMV Aliquots of homogenates and 
BBMV were diluted with 10 mM Tris-HCl buffer, pH 7 5, to obtain suitable 
protein concentration 
(i) Alkaline phosphatase (AP, E.C. 3.1 J.l): The activity of AP in homogenates 
and BBM was determined by the method of Shah et al (1979) as modified by 
Kempson et al (1979) The reaction mixture contained 1 4 ml assay buffer (SS 
mM glycine, 36 mM NaCl and 45 mM NaOH, pH 10 5) and 100 \i.\ homogenate 
or BBM (10-25 \ig protein for homogenate and 4-8 ng for BBM) The reaction 
was started by adding 15 \i\ of 0 6 M p-nitrophenyl phosphate (final 
0 
concentration 6 mM) and incubated at 30 C for the required time (5-20 mm ) 
The reaction was stopped by addition of 50 \i\ of 5 N NaOH A calibration curve 
was prepared simultaneously by using known amounts of p-nitrophenol (0 01-
0 2 ^moles) The yellow colour was read at 405 nm against a reagent blank 
(ii) Y'GIutamyl transferase (GGTase, E.C. 2.3.2.2): The activity of GGTase in 
BBM or cortical and medullary homogenates was determined according to the 
method of Glossmann and Neville (1972) The reaction was started by addition 
of 100 \i\ homogenate or BBM (containing 15-25 i^g protein for homogenate or 
2-5 ng for BBM) to 1 9 ml substrate buffer (20 mM MgCb, 2 mM y-glutamyl p-
nitroanilide, 4 mM glycylglycine, 100 mM Tris base, pH 8 2) and incubated in a 
0 
shaking water bath at 37 C for the required time (3-15 mm ) The reaction was 
stopped by adding 100 nl of 15 M acetic acid A calibration curve of known 
amounts of p-nitroaniline (0 025-0 2 jamoles) was prepared simultaneously The 
yellow colour obtained was read at 405 nm against a reagent blank 
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(iii) Maltase (Mlt, E.C. 3.2.1.20): The enzyme was assayed by the method of 
Dahlqvist (1964). This is a two step method, which consists of (i) incubating the 
BBMV or homogenate with maUose to generate glucose and (ii) measunng 
glucose. The reaction was started by addition of 100 \i\ enzyme (15-20 ^g 
protein for homogenate and 3-5 ^g for BBMV) to 100 [il substrate buffer (0.1 M 
maleic acid, 0.15 N NaOH, 56 mM maUose, pH 6.0). The reaction mixture was 
incubated at 37 °C at room temperature for 15 min. To this, 3.0 ml TGO reagent 
(0.5 M Tris-HCl, pH 7.0, 0.1% peroxidase, 25% Triton X-100 in 95% ethanol, 
0.4% o-dianisidine in 50% ethanol) was added and incubated at 37 "C for 60 
min. A calibration curve of standard glucose (0.1-1 p.mole) was also prepared 
simultaneously. The colour obtained was read at 420 nm 
(iv) L-Leucine aminopeptidase (LAP, E.C. 3.4.11.2): This enzyme was assayed by 
the method of Goldman et al (1976). The reaction was started by the addition of 
100 \i\ cortical or medullary homogenate or BBM (40-60 p.g protein for 
homogenate and 10-15 |j,g for BBM) to 1.9 ml substrate buffer (50 mM sodium 
phosphate buffer, 0.33 mM L-leucine p-nitroanihde, pH 7.2) and incubated at 25 
"C for the required time (15-30 min). The reaction was stopped with 100 l^i of 
15 M acetic acid. A calibration curve of standard p-nitroaniline (0.025-0.20 
^moles) was also prepared simultaneously. The yellow color obtained was read 
at 405 nm against a reagent blank. 
(d) Free radical scavanging enzymes: Kidney tissues (cortex and medulla) were 
homogenised (10% w/v) in chilled 0.15 M KCl and centrifuged at 10,000 rpm 
for 15 min at 4 "C. The supernatant was used for enzyme assays. 
(i) Superoxide dismutase (SOD, EC 1.15.1.1) It was assayed by the method of 
Marklund and Marklund (1974). To 0.08 ml of supernatant 2.82 ml of 0.05 mM 
Tris-succinate buffer, pH 8.2 was added, mixed well and incubated at 25 "C for 
20 min. The reaction was started by adding 0.1 ml of 8 mM pyrogallol solution 
Change in absorbance per minute was immediately recorded for the initial 
3 minutes at 420 nm A reference set, containing 0.08 ml distilled water instead 
of supernatant solution, was also run simultaneously. 
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(ii) Catalase (HiOj: H2O2 Oxidoreductase, E.C 1.11.1.6): This enzyme was 
assayed according to the method of Beers and Siezer (1952) After dilution of 
0 34 ml of 30% H2O2 (30 mM) to 100 ml with 50 mM sodium phosphate buffer 
(pH 7 0), 0 5 ml of supernatant was mixed with 3 0 ml of H^Oa-phosphate 
buffer The decrease in absorbance at 240 nm was immediately noted after every 
30 seconds for 3 minutes at 240 nm Enzyme activity was calculated using the 
molar extinction coefficient of H2O2 (436 M'' cm'' at 240 nm) 
•. Transport 
Measurment of inorganic phosphate ("Pi) uptake in BBMVs were was carried 
out at 25 V by the rapid filtration technique as described by Yusufi el al (1994) 
either in the presence or absence of a Na-gradient Uptake was initiated by 
addition of 30 ^1 incubation medium (100 mM NaCl/KCl, 5 mM Tns-HEPES, 
pH 7 5, 5 mM K2HPO4 and radioactive substrate C'^ Pi) to 15 (al BBM suspension 
(50-100 (ig protein) and incubated for the desired time intervals (see "Results") 
At the end of the incubation period the uptake was stopped by rapid addition of 
3 ml ice cold solution (delivered by a Cornwall Syringe type pipette) containmg 
135 mM NaCl, 10 mM sodium arsenate, 5 mM Tns-HEPES, pH 7 5, and filtered 
immediately through 0 45 |im DAWP millipore filters and washed 3 times with 
the same ice cold solution Correction for non-specific binding to filters was 
made by subtracting fi-om all data the value of the corresponding blank obtained 
by filtration of incubation medium without vesicles The radioactivity 
in the dried filters was measured by liquid scintillation counting (Pharmacia, 
Sweden) with 10 ml scintillation fluid ("Cocktail-T", SRL' hidia) 
Total Sulfliydryl Groups : 
Total SH groups were determined by the method of Sedlak and Lindsay (1968) 
Tissues from rat kidneys were homogenized in chilled 0 15 M KCl and the 
volume was adjusted to give 10% (w/v) homogenates To 0 1 ml of tissue 
homogenate 1 5 ml of 0 2 M Tns-HCl (pH 8 2) containing 0 2 M EDTA was 
added The reaction was started by addition of 0 1 ml DTNB (0 01 M) After 
mixing, the reaction was made to 10 ml with 8 3 ml of absolute methanol The 
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reaction mixture was centrifuged at 6,000 rpm for 5 minutes in cold The 
absorbance of the clear supernatant was read at 412 nm. A calibration curve with 
different amounts of glutathione (20-160 nmoles) was constructed by the same 
procedure as described above and used to calculate the total SH groups in the 
samples. 
8. Lipid Peroxidation: 
Lipid peroxidation in kidney homogenates was determined 
spectrophotometrically by the method of Ohkawa et al. (1979) To 0 1 ml of 
tissue homogenate (10% in 0.15 M KCl) 1.5 ml of 20% acetic acid, 0.2 ml of 
8% SDS, 0.7 ml distilled water and 1.5 ml of 0.8% thiobarbituric acid were 
added and after mixing incubated at 95 C for 20 min. After cooling to room 
temperature and centrifiigation at 4000 rpm for 10 min the absorbance of the 
supernatant was read at 532 nm against a reagent blank. 
Protein Estimation 
Protein was measured by the method of Lowry et al. (1951) with minor 
modifications as described by Yusufi et al. (1983). The samples were made to 
0.8 ml with 0.5% SDS. Then 2 ml alkaline copper reagent was added and after 
10 min incubation at room temperature (RT) 0.2 ml Folin's reagent (1 N) was 
added with brisk shaking and incubated for 30 min at RT. A calibration curve of 
standard BSA (5-80 fig) was prepared simultaneously. The blue colour obtained 
was read at 660 nm. 
Statistical Analysis: 
Unless specified, all experiments were repeated at least four or five times to 
document reproducibility. All data are expressed as Mean±SEM When 
appropriate, statistical evaluation was used and conducted employing group t-
test. 
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RESULTS 
1. Effect of CDDP on; 
(i) Body weight and food intake 
The administration of a single dose of CDDP (6mg/kg body weight) resulted in 
significant changes in the body weight and food intake of rats compared to saline 
treated controls (Table 1). Body weights of animals treated with CDDP decreased on 
day 2 after administration of the drug. Food intake in the treated rats also showed 
significant decline after 2 days, while after 4 days the animals almost completely 
stopped eating and showed maximum weight loss. However, 6 days after treatment the 
animals showed significant recovery in food intake and after 8 days they started gaining 
weight in a manner similar to the saline treated control rats. After 16 days the animals 
showed complete recovery in food intake and body weight compared to their respective 
controls. 
(ii) Urine parameters and GFR 
CDDP treatment resulted in changes in urine flow rate, proteinuria, glucosuria 
and GFR (Table 1). Urine flow rate was increased 2 days after treatment with the 
maximum increase observed on day 4 and its level reached normal value on day 16 
compared to the saline treated controls. CDDP treatment also resuUed in increased 
glucose excretion and significant non-specific proteinuria. Maximum enhancement in 
glucose excretion was observed on day 4, which recovered to normal value on day 16 
compared to the control group. 
Glomerular filtration rate (GFR), as estimated by the clearance of endogenous 
creatinine, fell in the CDDP treated group with maximum decrease observed on day 4 
(0.108 ml/min/lOOg body weight) when compared to the control group (0.36 
ml/min/lOOg body weight). GFR recovered to normal value 16 days after administration 
of CDDP. No significant change in all the urine parameters and GFR at all the time 
points was observed in saline treated control rats. 
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Table 1: Effect of CDDP treatment on body weight, food intake, urine flow rate, 
urinary protein and glucose. 
0 
Body weight (g) 
Control 200±10 
CDDP 205±11 
Food Intake (g/day) 
Control 20+1 
CDDP 20.5±0.95 
Urine flow rate (ml/day) 
Control 15.1±0.5 
CDDP 15.2±0.6 
Duration of treatment (days) 
2 4 8 
205±11 
189±9* 
21.5±0.9 
5±0.3* 
15.510.9 
32.4+1.5* 
Protein (mg/mmole creatinine) 
Control 2.3±0.15 
CDDP 2.35±0.13 
Glucose(nig/nig creatinine) 
Control 15.8±0.75 
CDDP 15.5±0.8 
2.28±0.13 
10.8±1.1* 
15.5+0.7 
27+1.6* 
Creatinine clearence (ml/min/lOOg body we 
Control 
CDDP 
0.345+0.013 
0.2210.009* 
210111 
181+8* 
2111 
2.510.15* 
15.210.8 
34.811.7* 
2.3110.1 
17.211.3* 
1610.8 
53+2,4* 
ight) 
0.3610.012 
0.10810.008* 
225112 
202+9* 
21.511 
20.5i l . l t 
15.410.7 
22.411.0* 
2.2410.11 
5.411.1* 
15.410.65 
3011.9* 
0.35510.011 
0.23410.01* 
16 
235113 
23011It 
20.511.1 
21l0.95t 
1510.6 
14.8+0.5t 
2.3510.13 
2.3+0.16t 
16.210.82 
16.8+0.9t 
0.3510.01 
0.37l0.01t 
Results are mean 1SEM of four different experiments. 
* significantly different at p< 0.01 as compared to day 0. 
t insignificantly different at p<0.01 as compared to saline-treated controls. 
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(iii) Blood chemistry 
Significant changes were seen in serum levels of creatinine, BUN, cholesterol 
(CH), phospholipids (PL) and inorganic phosphate (Pi) after CDDP treatment (Table 2). 
Serum creatinine level was increased significantly on day 2 while maximum 
enhancement was recorded on day 4 (1.41 mg/dl) compared to the control group (0.54 
mg/dl). The magnitude of increase was less on day 8 (0.832 mg/dl) when compared to 
the respective controls; this reached normal value 16 days after treatment. Saline-treated 
control group did not show any significant decrease in serum creatinine levels during 
the course of the experiment. 
In addition to serum creatinine, renal fiinction was also evaluated by 
determination of BUN level. CDDP-treated animals showed elevated BUN level 
compared to saline-treated controls. Elevation in the BUN level was first noted on day 2 
while day 4 showed maximum elevation; recovery was noticed on day 8 and after day 
16 the BUN level had recovered to the control values. In CDDP treated rats significant 
increase occurred in serum concentrations of CL and PL while there was a decrease in 
the Pi level. The magnitude of change was greatest on day 4 and on day 16 recovery to 
normal values was noted in the levels of CL, PL and Pi compared to their respective 
saline-treated controls. Saline-treated control animals demonstrated relatively constant 
values for BUN, CL, PL and Pi on all days of the experiment. 
2. Effect of CDDP on the activities of several enzymes of carbohydrate 
metabolism 
The major fiinction of kidney is the reabsorption of various ions and solutes which 
depends on the continuous energy supply as ATP. The generation of ATP is due to the 
contribution of various metabolic pathways including glycolysis and oxidative 
metabolism. 
The effect of CDDP treatment on enzymes of various metabolic pathways was 
determined 2, 4, 8 and 16 days after administration of the drug. The activities of various 
50 
Table 2: Effect of CDDP treatment on the serum parameters. 
2 
Sreum creatinine mg/dl) 
Control 0.55±0.016 
CDDP 0.7410.3* 
BUN (mg/dl) 
Control 20.5+0.89 
CDDP 26±1* 
Cholesterol (mg/dl) 
Control 51±1.8 
CDDP 63.2±2* 
Phospholipid (mg/dl) 
Control 0.49+0.023 
CDDP 0.65210.028' 
Phosphate(^moIes/mi) 
Control 2.4810.17 
CDDP 2.2610.15* 
Duration of treatment (days) 
4 8 
0.5410.012 
1.4110.15* 
2111.3 
4712.5* 
50.812 
8213* 
0.496+0.026 
* 0.75910.038* 
2.4510.15 
1.510.096* 
0.5210.015 
0.83210.05* 
19.810.1 
30.512.05* 
5311.6 
65.712.3* 
0.4810.024 
0.69610.031* 
2.4710.13 
1.8410.11* 
16 
0.510.013 
0.5110.015t 
2011.5 
2111.lt 
5412.2 
5512t 
0.510.025 
0.5210.026t 
2.510.18 
2.4910,16t 
Results are mean ± SEM of four different experiments. 
* significantly different at p<0.01 as compared to saline treated control. 
t insignificantly different from saline-treated control group. 
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metabolic enzymes e.g. LDH (glycolysis), MDH (TCA cycle), G6Pase and FBPase 
(gluconeogenesis), G6PDH (HMP-shunt pathway) and ME (an enzyme of biosynthetic 
importance) were determined in the homogenates of cortex and medulla. The results are 
summarized in Tables 3- 8 and Figs 1-6. Administration of single dose of CDDP caused 
an increase in LDH activity in both cortex and medulla. LDH activity showed 
significant increase in cortex (20%) and in medulla (23%) after 2 days with maximum 
enhancement seen after day 4 (cortex 31%, medulla 39%). Some signs of recovery were 
observed after day 8 while complete recovery took place 16 days after CDDP treatment 
compared to the saHne-treated controls (Table 3; Figl). Effects of CDDP treatment on 
MDH, an enzyme of the TCA cycle are shown in Table 4 and Fig 2. A decrease in 
MDH activity in both cortex and medulla was observed on all days except on day 16. 
The inter group comparison showed a maximum decrease in the activity 4 days after 
treatment (cortex 26%, medulla 38%) compared to the respective controls. 
The effect of CDDP treatment was also determined on the activities of 
gluconeogenic enzymes G6Pase and FBPase (Tables 5,6; Figs 3,4). The activities of 
G6Pase and FBPase were markedly and time dependently reduced, amounting to 25% 
and 23% after 2 days and 32% and 35% after 4 days of treatment in medulla while in 
the cortex they were reduced by 17% and 15% after day 2 and 23% and 24% after day 
4. After day 8 the activities of G6Pase and FBPase showed recovery in both cortex and 
medulla compared to day 4 while on day 16 complete recovery was noted. A 
comparison showed that the activities of these two enzymes in the medulla were 
effected to a greater extent than in the cortex after CDDP treatment. 
The effect of CDDP administration on the activities of G6PDH and ME is shown 
in Tables 7 and 8 and Figs 5 and 6. The activity of medullary G6PDH significantly and 
time dependently decreased 2 and 4 days after CDDP administration. After 8 days of 
treatment the activity began to recover and reached normal value after 16 days. G6PDH 
activity in the cortex showed a similar trend as in medulla. The activity of G6PDH in 
the homogenates of both cortex (29%) and medulla (38%) showed maximum decrease 4 
days after CDDP administration but recovered to normal values after day 16 compared 
to the saline treated control group. However, CDDP treatment resulted in an increase in 
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Table 3: Effect of CDDP treatment on the activity of lactate dehydrogenase in the 
homogenates of whole cortex and medulla. 
Duration of treatment (days) 
Groups 2 4 8 16 
Cortex 
Control 25±0.6 23.2±0.58 24±0.55 23±0.5 
CDDP 30±0.8* 30.4±0.9* 29.5±0.7* 24±0.5t 
(20%) (31%) (23%) 
Medulla 
Control 32±0.8 35±0.75 31.7±0.6 34±0.65 
CDDP 40.3±1.1* 48.7±1.3* 40.6±1.4* 35±0.8t 
(23%) (39%) (29%) 
Specific activity expressed as (a.moles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different fi-om saline-treated control group. 
Values in parenthesis represent percent increase from respective controls 
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Fig 1: Specific activity of lactate dehydrogenase (LDH) in the homogenates of 
cortex and medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
*significantly different from saline-treated control at p<0 01 
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Table 4: Effect of CDDP treatment on the activity of malate dehydrogenase in the 
homogenates of whole cortex and medulla. 
Groups 
Duration of treatment (days) 
2 4 8 16 
Cortex 
Control 
CDDP 
108±2.5 
90.7±1.3* 
112±2.8 
83±1.8* 
109±3 
89.4±2* 
111±3 
110±2.5t 
(16%) (26%) (18%) 
Medulla 
Control 
CDDP 
100±2.8 
77±1.5* 
95.8±2.5 
6^2" 
102±3 108±2.9 
76.5±1.8* 109±2.5t 
(23%) (38%) (25%) 
Specific activity expressed as |imoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 2: Specific activity of malate dehydrogenase (MDH) in the homogenates 
of cortex and medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
•significantly different from saline-treated control at p<0 01 
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Table 5: Effect of CDDP treatment on the activity of glucose-6-phosphatase in the 
homogenates of whole cortex and medulla. 
Groups 
Duration of treatment (days) 
2 4 8 16 
Cortex 
Control 
CDDP 
0.35±0.01 
0.29±0.009* 
0.3±0.012 
0.231±0.008* 
0.32±0.011 
0.269±0.009* 
0.38±0.01 
0.35±0.011t 
(17%) (23%) (16%) 
Medulla 
Control 
CDDP 
0.212±0.01 0.240±0.011 0.229±0.009 0.23±0.01 
0.159±0.007* 0.163±0.005* 0.171±0.004 0.225±0.008t 
(25%) (32%) (25%) 
Specific activity expressed as |imoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 3: Specific activity of glucose-6-phosphate (G6Pase) in the homogenates 
of cortex and medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0 01 
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Table 6: Effect of CDDP treatment on the activity of fmctosel,6 bisphosphatase in the 
homogenates of whole cortex and medulla. 
Groups 
Duration of treatment (days) 
4 8 16 
Cortex 
Control 
CDDP 
0.81±0.025 
0.688±0.0r 
0.83±0.028 0.795±0.023 0.8±0.03 
0.639±0.015* 0.692±0.018* 0.78±0.02t 
(15%) (23%) (13%) 
Medulla 
Control 
CDDP 
0.7±0.02 
0.539±0.01* 
0.71±0.023 
0.461±0.008* 
0.72±0.022 
0.511±0.009* 
0.75±0.018 
0.71±0.013 
(23%) (35%) (29%) 
Specific activity expressed as |amoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 4: Specific activity of fructose 1,6 bisphosphate (FBPase) in the homogenates 
of cortex and medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
*significantly different from saline-treated control at p<0 01 
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Table 7: Effect of CDDP treatment on the activity of glucose-6-phosphate 
dehydrogenase in the homogenates of whole cortex and medulla. 
Groups 
Duration of treatment (days) 
2 4 8 16 
Cortex 
Control 
CDDP 
1.5±0.04 1.45±0.05 1.53±0.045 1.5±0.05 
1.27±0.03* 1.03±0.4* 1.24±0.033* 1.51±0.04t 
(15.3%) (29%) (19%) 
Medulla 
Control 
CDDP 
0.91±0.04 0.85±0.042 0.943±0.038 0.9±0.034 
0.7U0.025* 0.527±0.03* 0.705±0.026* 0.92±0.28t 
(22%) (38%) (25%) 
Specific activity expressed as |imoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 5: Specific activity of glucose-6-phosphate dehydrogenase (G6PDH) in 
the homogenates of cortex and medulla from control and CDDP-treated 
rats 
Each bar represents (mean±SEM) of four different preparations 
*significantly different from saline-treated control at p<0 01 
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Table 8: Effect of CDDP treatment on the activity of malic enzyme in the homogenates 
of whole cortex and medulla. 
Duration of treatment (days) 
Groups 2 4 8 16 
Cortex 
Control 13.8±0.4 13.6±0.38 14±0.42 13.5±0.35 
CDDP I6.6±0.5* 17.6±0.6* 17.1±0.55* 13.3±0.37t 
(20%) (29%) (22%) 
Medulla 
Control 8.56±0.28 9.14±0.3 8.77±0.35 8.8±0.3 
CDDP 10.87±0.38* 12.8±0.45* 11.4±0.48* 8.6±0.28t 
(27%) (40%) (30%) 
Specific activity expressed as ^moles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent increase from respective controls 
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Fig 6: Specific activity of malic enzyme (ME) in the homogenates of cortex and 
medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
*significantly different from salme-treated control at p<0 01 
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the activity of ME in both cortex and medulla with the increase being greater in medulla 
than cortex. The activity of medullary and cortical ME showed a maximum increase of 
40% and 29% after day 4 of CDDP treatment. Activity begins to recover after day 8 and 
reaches normal value on day 16. The pattern of change in the activity of ME was, 
therefore, the same as that of G6PDH. 
3. Effect of CDDP on the activities of BLM and lysosomal marker enzymes 
The activity of Na*-K* ATPase, the marker enzyme of basolateral membrane 
(BLM), decreased significantly in cortex as well as medulla after CDDP treatment; the 
decrease in activity was more profound in medulla than cortex (Table 9; Fig 7). After 
day 4 of treatment Na" -^K^ATPase activity in both cortex (32%) and medulla (38%) 
showed maximum decrease. The magnitude of decrease was less after day 8, while after 
day 16 it showed complete recovery both in cortex and medulla as compared to the 
control groups. 
The activity of lysosomal enzyme AcidPase was also determined in the 
homogenates of cortex and medulla (Table 10; Fig 8). The activity increased 
significantly at all time points except after day 16 when complete recovery was gained 
compared to the respective controls. The increase in activity, on different days after 
CDDP treatment, in cortex and medulla is: 2 days- 20%, 26%; 4 days- 28%, 44%; 8 
days- 22%, 29% respectively. 
4. Effect of CDDP on the activities of BBM-marker enzymes in; 
(i) Homogenates of cortex and medulla 
The specific activities of BBM marker enzymes decreased significantly in the 
homogenates of both cortex and medulla 2, 4, 8, and 16 days after administration of 
CDDP compared to the respective controls (Tables 11-14; Figs 9-12). The maximum 
change in the activities of all the enzymes was after day 4 and after 16 days complete 
recovery was gained compared to the control groups. The magnitude of change in the 
enzyme activities at all the time points, except after day 16, was found to be greater in 
the homogenate of medulla than whole cortex. 
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Table 9: Effect of CDDP treatment on the activity of Na^ -K"" ATPase in the 
homogenates of whole cortex and medulla. 
Duration of treatment (days) 
Groups 2 4 8 16 
Cortex 
Control 
CDDP 
Medulla 
Control 
CDDP 
4.95±0.14 
4.3±0.09* 
(19%) 
4.2±0.086 
3.36±0.07* 
5±0.12 
3.4±0.1* 
(32%) 
4.4±0.09 
2.73±0.06* 
4.8±0.13 
3.7±0.09* 
(23%) 
4.12±0.09: 
3.09±0.07: 
5.1±0.11 
5.0±0.1t 
4.36±0.085 
(20%) (38%) (25%) 
Specific activity expressed as (imoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
66 
Cortex 
fc 
1 o 
a a. 
S 
-g 
•^  
£ 
^ 
& • 
? 
• = 
^ 
o 
« o 
SI C/3 
56 1 
48 -
4 
32 -
24 -
1 6 ^ 
08 -
0 J 
^^ ^ 
^^ 
g Control 
B CDDP 
Days 
Medulla 
o 
o. 
so 
I 
i. 
(Zl 
[3 Control 
B CDDP 
Fig 7: Specific activity of Na'^ -K* ATPase in the homogenates of cortex and medulla 
from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
*significantly different from saline-treated control at p<0 01 
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Table 10: Effect of CDDP treatment on the activity of acid phosphatase in the 
homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
CDDP 
Medulla 
Control 
CDDP 
Duration of treatment (days) 
2 4 8 
11.5±0.19 
13.8±0.23* 
(20%) 
7±0.16 
8.82±0.18* 
12.3±0.18 
15.8±0.28* 
(28%) 
6.5±0.15 
9.36±0.22* 
10.9±0.17 
13.3±0.22* 
(22%) 
7.3±0.15 
9.42±0.24* 
16 
10.3±0.15 
10.5±0.14t 
6.8±0.11 
6.9±0.11t 
(26%) (44%) (29%) 
Specific activity expressed as i^moles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent increase from respective controls 
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Fig 8: Specific activity of acid phosphatase (AcidPase) in the homogenates of cortex 
and medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0 01 
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Table 11: Effect of CDDP treatment on the activity of alkaline phosphatase in the 
homogenates of whole cortex and medulla 
Duration of treatment (days) 
Groups 2 4 8 16 
15±0.6 14.9±0.4 14.5±0.3 
9.75±0.2* 12.5±0.26* 14.3±0.22t 
Cortex 
Control 
CDDP 
14.2±0.5 
11.5±0.3* 
(19%) (35%) (16.1%) 
Medulla 
Control 
CDDP 
10.5±0.4 
7.67±0.3* 
11±0.45 10.7±0.4 11.5±0.46 
5.39±0.25* 7.17±0.35* ll±0.4t 
(27%) (51%) (33%) 
Specific activity expressed as ^moles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 9: Specific activity of alkaline phosphatase (AP) in the homogenates of cortex and 
medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0 01 
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Table 12: Effect of CDDP treatment on the activity of y-glutamyl transferase in the 
homogenates of whole cortex and medulla. 
Duration of treatment (days) 
Groups 2 4 8 16 
Cortex 
Control 37±1.5 35.5±1.6 36.2±1.4 34.5±1.3 
CDDP 27±1.2* 19.9±1.3* 27.2±1* 34.8±lt 
(27%) (44%) (25%) 
Medulla 
Control 
CDDP 
25±1 
16.2±0.9* 
26±1.1 23.8±1.2 24.5±1 
9.9±0.7* 14.5±1* 25±0.9t 
(35%) (62%) (39%) 
Specific activity expressed as fimoles/mg protein/hr 
Resuks are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig lOrSpecific activity of y-glutamyl transpeptidase (GGTase) in the homogenates of 
cortex and medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0 01 
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Table 13: Effect of CDDP treatment on the activity of maltase in the homogenates of 
whole cortex and medulla. 
Duration of treatment (days) 
Groups 2 4 8 16 
Cortex 
Control 19.5±0.7 19.8±0.8 20±0.6 19±0.5 
CDDP 15.4±0.4* 12.6±0.3* 16.2±0.4* 18.8±0.3t 
(21%) (36%) (19%) 
Medulla 
Control 14.3±0.6 14.8±0.7 15.2±0.5 14.3±0.35 
CDDP 10.1±0.5* 6.8±0.4* 9.9±0.4* 14±0.3t 
(29%) (54%) (35%) 
Specific activity expressed as M-moles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 11: Specific activity of maltase (Mlt) in the homogenates of cortex and medulla from 
control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0 01 
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Table 14: Effect of CDDP treatment on the activity of leucine aminopeptidase in the 
homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
CDDP 
Duration of treatment (days) 
2 4 8 
1.68±0.06 1.7±0.075 1.62±0.05 
1.24±0.04* 1.0±0.02* 1.27±0.04* 
16 
1.74±0.05 
1.69±0.03t 
(26%) (41%) (22%) 
Medulla 
Control 
CDDP 
1.28±0.04 1.2±0.05 1.25±0.048 1.3±0.042 
0.857±0.02* 0.507±0.013* 0.775±0.03* 1.32±0.028t 
(38.3%) (75%) (56%) 
Specific activity expressed as |imoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 12: Specific activity of leucine aminopeptidase (LAP) in the homogenates 
of cortex and medulla from control and CDDP-treated rats 
Each bar represents (mean±SEM) of four different preparations 
*significantly different from saline-treated control at p<0 01 
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(ii) BBM 
After 2, 4, 8 and 16 days of administration of a single a dose of CDDP the 
kidneys were harvested from the animals. Brush border membrane was prepared from 
the whole cortex of CDDP and saline treated control rats by differential precipitation 
with MgClj. The effect of CDDP administration was determined on marker enzymes of 
BBM and basolateral membrane. Relative enrichment of the BBM preparation was 
documented enzymatically using brush border markers such as alkaline phosphatase 
(AP), y-glutamyl transferase (GGTase), leucine aminopeptidase (LAP) and maltase 
(Mlt) and the basolateral membrane marker enzyme, Na^-K^ATPase. The results 
indicated that membrane preparations were several fold purified since BBM marker 
enzymes showed marked enrichment (9-11 fold) in the BBM over the homogenate. The 
activity of Na -^K'^ ATPase was not enriched in BBM preparations as compared to 
cortical homogenates. 
The specific activities of AP, GGTase, Mlt and LAP were significantly but 
differentially decreased in BBM from CDDP-treated rats compared to the specific 
activities of these enzymes in BBM prepared from control rats (Table 15; Figs 13, 14). 
Significant decline was observed after day 2 for all enzymes. The maximum decrease in 
the activities of AP, GGTase, Mlt and LAP occurred after day 4 of administration of 
CDDP indicating greater damage. The activities of these marker enzymes after day 8 
also showed decline; however, the extent of decrease was less compared to day 4. 
Complete recovery in the specific activities of all enzymes was observed in CDDP 
treated group after day 16 compared to the control group. Thus all four enzymes 
showed maximum decrease in specific activities on day 4 and recovered to control 
values 16 days after administration of CDDP. 
Since the decrease in the activities of AP, GGTase, Mlt and LAP in BBM from 
CDDP-treated rats relative to controls was maximum on day 4 the kinetic parameters of 
these enzymes were determined using BBM from animals administered CDDP four 
days earlier. Apparent Km and Vmax values were determined graphically from double 
reciprocal plots (Table 16; Figs 15-18). BBM preparations from control and treated rats 
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Table 15: Effect of CDDP treatment on the activities of alkaline phosphatase (AP), y-
glutamyl transferase (GGTase), maltase (Mlt) and leucine aminopeptidase (LAP) in 
BBMVs isolated from whole cortex 
Groups 
AP 
Control 
CDDP 
GGTase 
Control 
CDDP 
Mlt 
Control 
CDDP 
LAP 
Control 
CDDP 
2 
138±5 
96.5±4* 
(30%) 
360±9.8 
220±9* 
(39%) 
266±10 
183±9* 
(31%) 
18±1.1 
11.3±0.6* 
(37%) 
Duration of treatment (days) 
4 8 
142±7 
72.4±5* 
(49%) 
366± 11 
158±8.4* 
(57%) 
271±11 
141±9.5* 
(48%) 
17.4±1 
8±0.9* 
(54%) 
140±6 
103.6±3* 
(26%) 
362±10 
235±9.5* 
(35%) 
268±9 
198±8.9* 
(26%) 
17.8±1.2 
12.1±1* 
(32%) 
16 
143±4 
141±4t 
368 ±10 
365±9t 
273±9 
270±8t 
18.3±1 
18±0.9t 
Specific activity expressed as |imoles/mg protein/hr 
Resuhs are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Fig 13: Specific activity of (A) alkaline phosphatase (AP) and (B) y-glutamyl transferase 
(GGTase) in the BBMVs isolated from whole cortex of CDDP treated and control 
rats 
Each bar represents results (mean± SEM) of four different preparations 
*significantly different from saline treated control at p<0 01 
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Fig 14: Specific activity of (A) maltase (Mlt) and (B) leucine aminopeptidase (LAP) in 
the BBMVs isolated from whole cortex of CDDP treated and control rats 
Each bar represents results (mean± SEM) of four different preparations 
*significantly different from saline treated control at p<0 01 
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Table 16: Effect of CDDP treatment on kinetic parameters of BBMV alkaline 
phosphatase (AP), y-glutamyl transferase (GGTase), maltase (Mlt) and leucine 
aminopeptidase (LAP). 
AP 
Control 
CDDP 
GGTase 
Control 
CDDP 
Mlt 
Control 
CDDP 
LAP 
Control 
CDDP 
Vmax 
(^imoles/mg protein/hr) 
142.8±8 
75.6±5* 
280±12 
140±8* 
190±9 
111.8±7* 
18.5±1.4 
10.5±4.7* 
Km (xlO-^M) 
0.116±0.004 
0.119±0.003t 
0.88±0.006 
0.79±0.003t 
20±1.5 
20.4±1.8t 
0.36±0.005 
0.4±0.007t 
BBMV were prepared from whole cortex of rats 4 days after administration of CDDP or 
normal saline (control). 
Results are mean ± SEM of four different experiments. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
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Fig 15: Kinetics of alkaline phosphatase in BBMV from CDDP and control rats 
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Fig 16: Kinetics of y-glutamyl transferase in BBMV from CDDP and control rats 
(•)-control, (•)-CDDP. 
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were always tested on one experimental day under identical conditions. The results 
indicate that the decrease in enzyme activities is mainly due to a decrease in Vmax of 
the enzymes rather than due to changes in the Km values (Table 16). 
5. Effect of CPDP on Pi transport 
It is well known that toxic insult can cause alterations in renal functions mainly 
by affecting cellular metabolism of the FT and the structural integrity of its BBM. The 
effect of CDDP on Pi transport has not been studied in detail. The Pi is the chief 
contender to be involved in the restoration of the energy required for the transport 
across the BBM in the proximal tubule. In the present study the transport of Pi was 
determined in BBMV prepared from whole cortex of normal and CDDP treated 
animals. 
Animals were given a single a single dose of CDDP (treated) or saline (control) 
and the kidneys from control and CDDP treated rats were harvested 4 days later. 
BBMVs were prepared from whole cortex by Mg*^  precipitation technique as described 
in the "Methods" section. The transport of Pi was determined by microfiltration 
technique using ^^ Pi as radiotracer (see "Methods" for detail). The BBMVs were 
incubated with ^^ Pi at 37 °C for various times (5 s, 10s, 20s and 120 min) in the presence 
of 100 mM NaCl (Na^-gradient dependent) or 100 mM KCl (Na^-gradient 
independent). The Pi uptake was stopped by adding ice cold stop buffer (see Methods) 
and the solution was then passed through a 0.45 |im filter. The Pi uptake by BBMV was 
determined from the amount of radioactivity retained on the filters. The results showed 
a typical time course pattern of ^^ Pi uptake in the presence of Na^-gradient in BBMV 
prepared from control and CDDP treated rats (Table 17a). The initial uptake of ^^ Pi 
increased proportionally with the time of incubation (5-20 sec) and declined after 120 
min of incubation. However, the Na^-gradient dependent (Nao>Nai) transport of Pi was 
significantly reduced in CDDP treated rats determined at early time points (e.g. 5s, 10s, 
20s) compared to saline treated control rats. The uptake of Pi was, however, not 
significantly affected by toxic insult at equilibrium i.e. at 120 min. 
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Since it has been shown that nephrotoxins or ischemia cause damage to 
proximal tubular epithelia including the microvillar membrane and that the epithelia 
become leaky, the uptake of Pi was also determined in the absence of a Na'^ -gradient 
[NaCl replaced by KCl (Ko>Ki) in the incubation medium]. The uptake of ^^ Pi was 
greatly reduced in the absence of a Na^-gradient. The uptake of ^^ Pi was significantly 
more in the BBMV from CDDP treated rats compared to their respective saline treated 
controls (Table 17b). This indicates that CDDP causes alterations in the BBMVs to 
increase diffusional uptake capacity. However, the net uptake of ^^ Pi (Na^-gradient 
dependent-Na*-gradient independent) was reduced by -40% in BBMV from CDDP 
treated animals compared to the control group (Table 18). 
6. Protective effect of vitamin C before CDDP administration 
The results of the present studies indicate that CDDP administration caused 
alterations in the structure and fimction of proximal tubule. Vitamin C, an anti-oxidant, 
has been previously shown to have beneficial effect on the recovery of nephrotoxic 
ARF (Antunes and Takahashi, 1998). Considering this, the following experiment was 
designed to determine whether vitamin C pre-treatment could protect against CDDP 
induced damage to the kidney. The animals were injected intraperitonially with vitamin 
C (250 mg/kg body weight) 6 hr prior to administration of a single dose of CDDP. Four 
days after treatment the kidneys were harvested, homogenates and BBMV were 
prepared and following experiments were performed. Each experiment had four groups 
of rats: control, CDDP alone, vitamin C alone and vitamin C+CDDP. 
i) Serum creatinine and BUN 
The earlier results had shown that CDDP administration resulted in elevation of 
serum creatinine (Scr) and BUN levels that peaked on day 4 and fell to normal levels on 
day 16. The effect of vitamin C pre-treatment on CDDP induced nephrotoxicity was 
determined by measuring the levels of Scr and BUN 4 days after CDDP administration 
(Table 19). Pre-treatment with vitamin C resulted in significantly less enhancement in 
the levels of Scr (52%) and BUN (43%) than CDDP alone (Scr-156%, BUN-120%) 
compared to saline treated controls. However, rats treated with vitamin C alone showed 
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Table 17: 
(a): Effect of CDDP treatment on Na* gradient- dependent ^^ Pi uptake by BBMVs 
Group 
Control 
CDDP 
5 sec 
1055±40 
840.4±30* 
(20.4%) 
10 sec 
1400±60 
1080±48* 
(23%) 
20 sec 
2059±86 
1340±67* 
(35%) 
120 min 
365±18 
369±22t 
(b): Effect of CDDP on ^ P^i uptake by BBMVs in the absence of Na^ gradient (NaCl 
replaced by KCl) 
Group 
20 sec 120 min 
Control 
CDDP 
90.5±8 
144±12* 
(59%) 
287±15 
298±17t 
BBMV were prepared from whole cortex of rats 4 days after administration of CDDP or 
normal saline (control). 
Results are mean ± SEM of three different BBMV preparations. Uptake expressed as 
pmole/mg protein 
*significantly different from control at p<:0.05 or greater degree by group t-test. 
t insignificantly different from saline-treated control group 
Values in parenthesis represent percent change from respective saline-treated controls. 
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Table 18: Effect of CDDP treatment on net Na^  gradient dependent ^^ Pi uptake by 
BBMVs isolated from whole cortex. 
Groups 
Control 
CDDP 
Na^-gradient 
dependent 
(lOOmMNaCl) 
2059±86 
1340±67* 
Na^-gradient 
independent 
(lOOmMKCl) 
90.5±8 
144±12* 
Net uptake 
(Na-K) 
1968.5±87 
1196±68* 
(39%) 
BBMVs were prepared from whole cortex of rats 4 days after the administration of 
CDDP or normal saline (control) 
Results are mean ± SEM of three different BBNfVs preparations (Uptake is expressed 
as pmole/mg protein/20 sec). 
•significantly different from control at p<0.05 or greater degree by group t-test. 
Values in parenthesis represent percent change from saline-treated controls. 
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Table 19: The effect of vitamin C pretreatment on CDDP induced changes in 
senim creatinine and BUN levels. 
mg/dl 
Group Serum creatinine BUN 
Control 
Vit. C 
CDDP 
Vit.C+CDDP 
0.5±0.02 
0.53±0.018t 
1.28±0.14* 
(156%) 
0.76±0.05* 
(52%) 
20.3±1.2 
19.9±1.0t 
44.7±2.2* 
(120%) 
29.0±1.6* 
(43%) 
Rats were administered normal saline (control), vitamin C alone, CDDP alone and 
vitamin C+CDDP; serum creatinine and BUN levels were determined 4 days after these 
treatments. 
Results are mean ± SEM of four different experiments. 
* significantly different at p<0.01 as compared to saline treated control. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent increase from saline-treated controls. 
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no significant change in Scr and BUN levels in comparison to saline treated control 
group. 
ii) Activities of BBM marker enzymes 
Treatment of rats with CDDP alone resulted in a decrease in the activities of 
marker enzymes (AP-42%, GGTase-47%, Mlt-39% and LAP-45%) in BBM prepared 4 
days after treatment compared to respective controls. Vitamin C pre-treatment resulted 
in significant amelioration in the CDDP induced reduction in the activities of these 
marker enzymes (AP-22%, GGTase-26%, Mlt-19% and LAP-27%) compared to the 
saline treated controls (Table 20; Figs 19,20). Thus, the activities of the enzymes 
recovered significantly in rats treated with vitamin C plus CDDP, although the activity 
levels were not completely restored to normal values. Administration of vitamin C 
alone had no effect on the activities of these enzymes and they were the same as in the 
control group. 
The kinetic parameters. Km and Vmax, of these BBM enzymes were then 
determined from Lineweaver-Burk plot by assaying the enzymes at different substrate 
concentrations. The Km and Vmax values of AP, GGTase, Mlt and LAP were 
determined in BBMV from all four groups (vitamin C alone, CDDP alone and CDDP 
plus vitamin C and control groups). As seen earlier also, the Vmax values (expressed as 
jimoles/mg protein/hr) of the BBM enzymes were significantly lowered in CDDP 
treated group. However, pre-treatment with vitamin C led to significant recovery in the 
Vmax values of all the enzymes (Table 21). Treatment with vitamin C alone showed no 
significant change in Vmax compared to the control group. The apparent Km values of 
vitamin C alone, CDDP alone and vitamin C plus CDDP treated groups showed 
insignificant changes compared to saline treated control group. 
iii) Pi transport 
Na"^  gradient dependent ^^ Pi transport was lowered at early time points (5s, 10s, 
20s) in BBMVs prepared from rats 4 days after CDDP administration. However, in the 
BBMVs from rats treated with vitamin C before administration of CDDP the ^^ Pi 
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Table 20: The effect of vitamin C pre-treatment on CDDP induced changes in the 
activities of BBM marker enzymes. 
Groups 
AP 
Control 
Vit. C 
CDDP 
VitC+CDDP 
GGTase 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
MIt 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
LAP 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
|imoles/mg protein/hr 
149±5 
147±4.5t 
86.5±3* 
114+4* 
320+12 
315+llt 
169+9.2* 
226+9.5* 
265+9 
268+lot 
161+6* 
214+6.5* 
17.5+0.9 
17.8±0.8t 
9.6+0.4* 
12.7+0.5* 
(42%) 
(22%) 
(47%) 
(26%) 
(39%) 
(19%) 
(45%) 
(27%) 
BBM was prepared from whole cortex of animals 4 days after treatment. 
Results are mean ± SEM of four difiFerent experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.01 as compared to saline treated control 
Values in parenthesis represent percent decrease from saline-treated controls. 
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Fig 19: Specific activity of (A) allcaline phosphatase (AP) and (B) y-glutamyl transferase 
(GGTase) in the BBMVs isolated from whole cortex of saline treated control, 
vitamin C, CDDP and vitamin C+CDDP treated rats 4 days after the treatment. 
Each bar represents results (mean± SEM) of four different preparations. 
* significantly different from saline treated control at p<0.01 
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Fig 20: Specific activity of (A) maltase (Mlt) and (B) leucine aminopeptidase (LAP) in 
the BBMVs isolated from whole cortex of saline treated control, vitamin C, 
CDDP and vitamin C+CDDP treated rats 4 days after the treatment. 
Each bar represents results (mean± SEM) of four different preparations. 
*significantly different from saline treated control at p<0.01 
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Table 21:The effect of vitamin C pre-treatment on CDDP induced changes in the 
kinetic parameters of BBM marlcer enzymes. 
Groups 
AP 
Control 
Vit. C 
CDDP 
CDDP+Vit.C 
GGTase 
Control 
Vit.C 
CDDP 
CDDP+vit.C 
MIt 
Control 
Vit.C 
CDDP 
CDDP+vit.C 
Vmax 
(nmoles/mg protein/hr) 
140±4.7 
138±4.5t 
89.6±3.6* 
115±3.9* 
295±11.6 
300±11.4t 
165±9.0* 
227±9.8* 
230±8.0 
232±8.5t 
142.3±6* 
184±6.5* 
Km(xlO"'M) 
0.114±0.003 
0.115±0.002t 
0.117±0.005t 
0.115±0.004t 
0.87±0.01 
0.85±0.009t 
0.78±0.006t 
0.8±0.007t 
20.4±1.4 
20.2±1.5t 
19.8±1.6t 
20±1.46t 
LAP 
Control 
Vit.C 
CDDP 
CDDP+vit.C 
17.1±0.8 
16.8±0.75t 
10±0.44* 
13.3±0.52* 
0.4±0.005 
0.38±0.004t 
0.35±0.003t 
0.36±0.003t 
BBM was prepared from w h^ole cortex of animals 4 days after the treatment. 
Results are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.01 as compared to saline treated control 
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transport had significantly recovered at all the time points compared to CDDP treated 
group. The net uptake of ^ P^i was reduced to a lesser extent in BBMV of vitamin C plus 
CDDP (22%) treated group compared to the CDDP (36%) treated group from the 
controls after 20 sec of incubation. The BBMV from animals that received vitamin C 
alone showed no significant change in the uptake of ^^ Pi compared to the saline treated 
controls (Tables 22, 23). 
iv) Lipid peroxidation and total sulfhydryl groups 
The effect of CDDP plus vitamin C treatment on lipid peroxidation (in terms of 
malondialdehyde) and total sulfhydryl content in the cortex and medulla of the kidney 
was also determined (Tables 24,25 and Figs 21,22). CDDP treatment resulted in 
increased malondialdehyde (MDA) production in kidney tissues (cortex-25%, medulla-
43%) with respect to the saline treated control. The increase was more in medulla than 
cortex. Vitamin C pre-treatment resulted in amelioration of CDDP induced MDA 
production in both cortex (12%) and medulla (18%). 
Total sulfhydryl (SH) groups were also determined in the homogenates of cortex 
and medulla 4 days after treatment. The SH content was increased in cortex (15%) as 
well as medulla (26%) after CDDP treatment compared to the control group (Table 25; 
Fig 22). Vitamin C pre-treatment resulted in significant, but not complete, recovery in 
the SH content (cortex-6%, medulla-13%). No significant change was observed in 
vitamin C alone treated group when compared to the control group. 
v) Activities of superoxide dismutase and catalase 
The specific activities of free radical scavenging enzymes Cu,Zn-superoxide 
dismutase (Cu,Zn SOD) and catalase were determined in the homogenates of cortex and 
medulla 4 days after CDDP administration (Table 26; Figs 23,24). The effect of vitamin 
C pre-treatment was also studied. CDDP administration resuhed in decline in the 
activity of Cu,Zn-SOD in cortex (40%) and medulla (55%). Vitamin C pre-treatment 
resulted in significant but not complete recovery in the activity in the homogenates of 
kidney tissues (cortex-18%, medulla-23%). 
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Table 22: Effect of vitamin C pre-treatment on CDDP induced changes on Na^  
gradient dependent ^^ Pi uptake by BBNfVs. 
Group 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
5 sec 
1065±45 
1068±46t 
840.8±40* 
(21%) 
937±38t 
(12.4%) 
10 sec 
1405±65 
1400±62t 
1062±58* 
(24%) 
1208±55* 
(14.5%) 
20 sec 
2063±90 
2070±92t 
1400±82* 
(32%) 
1650±72* 
(20%) 
120 min 
370±20 
367±18t 
375±25t 
372±22t 
Results are mean + SEM of three different BBMV preparations. Uptake is expressed as 
pmole/mg protein/20 sec. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.05 as compared to saline treated control. 
Values in parenthesis represent percent decrease from saline-treated controls 
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Table 23: Effect of vitamin C pre-treatment on CDDP induced changes on net Na^  
gradient dependent ^^ Pi uptake by BBMVs. 
Groups 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
NaCl 
(lOOmM) 
2063±90 
2066±88t 
1400±82* 
(32%) 
1650±80* 
(20%) 
KCl 
(lOOmM) 
95.2±8.7 
93.7±8.5t 
148±10* 
(55%) 
112.4±9.3* 
(18%) 
Net uptake 
(Na-K) 
1967.8±86 
1966±84t 
1252±65* 
(36%) 
1537.6±70* 
(22%) 
BBMVs were prepared from whole cortex of rats 4 days after treatment. 
Results are mean ± SEM of three different BBMVs preparations. Uptake expressed as 
pmole/mg protein/20 sec. 
•significantly different from control at p<:0.05 or greater degree by group t-test. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent change from respective saline-treated 
controls. 
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Table 24: Effect of vitamin C pre-treatment on CDDP induced changes in 
malondialdehyde production in the homogenates of cortex and medulla. 
Groups 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
Malondialdehyde 
Cortex 
220±7.8 
225±7.6t 
275±9* 
(25%) 
246±8t 
(12%) 
(nmoles/g tissue) 
Medulla 
150±5 
146.2±5.3t 
201±6.4* 
(43%) 
177±5.9* 
(18%) 
Homogenates were prepared from animals 4 days after treatment 
Results are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.05 as compared to saline treated control. 
Values in parenthesis represent percent increase from respective saline-treated controls 
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Fig 21: Malondialdeh>de production in homogenates of cortex and medulla from 
control, vitamin C. CDDP and vitamin C+CDDP treated rats. 
Each bar represents results (mean± SEM) of four different preparations 
*significantly different from saline treated control at p<0.01 
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Table 25: Effect of vitamin C pre-treatment on CDDP induced changes in total 
sulfhydryl level in the homogenates of cortex and medulla. 
Sulfhydryl content (jimoles/g tissue) 
Groups Cortex Medulla 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
1.4±0.03 
1.32±0.028t 
1.61±0.04* 
(15%) 
1.5±0.036t 
(6%) 
1.2±0.02 
1.16±0.017t 
1.51±0.035* 
(26%) 
1.36±0.03* 
(13%) 
Homogenates were prepared from animals 4 days after treatment 
Results are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.05 as compared to saline treated control. 
Values in parenthesis represent percent increase from saline-treated controls 
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Fig 22: Total SH content in homogenates of cortex and medulla from control, vitamin 
C, CDDP and vitamin C+CDDP treated rats. 
Each bar represents results (mean± SEM) of four different preparations. 
*significantly different from saline treated control at p<0.01 
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Table 26; Effect of vitamin C pre-treatment on CDDP induced changes on the activities 
of Cu-Zn SOD and catalase in the homogenates of cortex and medulla. 
Groups 
Cu-Zn SOD 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
Catalase 
Control 
Vit.C 
CDDP 
Vit.C+CDDP 
U / mg protein 
Cortex 
2.63±0.085 
2.59±0.079t 
1.56±0.057* 
(40%) 
2.15±0.065* 
(18%) 
1175±66 
1169±64t 
730±40* 
(38%) 
950±45* 
(19%) 
Medulla 
1.5±0.038 
1.48±0.033t 
0.67±0.025 * 
(55%) 
1.15±0.032* 
(23%) 
996±49 
998±50t 
478±30* 
(52%) 
737±38* 
(26%) 
Homogenates were prepared from animals 4 days after treatment 
Results are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.01 as compared to saline treated control. 
Values in parenthesis represent percent decrease from saline-treated controls 
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Fig 23: The specific activity of Cu-Zn SOD in homogenates of cortex and medulla from 
control, vitamin C, CDDP and vitamin C+CDDP treated rats. 
Each bar represents results (mean± SEM) of four different preparations. 
* significantly different from saline treated control at p<0.01 
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Fig 24: The specific activity of catalase in homogenates of cortex and medulla from 
control, vitamin C, CDDP and vitamin C+CDDP treated rats. 
Each bar represents results (mean± SEM) of four different preparations, 
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The activity of catalase in the kidney was also decreased after CDDP 
administration (cortex-38%, medulla-52%). Pre-treatment with vitamin C caused 
recovery in cortex (19%) and medulla (26%). Insignificant change in Cu,Zn SOD and 
catalase activities was observed upon administration of vitamin C alone compared to the 
control group. 
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DISCUSSION 
It is well established that ischemia or toxic ARF results in the loss of renal 
epithelial cell viability and accumulation of cellular debris from injured tubule cells 
(Humes and Weinberg 1983). This leads to cell necrosis and death and renal excretory 
functions are altered. The proximal tubular segment of the nephron was shown to be 
the chief site of damage due to ischemia or toxic insult (Venkatachalam et al. 1978). A 
number of commonly used drugs can cause nephrotoxicity. ARF associated with 
CDDP, a drug commonly used in treatment of solid tumours, is a major complication 
associated with its use as a chemotherapeutic agent. Although CDDP induced 
nephrotoxicity is a limiting factor in the use of this of drug for cancer chemotherapy it 
has attracted considerable attention due to its potential use as a model for ARF. 
In this study a series of experiments were designed to better characterize the 
nephrotoxic effect of a singe dose of CDDP in rats. Animals were given a single 
intraperitoneal injection of CDDP at 6 mg/kg body weight. This dose of CDDP has 
been commonly used in numerous reports in literature; it causes nephrotoxicity in 
animals but is not lethal to them. Several parameters were studied on different days 
after administration of CDDP. Significant changes in food intake and body weight were 
observed in the animals after administration of CDDP. Four days after treatment the 
animals almost completely stopped eating and showed maximum weight loss. But later 
the animals recovered from toxicity and started eating and gaining weight similar to 
control animals. CDDP treatment is known to result in diarrhoea, vomiting and 
reversible damage to the small intestinal mucosa (Nomura et al, 1995). The 
gastrointestinal tract toxicity is probably responsible for changes in body weight and 
food intake after CDDP treatment. 
Increased urine volume and proteinuria were detected after CDDP treatment; 
this indicates polyuria and urinary concentrating defect. Glucosuria also developed after 
CDDP treatment; it was probably due to an inhibition of Na"" pump activity resulting in 
a decrease in active glucose reabsorption in the proximal tubule (Kim et al., 1995). A 
significant decrease in sodium dependent glucose transport in CDDP treated rats has 
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been reported (Halabe et al, 1991). GFR was reduced after CDDP treatment with 
maximum reduction on day 4 after administration of the drug. The fall in GFR is in part 
due to reduced renal blood flow and lowered effective filtration pressure. Winston et al. 
(1982) in their studies on CDDP induced nephrotoxicity reached the same conclusion. 
The most prominent abnormality present in CDDP treated animals was altered 
solute transport. CDDP treatment resuhed in increased creatinine and urea nitrogen 
concentrations in serum. Previous reports have shown that the greatest morphological 
change induced by CDDP is in the pars recta portion of proximal tubule (Ward and 
Fauvie, 1976; Dobyan et al, 1980). Such a damage in proximal tubule of pars recta 
region prevents uptake of urea and its excretion in urine (Kawamura and Kokko 1976). 
Nosaka et al (1992) have also reported that the creatinine level significantly increases 
in serum of CDDP treated rats. Since creatinine is filtered in the glomerulus its 
increased level in serum may be due to primary decrease in glomerular filtration and /or 
tubular back leak in addition to tubular obstruction (Choie el al, 1981; Chopra et al, 
1982). All the serum and urine parameters recovered to normal levels 16 days after 
CDDP administration indicating that CDDP induced changes in rat kidney are 
completely reversible at the dose administered in the present studies. 
The structure and fiinction of the kidney and its various components in animals 
and humans have been greatly characterized both in physiological and 
pathophysiological conditions (Blond and Whittam, 1964; Dousa and Kempson, 1982; 
Welling and Linshaw, 1988; Ali et al, 1992). The kidney consists of different tissue 
zones, such as cortex, outer and inner medulla which themselves behave as individual 
organs (Schmidt and Guder, 1976). Nephron, the structural unit of kidney, is also 
comprised of various subsegments of distinct structure with specific fiinction. The 
reabsorption of Na"" is considered to be the major fiinction of the kidney (Ullrich et al., 
1974, Ullrich et al., 1977), because the transport of water ions and various solutes 
depends directly or indirectly on Na"" reabsorption (Ullrich et al., 1974). The proximal 
tubule of the renal cortex has been shown to be the major nephron site where majority 
of ions and solutes including Na* are reabsorbed across the luminal BBM, mostly by 
active process (Gmay and Murer, 1986; Kempson and Dousa, 1986). The energy 
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required for these transport processes is usually provided by the hydrolysis of ATP 
supplied by various metabolic activities of the cell (Blond and Whittam, 1964). A 
direct relation between the transport of Na* and energy yielding metabolic reactions (eg. 
glycolysis and TCA cycle) concomitant with oxygen tension in kidney tissue zones or 
cells has been demonstrated (Stoffetal., 1976; Kinne, 1979; Cohen and Kamm, 1981). 
The existence of the major biosynthetic and catabolic pathways of intermediary 
metabolism, especially for carbohydrates, in adult mammalian kidney has been reported 
earlier (Cohen and Barae-Nieto, 1973; Kinne, 1979). However, the activities of 
enzymes of various metabolic pathways have not been studied in detail after CDDP 
induced ARF. In the present study the activities of several metabolic enzymes were 
determined in the homogenates of cortex and medulla of the rat kidney after 
administration of CDDP. As described in the "Results" section, administration of 
CDDP caused profound increase in the LDH activity, both in cortex and medulla. 
However, this increase was significantly greater in medulla than in cortex. In contrast, 
the activity of TCA cycle enzyme MDH was significantly decreased by CDDP 
administration. The marked reduction in MDH activity would reduce the production of 
oxaloacetate from malate which is required for the continuation of TCA cycle. These 
observations are in agreement with the results of earlier studies in which the activity of 
MDH was found to be lowered by toxic or ischemic injury (Abdel-Gayoum et al, 1994; 
el Daly, 1998). Although the actual rate of glycolysis was not determined, the increased 
activity of LDH, along with simuhaneous decline in MDH activity, suggests the shift of 
oxidative metabolism to glycolysis to meet the energy need of cells after toxic insuh. 
Thus, the increase in LDH activity appears to be an adaptive change to the depressed 
rate of TCA cycle. These observations, together with the earlier ones, suggest that in 
CDDP induced injury oxidative metabolism is affected to limit the production of ATP 
mainly due to mitochondrial dysfiiction (Bogin et al, 1994, Zhang nad Lindup, 1993). 
Kidney is a major site of gluconeogenesis in the body. Therefore, the activities 
of FBPase and G6Pase, the enzymes involved in the synthesis of glucose, were 
determined in the homogenates after CDDP administration. The resuhs clearly indicate 
that CDUP treatment resulted in significant decrease in the activities of both G6Pase 
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and FBPase in cortical and medullary homogenates. The decrease in the activities of 
these enzymes was again more profound in medulla than in cortex. The reduced activity 
of MDH may have decreased the production of oxaloacetate from malate which is 
required for the continuation of TCA cycle as well as for gluconeogenesis. Aspartate 
transaminase (AST) activity has also been shown to be markedly depressed in CDDP 
treated rats (Bogin et al., 1994). This would affect gluconeogenesis in renal cortex, 
since AST and MDH are involved in the malate-aspartate shuttle. The reduced activity 
of these enzymes would diminish the flux of the reducing equivalent and 
gluconeogenesis intermediates across the mitochondrial barrier. 
CDDP treatment resulted in decrease in the activity of G6PDH and increase in 
the activity of ME. The significant time dependent decline of G6PDH activity showed a 
maximum decrease 4 days after treatment with CDDP. The enhanced activity of ME 
could be possibly due to the depressed rate of glucose oxidation. ME and G6PDH are of 
immense importance in metabolism because the major supply of cellular NADPH, 
which is required for many biosynthetic pathways, is dependent on these two enzymes. 
However, NADPH required for biosynthetic pathways in CDDP treated rats seems to be 
provided by an enhanced ME activity rather than G6PDH. 
A significant decline in cortical and medullary AcidPase was observed after 
CDDP administration. AcidPase is present in lysosomes throughout the kidney and its 
activity decreased substantially after CDDP treatment. This may be the resuh of 
lysosomal build up until the cell lyses releasing the enzyme in urine in the functional 
form (Babu et al., 1999) thus decreasing the activity in the homogenates of cortex and 
medulla. 
A direct relation between transport of sodium and energy yielding metabolic 
reactions or dependence of transport of various solutes on sodium transport prompted 
the examination of the possible effect of CDDP on the activity of Na^ -K"^  ATPase. In 
CDDP treated rats a decrease in the activity of Na^ -K"^  ATPase was seen in both cortex 
and medulla. The decline in Na^ -K"^  ATPase activity in treated rats may be attributed to 
the limited supply of ATP due to mitochondrial dysfuction and depletion of substrate 
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level of TCA cycle intermediates. This is in agreement with the resuhs of previous 
experiments in isolated renal tubules which have shown significant inhibition of Na*-K^ 
ATPase as well as Ca^ -^Mg^^ ATPase activities upon exposure to CDDP; this effects 
the Na^-K^ pump, the Ca*^ pump and the mitochondrial synthesis of ATP (Uozomi and 
Litterst, 1985; Zhang and Lindup, 1994). 
To further localize the effect of CDDP on different kidney tissue zones the 
specific activities of BBM marker enzymes, AP, GGTase, Mlt and LAP were 
determined in the homogenates of cortex and medulla. The activities of all these 
enzymes were significantly decreased in both cortex and medulla, the extent being 
greater in medulla. This is in agreement with the earlier morphological and biochemical 
studies which suggested that the S3 segment (pars recta) of the proximal tubule, located 
in the outer stripe of outer medulla, was the most extensively damaged region of the 
nephron upon CDDP treatment (Dobyan et ai, 1980, Kuhlmann et al., 1997). The 
present results also show that the effect of CDDP is not confined exclusively to the 
medulla only as considerable damage was present in the cortical region of the kidney 
too. 
Morphological studies have shown that the proximal tubule, particularly its 
BBM, is an early and prominent site of morphological change in toxic injury. Therefore, 
a major aim of the present work was to study the effect of CDDP treatment on proximal 
tubular brush border membrane. Thus, the activities of different BBM marker enzymes 
AP, GGTase, Mlt and LAP were examined in BBM from control and CDDP treated rats 
as an indicator of the structural and functional integrity of proximal tubule afler toxic 
insult. The activities of all these enzymes declined in BBM after CDDP treatment. This 
decrease was evident on day 2 and was maximum 4 days after CDDP administration. 
Kinetic studies of BBM marker enzymes done 4 days after the treatment showed that 
the decline in activities was largely due to decrease in Vmax with no or insignificant 
effect on Km values. Thus, the decrease in enzyme activity upon administration of 
CDDP is mainly due to loss of active enzyme molecules per unit of BBM. These results 
suggest that the BBM was severely damaged during toxic insult. Dobyan et al. (1980) in 
their morphological studies reported that the pathological changes were evident 2 days 
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after the administration of CDDP and consisted of loss of brush border and cell 
swelling. 
All the serum and urine parameters, activities of enzymes of carbohydrate 
metabolism and BBM marker enzymes in both homogenates and BBMV showed 
maximum change 4 days after the CDDP treatment but recovered to normal values after 
16 days. This indicates that maximum damage to the kidney was 4 days after treatment 
and tubular regeneration then began 8 days after the treatment. This confirms that if a 
nephrotoxic but sublethal dose of CDDP is administered the mammalian kidney can 
repair the injured nephrons and result in active regeneration that begins 8 days after the 
treatment. Thus, the acute renal failure induced by a single dose of CDDP is reversible 
and the kidney completely regains its normal fiinction 16 days after the administration 
of the drug. 
A major fiinction of the kidney is the uptake of various substances including 
glucose, amino acids and inorganic phosphate (Pi). The transport of Pi during the toxic 
insult has not been studied in detail. The transport of Pi is especially required for the 
maintenance of energy yielding reactions as well as generation of ATP, the energy 
currency of the cell. Toxic insult results in failure of cells to maintain ATP levels. 
The effect of CDDP on Pi transport was examined in the present study using 
BBMV prepared from animals 4 days after they were administered CDDP or normal 
saline. In isolated vesicles from brush borders, phosphate transport was shown to be 
coupled with active sodium transport (Kinne et al., 1977). The driving force for Pi 
transport into the cell is sodium entry, which occurs along the electrochemical gradient 
created by Na^ -K"^  ATPase activity in basolateral membrane (Kupfer and Kosovsky, 
1970). The present results showed a marked reduction in the transport of ^^ Pi. As 
described in "Results", Na^-gradient dependent (Nao>Nai) transport of Pi was 
significantly reduced in the initial uphill phase (5-20 sees). As expected, the uptake of 
•'^ Pi after equilibration for 120 min was not affected. The effect of CDDP on •'^ Pi 
transport was observed only when an inward Na^-gradient (Nao>Nai) was present while 
in the absence of Na^  gradient (when NaCl in the incubation media was replaced by 
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KCl) the uptake of ^^ Pi at 20 sec was even higher in CDDP-treated groups of rats 
compared to control rats. This indicates that CDDP may have caused an increase in 
diffusional uptake capacity of BBM. The decreased transport also shows that CDDP 
causes a toxic effect in the proximal segment of the nephron. As discussed earlier, the 
transport of Pi is an active process and requires energy. The insufficient supply of 
intermediates of carbohydrate metabolic pathway and mitochondrial dysfunction results 
in a decline in ATP production and thus inhibits the activity of Na*-K^ ATPase which in 
turn may decrease '^ Pi transport in BBM. Alterations in the intrinsic properties of 
transporter molecules due to toxic injury may also be one of the causes of reduced ^^ Pi 
transport as suggested for ischemic ARF (Molitoris and Kinne, 1987). Williams and 
Holtendorf (1985) have reported that CDDP inhibits cation transport in brush border 
and basolateral membranes from rat kidney cortex. 
Besides the changes discussed above, CDDP administration also resulted in 
increased lipid peroxidation, change in total sulfhydryl content and inhibition in the 
activity of antioxidant enzymes in renal tissue. Renal lipid peroxidation, determined by 
malondialdehyde content, was increased after CDDP treatment. The increase in lipid 
peroxidation may be due to the damage caused by free radicals generated which react 
with membrane lipids. An increase in lipid peroxidation is well known to affect both 
membrane structure and fiinction. The peroxidation of membrane lipids can result in 
enzyme leakage in tubule (Sugiyama et al., 1987). Other investigators have also shown 
that administration of CDDP results in generation of free radicals that led to lipid 
peroxidation (Matsushima et al, 1998). Total sulfhydryl groups determined after CDDP 
treatment showed an increase in the homogenates of cortex and medulla. These results 
do not agree with earlier reports that administration of CDDP resulted in depletion of 
glutathione and sulfhydryl groups (Levi et al., 1980; Nakano and Gemba 1980) and that 
there was a relation between the CDDP nephrotoxicity and depletion of glutathione 
content. However, an increase in renal SH groups has been reported by Leyland-Jones 
et al. (1983) and al Harbi et al. (1995) in agreement with our observation. The 
mechanism of such an increase is not understood. It has been reported that 
administration of the heavy metal arsenic to rats caused doubling of glutathione level 
after 3 hours and was attributed to the stimulation of de novo glutathione synthesis. The 
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activities of free radical scavenging enzymes, catalase and Cu-Zn SOD, were 
determined in the cortical and medullary homogenates after CDDP treatment. It was 
found that the activities of catalase and Cu-Zn SOD were significantly decreased in 
both the homogenates. It is well known that these enzymes play an important role in 
protecting against oxidative stress and lipid peroxidation in tissues. It has been shown 
that CDDP does not directly increase lipid peroxidation in vitro (Sadzuka et ai, 1992). 
Therefore, the increase in lipid peroxidation in the kidney of rats treated with CDDP 
can be attributed to decrease in the activities of enzymes that protect against lipid 
peroxidation. 
Since CDDP generates free radicals in vivo, much attention has been given in 
recent years to the role of anti-oxidants in protecting against CDDP-induced 
nephrotoxcity (Appenroth et ai, 1997; Bogin et al., 1994). In the present study vitamin 
C was used as an anti-oxidant to see if it could protect against CDDP-induced 
nephrotoxicity. Vitamin C, given 6 hr prior to single dose of CDDP, resulted in 
significant amelioration of CDDP induced nephrotoxicity. Rats sacrificed 4 days after 
vitamin C plus CDDP treatment showed significant, but not complete, recovery in all 
the parameters studied: BUN and serum creatinine levels, the activities of BBM marker 
and free radical scavenging enzymes. Transport of Pi along of the BBMV, lipid 
peroxidation and total SH groups also recovered significantly. 
Vitamin C can also act as a reducing agent in many biological processes (Padh, 
1990; Antunes and Takahashi, 1998). Thus it may have inhibited the chain reaction of 
the CDDP generated free radicals before they reached the cell targets. Thus the damage 
to the cell membrane, the inhibition of glomerular kidney fiinction and the cellular 
necrosis associated with CDDP induced ARF is greatly reduced. The decrease in the 
level of free radicals prevented lipid peroxidation and also inhibition of the activity of 
Cu-Zn SOD and catalase. The decrease in lipid peroxidation prevents membrane 
disruption and may prevent loss of BBM marker enzymes as well as show recovery in 
^^ Pi transport across BBMV. The ability of vitamin C to significantly decrease renal 
lipid peroxidation caused by CDDP in vivo supports the idea that pre-treatment with 
this anti-oxidant could maintain integrity of lipids in kidney tissue under oxidative 
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stress induced during chemotherapy. Administration of vitamin C to patients 
undergoing CDDP therapy, therefore, has the potential to reduce the nephrotoxicity of 
this drug. This will reduce the major toxic side effect of this chemotherapeutic agent 
and alleviate the pain and suffering of patients undergoing treatment. 
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RESULTS 
1. Effect of K>Cr?07 on: 
(i) Body weight and food intake 
The body weight and food intake of the animals were studied 1, 2, 4 and 8 days 
after a single intraperitoneal injection of K2Cr207 (15 mg/kg body weight) in normal 
saline. The control animals were given an equal volume of normal saline only. The 
K2Cr207 treated animals showed significant change in food intake 1 and 2 days after the 
treatment compared to the corresponding controls (Table 1). Due to this the body 
weights of the treated animals also showed significant change compared to the animals 
in the control group. Four days after the treatment rats showed some recovery in food 
intake and body weights; 8 days after treatment the pattern of weight gain was the same 
for animals in K2Cr207 treated and control group. 
(ii) Urine parameters and GFR 
The time course of K2Cr207 induced changes in urine flow rate, proteinuria and 
glucosuria was studied in animals 1, 2, 4 and 8 days after a single intraperitoneal 
injection of K2Cr207. The results are shown in Table 1. Urine flow in K2Cr207 treated 
animals rose significantly after 1, 2 and 4 days but declined to near normal value after 
day 8 of the treatment compared to the respective controls. The maximum urine flow 
rate was after 2 days which was almost double that of the control group. Glucose and 
protein excretion in urine was also increased, with maximum increase after day 2. The 
extent of increase was less after day 4, and went back to normal level after day 8, 
compared to the saline treated control groups. 
In K2Cr207 treated animals the GFR fell on days 1, 2 and 4 after treatment 
(Table 1). Maximum decrease was noted after day 2 (0.132 ml/min/100 g body wt) 
compared to control group (0.345 ml/min/100 g body wt). After this the GFR began to 
show recovery and reached normal level after day 8 compared to control group. The 
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Table 1- Effect of KjCrzO? treatment on body weight, food intake, urine flow rate, 
proteinuria and glucosuria. 
Groups 0 
Body weight (g) 
Control 195±10 
KjCrzOy 200±11 
Food Intake (g/day) 
Control 20±1 
KzCrjOy 20±0.9 
Urine flow rate (ml/day) 
Control 15.4±0.4 
KzCrzOv 15.2±0.5 
16.3±0.41t 
Protein (mg/mmoies creatinine) 
Control 2.25±0.1 
KzCrzO? 2.28±0.1 
Glucose (mg/mg protein) 
Control 14.8±0.68 
KjCrjOt 15.2±0.75 
Duration of treatment (days) 
1 2 4 
195±10 
190±10t 
21±1 
16±0.9* 
15.2±0.5 
25.1±0.7* 
2.3±0.15 
8.8±1.1* 
15±0.75 
25.5±1.6* 
Creatinine clearence (ml/min/lOOg body weight) 
Control 
KzCrjOT 
0.35±0.012 
0.248±0.008* 
197±11 
177±9* 
21.4±0.9 
11±0.7* 
I5.4±0.7 
32±0.9* 
2.31±0.13 
14±1.5* 
15.8±0.72 
46±2.5* 
" 
0.345±0.011 
0.132±0.006* 
200±10 
187±10t 
21±0.8 
18±0.8* 
15.5±0.48 
20.1±0.6* 
2.28±0.11 
6.4±0.8* 
14.5±0.75 
23.3±1.8* 
0.365±0.009 
0.274±0.007* 
8 
210±9 
205±llt 
21±1 
20.6±lt 
15.6±0.4 
2.3±0.13 
2.4±0.11t 
16±0.8 
I5.8±0.9t 
0.361±0.012 
0.354±0.011t 
Results are mean ± SEM of four different experiments. 
* significantly different at p<0.01 as compared to day 0 and saline treated control. 
t insignificantly different at p<0.01 compared to day 0 and saline treated control. 
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change in GFR in saline treated control group was insignificant during the course of the 
experiment. 
(iii) Blood chemistry 
The effect of K2Cr207 administration on BUN and serum levels of creatinine 
(Scr), cholesterol (CL), phospholipids (PL) and inorganic phosphate (Pi) are shown in 
Table 2. Serum creatinine and BUN are the two important parameters that are used to 
assess kidney function and determine ARF. Administration of K2Cr207 resulted in 
enhanced levels of Scr and BUN. Increase in the levels of Scr and BUN was noted afler 
day 1 and maximum increase was observed after day 2 (Scr-1.13 mg/dl, BUN-38.8 
mg/dl) compared to control group (Scr-0.525 mg/dl, BUN-19.3 mg/dl). Both Scr and 
BUN levels reached normal values after day 8 compared to the values for the 
corresponding saline treated control group. K2Cr207 treated group also showed 
significant increase in the serum CL and PL levels but a decrease in Pi level. The 
magnitude of increase was again maximum after day 2 of the treatment but recovered to 
normal levels after day 8. Saline-treated control animals had relatively constant values 
for serum creatinine, BUN, PL, CH and Pi over the experimental period. 
The above studies show that the changes caused by K2Cr207 induced ARF are 
reversible. The maximum change in all parameters is 2 days after adminstration of 
K2Cr207 with recovery to near normal values after day 8 of the treatment. 
2. Effect of KiCr-iOi on the activities of certain enzymes of carbohydrate 
metabolism 
The activities of enzymes of glycolytic pathway (LDH), TCA cycle (MDH), 
gluconeogenesis (G6Pase and FBPase), HMP-shunt pathway (G6PDH) and of 
biosynthetic importance (ME) were determined in the homogenates of cortex and 
medulla 1, 2, 4 and 8 days after administration of a single dose of K2Cr207. 
The activity of LDH increased, but to different extent, both in the cortex and 
medulla (Table 3; Fig. 1). Increase in the activity of LDH was first noted after day 1 
(cortex - 22%, medulla - 14%), after 2 days both cortex (30%) and medulla (20%) 
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Table 2: Effect of KaCrjO? treatment on serum parameters 
Groups 1 
Serum creatinine (mg/dl) 
Control 
KiCrjO, 
BUN (mg/dl) 
Control 
KzCraOT 
Cholesterol (mg/dl) 
Control 
KzCrzOy 
Phospholipid (mg/dl) 
Control 
KzCrzO; 
0.53±0.015 
0.8±0.033* 
19.5±1.2 
28.8±1.7* 
51±2 
66.5±2.8* 
0.496±0.011 
0.665±0.017* 
.Phosphate (fimoles/ml) 
Control 
KzCrjOy 
2.47±0.165 
2.25±0.16* 
Duration of treatment (days) 
2 4 
0.525±0.018 
1.13±0.042* 
19.3±1 
38.8±2.5* 
53±2.2 
83.8±3.5* 
0.51±0.0I3 
0.826±0.2* 
2.46±0.17 
1.98±0.11* 
0.49±0.02 
0.66±0.038* 
18±0.98 
25.2±1.6* 
52±1.8 
61±3.2* 
0.56±0.012 
0.638d=0.015* 
2.45±0.136 
2.3±0.12t 
8 
0.5±0.015 
0.508±0.018t 
19.2±0.95 
18.8±1.2t 
50.9±1.5 
52.4±1.9t 
0.48±0.015 
0.53±0.013t 
2.48±0.15 
2.43±0.14t 
Results are mean ± SEM of four different experiments. 
* significantly different at p<0.01 as compared to saline treated control. 
t insignificantly different as compared to saline treated control. 
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showed maximum change. Some signs of recovery were evident after day 4 and normal 
value was reached after day 8 of K2Cr207 treatment. The administration of K2Cr207 also 
resulted in decline in the activity of MDH. The activity of MDH was maximally 
affected after day 2 in both cortex (26%) and medulla (20%). The magnitude of decline 
was less after day 4 with recovery to normal value after day 8, when compared to the 
control group (Table 4; Fig 2). As seen with LDH, the activity of MDH was affected to 
a greater extent in cortex than in medulla. 
The effect of K2Cr207 treatment on the activities of G6Pase and FBPase was 
also studied; the activities of these enzymes decreased significantly at all time points till 
day 4, both in cortex and medulla (Tables 5,6; Figs 3,4). The single dose treatment had 
greater effect on cortex than medulla. Activities measured 2 days after treatment 
showed maximum change. The decrease in the activity of FBPase in cortex (41%) was 
slightly more than the decrease in G6Pase (36%) after day 2 of the treatment. After day 
4 recovery in the activities of both G6Pase and FBPase was seen compared to day 2 
The recovery continued and reached normal values after day 8 compared to the controls 
Single dose treatment of K2Cr207 also affected the activities of G6PDH and ME 
(an enzyme of biosynthetic importance which is responsible for the supply of NADPH) 
(Tables 7,8; Figs 5,6). The activity of G6PDH was increased when measured in 
homogenates of cortex (32%) and medulla (24%) after day 1 of the treatment. The 
activity was fiirther increased and reached maximum value on day 2 (cortex-40%, 
medulla-30%). After day 4 the activity of G6PDH started recovering with complete 
recovery after 8 days of treatment. G6PDH also showed greater effect in cortex than in 
medulla. However, the activity of ME showed a decline after K2Cr207 treatment. The 
activity of cortical ME showed greater change than medullary ME, amounting to 26% 
and 19% reduction in cortex and medulla after 1 day of the treatment. The decrease in 
activity in cortex and medulla at other time points were: 36%, 24% after 2 days and 
20%, 14% after 4 days. After 8 days of administration of K2Cr207 the activity had 
recovered to normal value compared to the saline treated control group. 
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Table 3: Effect of KaCrjO? treatment on the activity of lactate dehydrogenase in the 
homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
K2Cr207 
Medulla 
Control 
K2Cr207 
1 
20±0.6 
24.4±0.75* 
(22%) 
31.5±0.65 
35.9±0.68* 
(14%) 
Duration of treatment (days) 
2 4 
19.8±0.65 
25.8±0.8* 
(30%) 
30±0.6 
36±0.7* 
(20%) 
18.9±0.55 
22.3±0.7* 
(18%) 
30.5±0.5 
33.3±0.52* 
(10%) 
8 
19±0.6 
20±0.65t 
32±0.63 
31.5±0.6t 
Specific activity expressed as )imoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
*significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent increase from respective controls 
1 2 2 
Cortex 
H Control 
H KjCriOv 
Days 
Medulla M Control 
B KjCr.OT 
Fig 1: Specific activity of lactate dehydrogenase (LDH) in the homogenates of cortex 
and medulla from control and K,Cr.O^-treated rats. 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0.01 
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Table 4: Effect of K2Cr207 treatment on the activity of malate dehydrogenase in the 
homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
K2Cr207 
Medulla 
Control 
K2Cr207 
I 
110±3.5 
81.5±2.8* 
(26%) 
103±3 
82±2.5* 
(20%) 
Duration of treatment (days) 
2 4 
n5.2±3.2 
78.3±3*. 
(32%) 
105±3.5 
80.8±3* 
(23%) 
109±3.6 
86.1±2.6* 
(21%) 
100±2.8 
83±2.4* 
(17%) 
8 
112±3 
110±3t 
108±3.2 
103±2.7t 
Specific activity expressed as nmoles/mg protein/hr 
Results are mean ± SEM of four different preparations, 
•significantly different at p< 0.01 from their respective controls, 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent decrease from respective controls 
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Fig 2: Specific activity of malate dehydrogenase (MDH) in the homogenates of cortex 
and medulla from control and K,Cr,0^-treated rats 
Each bar represents (mean±SEM) of four different preparations 
•significantly diflferent from saline-treated control at p<0 1 
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Table 5: Effect of K2Cr207 treatment on the activity of glucose-6-piiosphatase in the 
homogenates of whole cortex and medulla. 
Groups 
Duration of treatment (days) 
1 2 4 
Cortex 
Control 
KjCrzOy 
0.31±0.013 0.28±0.012 0.29±0.011 0.26±0.012 
0.226±0.01* 0.179±0.011* 0.223±0.01* 0.253±0.01t 
(27%) (36%) (23%) 
Medulla 
Control 
K2Cr207 
0.2±0.009 0.188±0.01 0.212±0.007 0.22±0.01 
0.158±0.005* 0.13±0.007* 0.174±0.005* 0.2±0.008t 
(21%) (28%) (18%) 
Specific activity expressed as fimoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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*significantly different from saline-treated control at p<0 01 
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Table 6: Effect of K2Cr207 treatment on the activity of fructose 1,6 bisphosphatase in 
the homogenates of whole cortex and medulla. 
Groups 
Duration of treatment (days) 
1 2 4 
Cortex 
Control 
KiCriOi 
0.85±0.038 0.83±0.035 0.87±0.041 0.79±0.04 
0.569±0.026* 0.49±0.03* 0.618±0.031* 0.76±0,035t 
(33%) (41%) (29%) 
Medulla 
Control 
K2Cr207 
0.717±0.03 
0.53±0.02* 
(26%) 
0.74±0.032 0.75±0.026 0.73±0.034 
0.503±0.025* 0.6±0.021* 0.74±0.03t 
(32%) (20%) 
Specific activity expressed as ^moles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
•significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
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Table 7: Effect of K2Cr207 treatment on the activity of glucose-6-phosphate 
dehydrogenase in the homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
KjCrzOT 
Medulla 
Control 
KjCrzO? 
Duration of treatment (days) 
1 2 4 
1.39±0.045 1.42±0.048 
1.84±0.06* 1.99±0.065* 
(32%) (40%) 
0.88±0.025 0.85±0.02 
1.09±0.038* 1.1U0.04* 
0.093±0.026t 
1.49±0.05 
1.88±0.061* 
(26%) 
0.91±0.028 
1.1±0.032* 
8 
1.45±0.04 
1.5±0.045t 
0.095±0.03 
(24%) (30%) (20%) 
Specific activity expressed as |xmoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent increase from respective controls 
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Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0 01 
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Table 8: Effect of K2Cr207 treatment on the activity of malic enzyme in the 
homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
KjCrjOy 
Medulla 
Control 
KzCrjO? 
1 
12.9±0.5 
9.45±0.45* 
(26%) 
9.16±0.34 
7.42±0.26* 
(19%) 
Duration of treatment (days) 
2 4 
13.6±0.57 
8.7±0.48* 
(36%) 
8.9±0.37 
6.76±0.29* 
(24%) 
13.1±0.54 
10.5±0.5* 
(20%) 
9.3±0.36 
8±0.31* 
(14%) 
8 
13.3±0.52 
13±0.54t 
9.2±0.38 
9.4±0.4t 
Specific activity expressed as ^moles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
•significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls 
132 
Cortex 
15 
! " 
o 
E 
I 
* 
V 
T, m 
8 
^^ ^ 
m 
n Control 
• K2Cr207 
Medulla 
n Control 
H K^CriOi 
Fig 6: Specific activity of malic enzyme (ME) in the homogenates of cortex and medulla 
from control and K^Cr^O^-treated rats Each bar represents (mean±SEM) of four 
different preparations 
*significantly different from saline-treated control at p<0 01 
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3. Effect of KiCr^O? on the activities of BLM and lysosomal enzymes 
After K2Cr207 treatment the basolateral membrane marker enzyme Na^ -K"^  ATPase 
showed change in its activity in the homogenates of both cortex and medulla (Table 9; 
Fig 7). Maximum decrease in the activity was seen on day 2 after the treatment (cortex-
33%, meduIIa-22%) compared to corresponding saline treated control. The change 
persisted between treated and control group even after day 4 and reached normal value 
after day 8. The activity of Na*-K* ATPase in cortical homogenate showed greater 
change than in medullary homogenate. 
The effect of K2Cr207 administration on the activity of acid phosphatase 
(AcidPase), a lysosomal enzyme, was determined at different time points (1, 2, 4 and 8 
days). The activity of AcidPase declined after the treatment compared to the saline-
treated controls (Table 10; Fig 8). The change in activity after day 2 was found to be 
maximum in both cortex and medulla (30%, 20%) and reached to normal level after day 
8 of K2Cr207 treatment. As seen with Na*-K^ ATPase also, the activity of AcidPase was 
affected to a greater extent in cortex than in medulla. 
4. Effect of KiCriO? on the activities of BBM marker enzymes in: 
(i) Homogenates of cortex and medulla 
Significant changes in the activities of BBM marker enzymes in cortex and 
medulla were observed after K2Cr207 treatment. The activities of AP, GGTase, LAP 
and Mlt showed significant decline 1, 2 and 4 days after treatment. Changes in the 
activities of all these BBM marker enzymes after K2Cr207 administration were more 
profound in cortex than in medulla (Tables 11-14; Figs 9-12). The decrease in the 
activities was first observed after day 1 and showed maximum decrease after day 2. 
However, after day 4 the magnitude of decrease was less than day 2 and after 8 days of 
the treatment complete recovery in the activities of all the BBM marker enzymes, both 
in cortex and medulla, was noted when compared to their respective controls. The 
activities of AP and Mlt were affected to a slightly greater extent than GGTase and 
LAP. 
134 
Table 9: Effect of K2Cr207 treatment on the activity of Na* K* ATPase in the 
homogenates of whole cortex and medulla 
Duration of treatment (days) 
Groups 1 2 4 
Cortex 
Control 
K2Cr207 
5±0.145 
3.95±0.12* 
5.09±0.14 4.98±0.135 4.51±0.13 
3.41±0.13* 4.23±0.11* 4.56±0.132t 
(20%) (33%) (15%) 
Medulla 
Control 
K2Cr207 
4.5±0.07 
3.89±0.065* 
(13%) 
4±0.075 
3.1±0.07* 
(22%) 
4.1±0.065 
3.69±0.062* 
(10%) 
3.7±0.063 
3.58±0.06t 
Specific activity expressed as nmoles/mg protein/hr 
Resuhs are mean ± SEM of four different preparations. 
*significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls. 
135 
Cortex 
c S 
•5 \— a. 
% 
s 
o 
> 
a. 
Control 
K2Cr207 
Medulla 
•g 4 
I 
n Control 
g K.Cr.OT 
Days 
Fig 7: Specific activity of Na^-K^ATPase in the liomogenates of cortex and medulla from 
control and K^Cr^ O -^treated rats Each bar represents (mean±SEM) of four different 
preparations 
*significantly different from saline-treated control at p<0 01 
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Table 10: Effect of K2Cr207 treatment on the activity of acid phosphatase in the 
homogenates of whole cortex and medulla. 
Duration of treatment (days) 
Groups 1 2 4 8 
Cortex 
Control 10.5±0.2 10.8±0.18 10.3±0.17 10.9±0.19 
KjCrjOT 12.7±0.23* 14.1±0.28* 12.1±0.22* 11.3±0.21t 
(21%) (30%) (17%) 
Medulla 
Control 
K2Cr207 
6±0.15 
6.9±0.12* 
(15%) 
6.5±0.16 
7.8±0.14* 
(20%) 
6.3±0.13 
6.93±0.1* 
(10%) 
6.1±0.11 
5.8±0.12t 
Specific activity expressed as nmoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
*significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent increase from respective controls. 
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Fig 8:Specific activity of acid phosphatase (AcidPase) in the homogenates of 
cortex and medulla from Saline treated and K,Cr,0^-treated rats. 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0.01 
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Table 11: Effect of K2Cr207 treatment on the activity of alkaline phosphatase in the 
homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
KzCriOv 
Medulla 
Control 
K2Cr207 
1 
16.2±0.6 
10.5±0.5* 
(35%) 
11.5±0.3 
8.62±0.2* 
(25%) 
Duration of treatment (days) 
2 4 
15.8±0.7 
7.1±0.6* 
(55%) 
11±0.28 
7.1±0.25* 
(35%) 
16±0.7 
11.8±0.4* 
(26%) 
10.8±0.31 
8.96±0.22* 
(17%) 
8 
16.5±0.5 
16.8±0.3t 
11.7±0.26 
11.2±0.24t 
Specific activity expressed as |amoles/mg protein/hr 
Resuhs are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent decrease from respective controls 
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Table 12: Effect of K2Cr207 treatment on the activity of y-glutamyl transferase in the 
homogenates of whole cortex and medulla. 
Groups 
Cortex 
Control 
K2Cr207 
Medulla 
Control 
K2Cr207 
1 
32±1.2 
22.7±0.8* 
(29%) 
23±0.5 
18.6±0.35* 
(19%) 
Duration of treatment (days) 
2 4 
34±1.25 
18.7±0.95* 
(45%) 
20± 0.45 
13±0.4* 
(32%) 
33±1 
26.4±0.9* 
(20%) 
23±0.42 
20.4±0.3* 
(11%) 
8 
35±0.9 
33.5±0.75t 
25±0.45 
23±0.32t 
Specific activity expressed as |xmoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls. 
141 
Cortex 
35 
28 
5 c 
0) 
a. 
o> 
8 2 n 
o 
E 
>. 14 • 
•c 
ID 
O 
0 - 1 -
^ Control 
Medulla 
1 
o 
E 
t3 
ID 
U 
24 
18 
12 
6 -
0 4 
^^ 
> 
* 
'^^M 
'^ ^^^B 
^^m 
^M W^ 
m^i 
• ^ 1 
•A 
• * / ^ 
^ 
^^ ^ 
''/7 
••#*'j 
2 4 
Days 
[3 Control 
• K2Cr207 
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cortex and medulla from control and K,Cr,0,-treated rats 
Each bar represents (mean±SEM) of four different preparations 
* significantly different from saline-treated control at p<0 01 
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Table 13: Effect of K2Cr207 treatment on the activity of maltase in the homogenates of 
whole cortex and medulla. 
Groups 
Cortex 
Control 
K2Cr207 
Medulla 
Control 
K2Cr207 
1 
19.2±0.4 
13.8±0.35' 
(28%) 
14.5±0.3 
11.6±0.2* 
(20%) 
Duration of treatment (days) 
2 4 
20± 0.38 
" 10±0.4* 
(50%) 
15±0.28 
9.75±0.25* 
(35%) 
19±0.41 
15.9±0.36* 
(21%) 
15.6±0.36 
13.26±0.2* 
(15%) 
8 
19.4±0.35 
19.4±0.37t 
14.8± 0.28 
14.7± 0.22t 
Specific activity expressed as nmoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls. 
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Fig 11: Specific activity of maltase (Mlt) in the homogenates of cortex and medulla from 
control and K,Cr,0^-treated rats 
Each bar represents (mean±SEM) of four different preparations 
*significantly different from saline-treated control at p<0 01 
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Table 14: Effect of K2Cr207 treatment on the activity of leucine aminopeptidase in the 
homogenates of whole cortex and medulla. 
Duration of treatment (days) 
Groups 1 2 4 8 
Cortex 
Control 1.83± 0.065 1.8±0.06 1.75± 0.055 1.7± 0.058 
K2Cr207 1.23±0.04* 0.93±0.05* 1.33± 0.045* 16.9±0.046t 
(25%) (47%) (17%) 
Medulla 
Control 1.3±0.03 1.25± 0.032 1.32± 0.028 1.26± 0.025 
K2Cr207 1.09±0.02* 0.87±0.03* 1.13± 0.018* 1.27±0.02t 
(16%) (30%) (14%) 
Specific activity expressed as |xmoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
•significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls. 
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(ii) BBM 
The administration of K2Cr207 resulted in changes in the activities of BBM 
marker enzymes not only in the homogenates but also in BBM prepared fi-om whole 
cortex. The activities of AP, GGTase, Mh and LAP were significantly but differentially 
decreased after 1, 2, 4 and 8 days of treatment. The activities of all four enzymes 
declined after day 1 and were maximally decreased after day 2 (AP-67%, GGTase-58%, 
Mlt-63% and LAP-56%) compared to the control group. The magnitude of decrease 
was less after day 4, while the activities were completely restored to the normal values 
after day 8 of the treatment (Table 15; Figs 13,14). As seen in cortical homogenates 
also, the activities of AP and Mh were decreased more in the BBM than the activities of 
GGTase and LAP 
Since K2Cr207 markedly lowered the activities of BBMV marker enzymes 
compared to their respective controls their kinetic parameters. Km and Vmax, were 
determined using BBM from animals 2 days after treatment with K2Cr207. This was 
done because the maximum changes in the activities of these enzymes were 2 days after 
the administration of K2Cr207. The enzymes were assayed at different substrate 
concentrations and Km and Vmax were determined from Lineweaver-Burk plot (1/v vs 
1/[S]). The results indicate that the Vmax values (expressed as ^moles/mg protein/hr) of 
all the four BBM enzymes were significantly lowered in BBM from K2Cr207 treated 
rats compared to the controls. The apparent Km values of the four enzymes showed 
insignificant changes compared to the controls (Table 16; Figs 15-18). 
5. Effect of KrCr^ pT on Pi transport 
Transepithelial Pi transport in the kidney is one to two orders of magnitude more 
extensive than that in any other organ of the body. Pi absorption in kidney takes place 
predominantly in the proximal tubule through an energized transport system. Previous 
resuhs indicate that K2Cr207 administration alters renal functions by affecting the 
structural integrity of BBM. However, the effect of K2Cr207 on the BBM transport has 
not been studied. In the present work the transport of Pi was determined using BBMV 
prepared from animals 2 days after administration of saline (control) or K2Cr207. 
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Table 15:.EfFect of K2Cr207 treatment on the activities of alkaline phosphatase (AP), y-
glutamly transferase (GGTase), maltase (Mlt) and leucine aminopeptidase (LAP) in 
BBMVs isolated from whole cortex. 
Groups 
AP 
Control 
K2Cr207 
GGTase 
Control 
K2Cr207 
Mlt 
Control 
1 
140±6 
70±5* 
(50%) 
365±10 
226±8* 
(38%) 
262±10 
Duration of treatment (days) 
2 4 
142±7 
46.8±6* 
(67%) 
360±8 
151±10.5* 
(58%) 
258±11 
145.5±8 
106±5* 
(35%) 
367±10 
282±8* 
(23%) 
266±10 
8 
139±6 
136±4t 
359.8±11 
355±9t 
268±9 
K2Cr207 157±9* 95±10.5* 
(63%) 
186±9* 266±8t 
LAP 
Control 
K2Cr207 
18.3±1 
11.7±0.4* 
(36%) 
18±0.8 
7.92±0.7* 
(56%) 
17.5±0.7 
13.1±0.5* 
(25%) 
17.6±0.75 
17.3±0.6t 
Specific activity expressed as |amoles/mg protein/hr 
Results are mean ± SEM of four different preparations. 
* significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent decrease from respective controls. 
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(GKjTase) in the BBMVs isolated from whole cortex of K,Cr,0^ treated and control rats 
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Table 16: Effect of K2Cr207 treatment on kinetic parameters of BBMV alkaline 
phosphatase (AP), y-glutamyl transferase (GGTase), maltase (Mh) and leucine amino 
peptidase (LAP). 
AP 
Control 
K2Cr207 
GGTase 
Control 
KiCriOv 
MIt 
Control 
K2Cr207 
Vmax 
(funoles/mg protein/hr) 
142.8±8 
71.4±3* 
280±12 
15l±7* 
230±10.4 
119.5±8* 
Km (xlO'^M) 
0.n6±0.004 
0.119±0.002t 
0.88±0.006 
0.76±0.004t 
20±1.5 
20.6±1.8t 
LAP 
Control 
K2Cr207 
18.5±1.4 
10.1±5* 
0.39±0.005 
0.38±0.006t 
BBMVs were prepared from whole cortex of animals 2 days after administration of 
K2Cr207 or normal saline (control). 
Results are mean ± SEM of four different preparations. 
"significantly different at p< 0.01 from their respective controls. 
t insignificantly different from saline-treated control group. 
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Fig 16: Kinetics of y-glutamyl transferase in BBMV from K2Cr207 and control rats 
(•)-control, (•)-K2Cr207. 
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Fig 18: Kinetics of leucine aminopeptidase in BBMV from K2Cr207 and control rats 
(•)-control, (•)-K2Cr207. 
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The transport of Pi across BBMV from K2Cr207 and saline treated groups was 
determined by the microfiltration technique using ^^ Pi as radiotracer. ''^ Pi uptake in the 
presence of Na^-gradient in whole cortex BBMV of treated and control groups were 
studied at different incubation times (5-20 sec). It was observed that the uptake of ^^ Pi 
increased with the time of incubation (5s, 10s, 20s), then declined at 120 min. The 
experiment showed a significant reduction in Na*-gradient dependent (Nao>Nai) uphill 
transport of Pi across BBMV following K2Cr207 administration, compared to saline 
treated control group. However, the uptake of ^^ Pi after equilibrium was established 
(120 min) was the same in treated and control groups (Table 17a). 
The uptake of'^Pi was also determined in the absence of Na^-gradient but in the 
presence of K^-gradient (K<j>Ki). In the absence of Na^-gradient, ^^ Pi uptake was 
significantly increased in BBMV from K2Cr207 treated group compared to the control 
group at 20 sec of incubation while after 120 min there was no significant difference in 
uptake (Table 17b). Most importantly, the net ^^ Pi uptake (Na^-gradient dependent 
minus Na"* -^independent uptake) showed a significant decline (50%) after K2Cr207 
administration (Table 18). 
6. Protective efTect of vitamin C before KiCtiOi adminstration 
K2Cr207 administration to rats caused significant alterations in different 
parameters of kidney with maximum change observed 2 days after the treatment. 
K2Cr207 is also known to generate free radicals and cause lipid peroxidation. Vitamin C, 
an active reducing agent in many biological processes and also an anti-oxidant, was 
used in the present study to see if it could protert against K2Cr207 induced renal 
damage. Since all the previous experiments had indicated that K2Cr207 induced 
nephrotoxicity was maximum 2 days after administration the effect of vitamin C pre-
treatment was, therefore, studied on day 2 after administration of K2Cr207. Animals 
were treated with vitamin C (250mg/kg body weight) and 6 hr later K2Cr207 was 
administered as a single dose. The rats were then sacrificed 2 days after the treatment. 
Each experiment had four groups: control, vitamin C alone, K2Cr207 alone and K2Cr207 
+ vitamin C. 
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Table 17: 
(a). Effect of K2Cr207 treatment on Na^-gradient dependent uptake of ^ P^i by 
BBMVs 
Group 
Control 
K2Cr207 
5 sec 
1055±40 
778±28* 
(26%) 
10 sec 
1400±59 
980±37* 
(30%) 
20 sec 
2059±85 
1130±65* 
(45%) 
120 min 
365±17 
373±21t 
(b). Effect of K2Cr207 treatment on uptake of ^ P^i by BBMVs in the absence of Na^  
gradient (NaCl replaced by KCl). 
Group 
20sec 120 min 
Control 
K2Cr207 
90.5±8 
159.3±11* 
279±15 
302±19t 
BBMVs were prepared from whole cortex of rats 2 days after administration of 
K2Cr207 or saline (control). 
Results are mean ± SEM of three different BBMVs preparations. Uptake expressed as 
pmole/mg protein. 
* significantly different from control at p<0.05 or greater degree by group t-test. 
Values in parenthesis represent percent change from respective saline-treated 
controls. 
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Table 18: Effect of K2Cr207 treatment on net Na^-gradient dependent uptake of ^ P^i 
by BBMVs 
Groups 
Control 
K2Cr207 
Na+-gradient 
dependent 
(lOOmMNaCl) 
2059±85 
1130±66* 
Na+-gradient 
independent 
(lOOmMKCl) 
90.5±8 
159.3±11* 
Net uptake 
(Na-K) 
1968.5±87 
970.7±58* 
(50%) 
BBMVs were prepared from whole cortex of rats 2 days after administration of 
K2Cr207 or normal saline (control). 
Results are mean ± SEM of three different BBMV preparations. Uptake expressed as 
pmole/mg protein/20 sec. 
* significantly different from control at p<0.05 or greater degree by group t-test. 
Values in parenthesis represent percent change from respective saline-treated 
controls. 
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(i) Serum creatinine and BUN 
K2Cr207 administration resulted in an increase in serum creatinine (Scr) and 
BUN levels 2 days after the treatment (Scr-122%, BUN-91%) compared to their 
respective controls. A similar result was seen in an earlier experiment too (Table 2). 
Pre-treatment with vitamin C showed significant recovery and resulted in reduction of 
both creatinine (32%) and BUN (22%) levels (Table 19). Animals treated with vitamin 
C alone showed insignificant change in BUN and Scr levels compared to saline treated 
control. 
(ii) Activities of BBM marker enzymes 
Activities of BBM marker enzymes declined after K2Cr207 administration. This 
decline was maximum 2 days after the treatment (AP-62%, GGTase-50%, Mlt-55% and 
LAP-48%) compared to the respective controls. A similar resuh was seen earlier also 
(Table 15). It was observed that pre-treatment with vitamin C significantly protected 
against this K2Cr207 induced decline in the activities of BBM marker enzymes (AP-
24%, GGTase-18%, Mlt-22% and LAP-15%). The administration of vitamin C alone 
had no effect on the activities of these enzymes compared to the control group (Table 
20; Figs 19,20). 
Determination of the kinetic parameters of the BBM enzymes shov/ed that 
Vmax values of the enzymes were significantly decreased after K2Cr207 treatment. 
However, vitamin C pre-treatment resulted in significantly recovery in the Vmax values 
compared to the saline treated control group (Table 21). Vmax values of the enzymes in 
the vitamin C alone treated group showed insignificant changes. The apparent Km 
values remained unchanged in K2Cr207, vitamin C+ K2Cr207 and vitamin C alone 
treated groups. 
(iii) Pi transport 
K2Cr207 treatment resulted in decrease in Na"-gradient dependent Pi transport at 5, 
10 and 20 sec of incubation. Recovery at all time points was observed when the animals 
were pre-treated with vitamin C. At 20 sec maximum decrease was observed (45%) 
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Table 19: The effect of vitamin C pre-treatment on K2Cr207 induced changes in semm 
creatinine and BUN levels. 
Groups 
Control 
Vit. C 
K2Cr207 
Vit.C+ KiCrzO? 
(mg/dl) 
Serum creatinine 
0.54±0.018 
0.49±0.016t 
1.20±0.12* 
(122%) 
0.72±0.035* 
(33%) 
BUN 
19.8±1.0 
19.5±0.097t 
37.8±2.0* 
(91%) 
24.4±1.3* 
(23%) 
Rats were administered normal saline (control), vit.C alone, K2Cr207 alone or 
vit.C+K2Cr207; serum creatinine and BUN levels were determined 2 days after these 
treatments. 
Results are mean ± SEM of four different experiments. 
* significantly different at p<0.01 as compared to saline treated control. 
t insignificantly different from saline-treated control group. 
Values in parenthesis represent percent increase from respective saline-treated 
controls. 
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Table 20: The effect of vitamin C pre-treatment on K2Cr207 induced changes in 
the activities of BBM marker enzymes. 
Groups Hmoles/mg protein/hr 
AP 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
GGTase 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
Mlt 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
LAP 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
140±4.7 
142±4.5t 
52.3±3* 
106.4±3.6* 
340±11.5 
336±llt 
170±7.6* 
279±8* 
225±8.8 
230±9.2t 
101±5.7* 
175.5±6.2* 
18.3±0.85 
18.0±0.84t 
9.52±0.5* 
15.5±0.65* 
(62%) 
(24%) 
(50%) 
(18%) 
(55%) 
(22%) 
(48%) 
(15%) 
BBM were prepared from whole cortex of animals 2 days after treatment. 
Results are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.01 as compared to saline treated control 
Values in parenthesis represent percent decrease from respective saline-treated 
controls. 
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Fig 19: Specific activity of (A) alkaline phosphatase (AP) and (B) y-glutamyl 
transferase (GGTase) in the BBMVs isolated from whole cortex of control, 
vitamin C, K2Cr207 and vitamin C+ K2Cr207 treated. 
Each bar represents results (mean± SEM) of four different preparations. 
* significantly different from saline treated control at p<O.Ol 
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Fig 20: Specific activity of (A) maltase (Mlt) and (B) leucine aminopeptidase (LAP) in 
the BBMVs isolated from whole cortex of control, vitamin C, K2Cr207 and 
vitamin C+ K2Cr207 treated rats 
Each bar represents results (mean± SEM) of four u...l^... preparations 
*significantly different from saline treated control at p<0 01 
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Table 21: The effect of vitamin C pre-treatment on K2Cr207 induced changes in 
the kinetic parameters of BBM marker enzymes. 
Groups 
AP 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
GGTase 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
MIt 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
LAP 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
Vmax 
(jimoles\mg protein\hr) 
145±4.8 
143.8±4.3t 
65±3.1* 
115.9±4.0* 
320±11.2 
310±11.5t 
169±9.2* 
265±9.4* 
215±7.5 
221±7.4t 
92±5.2* 
172±5.9* 
18.0±0.82 
18.2±0.83t 
9.0±0.45* 
15.3±0.47* 
Km(xlO-'M) 
0.114±0.003 
0.113±0.002t 
0.118±0.006t 
0.114±0.004t 
0.91±0.012 
0..89±0.01t 
0.79±0.007t 
0.85±0.008t 
20.2±1.3 
20±1.4t 
19.2±1.56t 
19.8±1.52t 
0.46±0.005 
0.43±0.005t 
0.35±0.003t 
0.40±0.004t 
BBM were prepared from whole cortex of animals 2 days after treatment. 
Resuhs are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.01 as compared to saline treated control 
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while vitamin C pre-treatment resulted in significant recovery in this value (20%) 
(Table 22). No change in ^ Pi uptake was observed in vitamin C alone treated group. The 
net uptake of ^^ Pi by BBMV was decreased by 50% upon administration of K2Cr207 
This was reduced to 20% only upon vitamin C pre-treatment (Table 23) 
iv) Lipid peroxidation and total sulfhydryl content 
Lipid peroxidation and total sulfhydryl groups were determined in the 
homogenates of cortex and medulla 2 days after treatment. Administration of K2Cr207 
alone resulted in increased level of malondialdehyde (MDA) in cortex (36%) and 
medulla (33%) compared to the saline treated control group. Vitamin C pre-treatment 
resulted in significant recovery in cortex (13%) and medulla (9%). Treatment with 
vitamin C alone had no effect on MDA levels in either cortex or medulla (Table 24; Fig 
21). 
Total sulfhydryl (SH) groups were determined after K2Cr207 administration and 
vitamin C pre-treatment in the homogenates of cortex and medulla (Table 25; Fig 22). 
Depletion in the level of total SH groups was noted in cortex (21%) as well as medulla 
(18%) compared to the control group. Vitamin C pre-treatment resulted in significant 
amelioration of K2Cr207-induced depletion of total SH groups (cortex-7%, medulla-
5%).. Administration of vitamin C alone had no significant effect compared to control 
group. The changes in MDA production and SH content upon treatment with K2Cr207 
alone were greater in cortex than in medulla. 
(iv) Activities of superoxide dismutase and catalase 
The activities of Cu,Zn-SOD and catalase were determined in the homogenates 
of cortex and medulla 2 days after treatment (Table 26; Figs 23,24). K2Cr207 
administration significantly reduced the activity of Cu-Zn-SOD in cortex (35%) and 
medulla (47%). Vitamin C pre-treatment resuhed in recovery in these values (cortex-
12%, medulla-18%) compared to the saline treated control. 
Catalase activity determined in cortical and medullary homogenates also showed 
a decline 2 days after treatment (cortex-33%, medulla-44%). Animals pre-treated with 
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Table 22: Effect of vitamin C pre-treatment on KjCriO? induced changes on Na^  
gradient dependent uptake of ^ P^i by BBMVs. 
Group 
Control 
Vit.C 
K2Cr207 
Vit. C+K2Cr207 
5 sec 
1055±40 
1050±28t 
778±28* 
(26%) 
945±35t 
(12.4%) 
10 sec 
1400±59 
1410±37t 
980±37* 
(30%) 
1229±46t 
(14.5%) 
20 sec 
2059±85 
2055±65t 
1130±65* 
(45%) 
1681±75* 
(20%) 
120 min 
365±17 
363±18t 
373±25t 
368±22t 
BBMVs were prepared from whole cortex of rats 2 days after treatment. 
Results are mean ± SEM of four different experiments. Uptake is expressed as 
pmoles/mg protein. 
t insignificantly different from saline-treated control group. 
•significantly different at p<0.05 as compared to saline treated control. 
Values in parenthesis represent percent decrease from respective saline-treated controls 
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Table 23: Effect of vitamin C pre-treatment on KiCriO? induced changes on net Na^  
gradient dependent ^^ Pi uptake by BBMVs. 
Groups 
Control 
VitC 
K2Cr207 
Vit.C+ K2Cr207 
Na^-gradient 
dependent 
(lOOmMNaCl) 
2059±85 
2055±88t 
1130±66* 
(45%) 
1681±75* 
(18%) 
Na^-gradient 
independent 
(lOOmMKCl) 
90.5±8 
94±8t 
159.3±11* 
(76%) 
103±89* 
(14%) 
Net uptake 
(Na-K) 
1968.5±87 
1961±88t 
970.7±58* 
(50%) 
1578±71* 
(20%) 
BBMVs were prepared from whole cortex of rats 2 days after treatment. 
Results are mean ± SEM of three different BBMVs preparations. Uptake expressed as 
pmole/mg protein/20 sec. 
t insignificantly different from saline-treated control group. 
•significantly different from control at p<0.05 or greater degree by group t-test. 
Values in parenthesis represent percent change from respective saline-treated 
controls. 
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Table 24: Effect of vitamin C pre-treatment on KjCrjO? induced changes in 
malondialdehyde production in the homogenates of cortex and medulla. 
Groups 
Malondialdehyde (nmoles\g tissue) 
Cortex Medulla 
Control 
Vit.C 
K2Cr207 
Vit.C+K2Cr207 
235±8.5 
238±8.4t 
320±10* 
(36%) 
265.8±9t 
(13%) 
I62±6.3 
I65±6t 
217±7.8* 
(33%) 
177±7t 
(9%) 
Homogenates were prepared from animals 2 days after treatment 
Results are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
*significantly different at p<0.01 as compared to saline treated control. 
Values in parenthesis represent percent increase from respective saline-treated controls 
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Fig 21: Malondialdehyde production in homogenates of cortex and medulla from 
control, vitamin C, KaCraO? and vitamin C+ K2Cr207 treated rats. 
Each bar represents results (mean± SEM) of four different preparations. 
* significantly different from saline treated control at p<0.01 
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Table 25: Effect of vitamin C pre-treatment on KiCriO? induced changes in total 
sulfhydryl level in the homogenates of cortex and medulla 
Groups 
Control 
Vit.C 
K2Cr207 
Vit.C+ KaCrjOy 
Sulfhydryl content 
Cortex 
1.36±0.032 
1.42±0.034t 
1.09±0.02* 
(21%) 
1.26±0.026t 
(7%) 
(nmoles/g tissue) 
Medulla 
1.1±0.022 
1.16±0.026t 
0.9±0.018* 
(18%) 
1.04±0.02t 
(5%) 
Homogenates were prepared from animals 2 days after the treatment 
Resuhs are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
* significantly different at p<0.01 as compared to saline treated control. 
Values in parenthesis represent percent decrease from respective saline-treated controls 
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Fig 22: Total SH content in homogenates of cortex and medulla from 
control, vitamin C, K2Cr207 and vitamin C+ K2Cr207 treated rats.. 
Each bar represents results (mean± SEM) of four different preparations. 
*significantly different from saline treated control at p<0.01 
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Table 26: Effect of vitamin C pre-treatment on KiCrjO? induced changes on the 
activities of Cu-Zn SOD and catalase in the homogenates of cortex and medulla. 
Groups 
Cu-Zn SOD 
Control 
Vit.C 
KaCrzOT 
Vit.C+ K2Cr207 
Catalase 
Control 
Vit.C 
K2Cr207 
Vit.C+ K2Cr207 
U /mg protein 
Cortex 
2.69±0.086 
2.65±0.084 t 
1.75± 0.063* 
(35%) 
2.36± 0.068t 
(12%) 
1162±61 
1158±42t 
778±42* 
(33%) 
1035±49t 
(11%) 
Medulla 
1.6±0.043 
1.55±0.04t 
0.847±0.03* 
(47%) 
1.31±0.037* 
(18%) 
990±46 
986±44t 
555±32* 
(44%) 
830±39* 
(16%) 
Homogenates were prepared from animals 2 days after treatment 
Results are mean ± SEM of four different experiments. 
t insignificantly different from saline-treated control group. 
*significantly different at p<0.01 as compared to saline treated control. 
Values in parenthesis represent percent decrease from respective saline-treated controls 
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Fig 23 : The specific activity of Cu-Zn SOD in homogenates of cortex and medulla 
from control, vitamin C, K2Cr207 and vitamin C+KiCriO? treated rats. 
Each bar represents results (mean± SEM) of four different preparations, 
•significantly different from saline treated control at p<0.01 
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Fig 24: The specific activity of catalase in homogenates of cortex and medulla from 
control, vitamin C, K2Cr207 and vitamin C+KiCraO? treated rats. 
Each bar represents results (mean± SEM) of four different preparations, 
•significantly different from saline treated control at p<0.01 
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vitamin C showed significant recx)very in the activity of catalase (cortex-11%, medulla-
16%). However, animals treated with vitamin C alone showed insignificant change in 
the activities of both Cu,Zn-SOD and catalase compared to the control group (Table 
26). 
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DISCUSSION 
The kidney is of paramount importance in the excretion of many drugs and 
chemicals some of which are toxic to it. Investigations into the renal toxicity of such 
agents aid in providing information about the mechanism involved in renal functions. 
ARF is a common problem associated with many drugs and chemicals used in our daily 
life, this leads to attrition in renal excretory function, cell necrosis and death. Potassium 
dichromate (K2Cr207) is very commonly used in industries and exposure to it leads to 
renal toxicity; K2Cr207 is in fact used as a model of ARF. The present study was done 
to understand in detail the ARF associated with K2Cr207 exposure and to look at ways 
of decreasing its renal toxicity. 
The rats were given intraperitonially a single dose of K2Cr207 at 15 mg/kg body 
weight. The administration of K2Cr207 resulted in weight loss as animals showed 
decrease in food intake. This may be due to K2Cr207 induced toxicity to the 
gastrointestinal tract. Eight days after K2Cr207 treatment the animals started gaining 
normal weight and showed normal food intake indicating recovery in gastrointestinal 
tract toxicity. Michie et al. (1991) reported that gastroscopy after K2Cr207 ingestion 
revealed severe gastritis and oesaphagitis. Urine volume was maximally increased 2 
days after K2Cr207 treatment indicating polyuria. In addition to polyuria, both 
proteinuria and glucosuria were also observed. Gumbleton and Nicholls (1988) reported 
that the earliest and most sensitive indicator of renal damage was an elevation in the 
urinary excretion rate of protein. Polyuria along with proteinuria and glucoseuria may 
be due to tubular dysfunction or urinary concentration defect. Reduced GFR was also 
reported after K2Cr207 administration. Glomerular damage or reduction in blood flow 
through renal arteries may result in reduced GFR. Serum creatinine (Scr) and BUN 
levels are two other important parameters of detecting renal function. In the present 
study the administration of K2Cr207 increased creatinine and BUN concentrations in 
serum The increased level of creatinine in serum may be due to defect in fihration at 
glomerulus due to which creatinine is not filtered properly and retained more in serum. 
BUN level increases in serum due to failure in excretion of urea. As discussed in the 
CDDP section, failure of urea recyling in the Loop of Henle would undoubtedly 
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contribute to reduced interestitial solute concentration. The loss of filtrate from tubule 
because of glomerular damage can also result in cell atropy (Schleifer, 1962). Besides 
alterations in Scr and BUN levels changes in serum phospholipids and cholesterol were 
also observed in the present studies. These can be regarded as biochemical changes 
responsible for altered structural and flinctional integrity of proximal tubule and /or its 
BMM. 
Transport of various solutes is dependent upon reabsorption of Na^  across the 
luminal BBM; it is an active process that requires energy supplied by carbohydrate 
metabolism. In the present study the activities of different metabolic enzymes were 
determined to see if the carbohydrate metabolism was effected after K2Cr207 
administration. The activities of these enzymes have not been studied in detail although 
Kim and Na (1990) have reported that chromium (VI) compounds induce metabolic 
disturbances. LDH, the enzyme of glycolytic pathway, was found to be increased is 
homogenates of both cortex and medulla, with the increase being greater in cortex than 
medulla. The activity of MDH, an enzyme of TCA cycle, was decreased after K2Cr207 
administration. This indicates that energy requirement i.e. generation of ATP is met by 
increased glycolysis. Due to decrease in activity of MDH the synthesis of oxaloacetate 
is reduced, which is required for continuation of TCA cycle. Kim and Na (1990) 
showed that there was a significant and rapid increase in lactate, pyruvate and 
creatinine concentrations soon after a single injection of dichromate. This suggests that 
the primary energy generating pathway is promptly impaired by dichromate. The 
accelerated glycolysis is the metabolic consequence of activation of a back up system 
for generation of ATP when the primary energy forming pathway is impaired 
(Lehninger, 1982). Kim and Na (1990) also reported that dichromate decreased the total 
amino acid concentration in the 2 hr period after administration. It is apparent that the 
early serious impairment of energy conservation from carbohydrates causes utilization 
of free amino acids or proteins with a consequent increase in BUN concentration in 
vivo. 
The activities of enzymes of gluconeogenesis, G6Pase and FBPase, were 
determined in cortical and medullary homogenates after K2Cr207 treatment. These 
177 
enzymes are involved in the synthesis of glucose and their activities are always higher 
in cortex than medulla. The activities of G6Pase and FBPase were significantly 
decreased in cortex and medulla. However, the decrease was more prominent in cortex. 
The administration of dichromate decreases the activity of aspartate transaminase 
(Gumbleton and Nicholls, 1988) along with marked decrease in the activity of MDH, 
thus diminishing the availability of reducing equivalents and gluconeogenic 
intermediates across the mitochondrial barrier. Kidney utilizes intermediate products of 
citric acid cycle for glucose biosynthesis. Thus the decreased activity of 
gluconeogenesis enzymes may be due to depleted TCA cycle intermediates as KiCraO? 
treatment significantly reduced the activity of TCA cycle enzyme MDH and lowered 
the level of mitochondrial energy production. 
Administration of KiCrjO? showed contrasting result on the activities of 
G6PDH and ME. Activity of G6PDH was increased while ME was decreased in cortex 
and medulla; the changes in cortical homogenate were greater than in medulla. The 
increased activity of G6PDH indicates the generation of NADPH as energy source to 
meet energy requirement during kidney damage. The utilization of NADPH leads to 
increased NADP/NADPH ratio, a condition known to activate G6PDH. The decreased 
activity of ME could be because of inadequate supply of substrate especially malate due 
to inhibition of AST and MDH, the enzymes involved in malate-asparate shuttle. 
A significant increase in the activity of cortical and medullary AcidPase was 
observed after K2Cr207 administration. The increased activity of this lysosomal enzyme 
might be due to the ahered properties of the lysosomal membrane resulting in the 
leakage of AcidPase and its increased cytosolic activity. Earlier investigators also 
suggested that increased AcidPase activity in degenerating organelles as lysosomes 
played an important role in cellular destruction (Swift and Hruban, 1964; Novikoff and 
Essner, 1962). 
The administration of K2Cr207 resulted in decreased activity of Na'^ -K^ ATPase 
in cortex and medulla. Earlier reports had shown that the effect of K2Cr207 was more 
predominent in pars convoluta (Gumbleton and Nicholls, 1988) i.e. SI and S2 segments 
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of the kidney which are located in cortex. In the SI segment Na*-K^ ATPase activity 
and active transport of solutes is relatively high. Bemdt (1975) reported that dichromate 
effects the energy metabolism and depresses tissue respiration significantly. This 
indicates mitochondrial dysfunction that results in an inadequate supply of ATP. 
Decreased activities of enzymes of TCA cycle also result in decreased ATP synthesis. 
Inadequate ATP synthesis may result in lower activity of Na*-K* ATPase in K2Cr207 
treated rats. 
The activities of BBM marker enzymes AP, GGTase, Mlt and LAP were 
determined in the homogenates of cortex and medulla. The activities of all these 
enzymes were decreased and the extent of this decrease was greater in cortex than 
medulla. This result is in agreement with earlier reports that showed that the region 
most effected by K2Cr207 administration was pars convoluta (Gumbleton and Nicholls, 
1988). Our studies indicate that renal damage was not restricted to cortex only but the 
medulla was also affected, although to a lesser extent than cortex. 
The activities of the BBM marker enzymes were then studied in BBM isolated 
from whole cortex of animals 1, 2, 4 and 8 days after K2Cr207 administration. All 
enzymes showed a decline in their activities, with maximum decrease 2 days after the 
treatment. The administration of K2Cr207 decreased the activities of AP and Mlt to a 
greater extent than GGTase and LAP. Both AP and Mlt are considered to be the marker 
enzymes of pars convoluta (SI and S2 subsegments) of the proximal tubule. This 
confirms that the region more severely effected is pars convoluta which is present in the 
cortical region of the kidney. Thus BBM from superficial proximal tubular region was 
more effected than the deep proximal tubular subsegments. The disappearance of brush 
border membrane is a prominent index of renal damage. Various nephrotoxins such as 
cephaloridine, mercuric chloride, puromycin and vinblastin (Silverblatt et ai, 1970; 
Nagle et ai, 1972; Siegel et al., 1984; Kruidering et al., 1997) result in loss of 
microvilli from proximal tubular cells; when the damage caused by these drugs was 
greater the regeneration process required longer time. However, if the damage is not 
severe, the BBM can be reformed and the integrity of the proximal tubule restored as 
reported after K2Cr207 induced renal tubular necrosis (Baines, 1965). Several 
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investigators have noted that bmsh border degeneration occurs early in toxicity (Evan 
and Dail, 1974; Andrews, 1975). Since an early change in the kidney after chemical 
insult is an alteration of brush border due to this there is loss of these enzymes in urine. 
The release of tissue enzymes into the urine is considered to be an early and sensitive 
indicator of nephrotoxic damage (Stroo and Hook, 1977). 
The kinetic parameters. Km and Vmax, were determined by assaying the BBM 
marker enzymes at different substrate concentrations. The results showed that the 
changes in the activities of these enzymes were due to a decrease in Vmax. There was 
no significant difference in Km values of these enzymes in treated and control groups. 
This shows that loss of active enzyme molecules per unit of BBM may be responsible 
for the decline in the activity of BBM marker enzymes 
All the serum parameter, BBM marker enzymes and metabolic enzymes showed 
maximum change 2 days after administration of K2Cr207. However, 8 days after the 
treatment complete recovery in renal function was observed as all the parameters had 
recovered to normal values. This indicates that administration of a single dose of 
K2Cr207 at 15 mg/kg body weight results in ARF that is completely reversible. Several 
papers have reported that nephrotoxic dose of K2Cr207 led to the development of 
reversible acute tubular necrosis located largely in proximal tubule (Oliver, 1953; Biber 
et al, 1968; Ruegg et ai, 1987). The detailed mechanism of this toxic injury is not 
clearly understood. However, morphological studies indicate that nephrotoxins cause 
aherations in the BBM and it can be lost into the lumen and internalized within the cell 
(Mathur et al, 1977; Porter and Bemett, 1981). 
The transport of Pi is an important flinction of kidney. Pi transport in the kidney 
is predominently, if not exclusively, localized in the early proximal tubule rather than 
the later segment of proximal tubule. The energy required for this transport process is 
only indirectly coupled since the primary energy requirements for Pi transport and 
sodium transport are located in the basolateral membrane. Although renal toxic injury is 
reported to markedly reduce proximal tubular fluid, sodium, glucose and organic cation 
reabsorption, the effect of K2Cr207 on Pi transport has not been studied so far. 
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The transport of''^Pi in BBMV isolated from whole cortex was examined 2 days 
after K2Cr207 administration. Marked reduction in the transport of Na^-gradient 
dependent ^^ Pi transport in the initial uphill phase (5-20 sec) was observed. After 
equilibrium at 120 min the uptake of ^^ Pi was the same in BBMV from control and 
K2Cr207 treated rats. The uptake of'^Pi in the absence of Na'^-gradient (NaCl replaced 
by KCl) at 20 sec was higher in K2Cr207 treated group compared to the normal group 
which indicates uptake of''^Pi by diffusional capacity of BBM. After incubation for 120 
min similar uptake of ^^ Pi was observed in both groups. The net uptake (Na dependent 
minus Na independent) of '^Pi was lowered by 50% in BBMV from K2Cr207 treated 
rats compared to the control group. Inadequate oxygen consumption due to 
mitochondrial damage and lack of necessary metabolites due to impaired carbohydrate 
metabolism may result in the decreased ATP levels required for active transports of Na^ 
and other Na'* -^dependent transport processes. Reduced ATP level and decreased activity 
of Na^ -K"^  ATPase reduces "Pi transport. 
Anti-oxidant and free radical scanvanging systems exist in the cell to protect it 
from the damaging effect of free radicals produced as part of normal cell respiration and 
other cellular processes (Flohe et al, 1973; Julicher et al., 1986; Sastre ei al., 2000). 
Free radicals and free radical reactions are involved in the etiology and development of 
a number of diseases some of which are life limiting (Florence, 1995). In the present 
study several parameters were studied that reflect the anti-oxidant status of the kidney. 
These include induced lipid peroxidation, change in total sulfhydryl (SH) groups and 
the activities of Cu-Zn SOD and catalase. All these parameters were determined in the 
cortical and medullary homogenates of kidneys from K2Cr207 treated and control rats. 
There was an increase in lipid peroxidation in K2Cr207 treated rats. It is well known that 
K2Cr207 administration causes generation of reactive oxygen species (Qi et al., 2000; 
Ueno et al., 2001). The abnormal levels of free radicals generated react with lipids and 
resuh in an increase in lipid peroxidation as seen here. Roginski and Mertz (1965) also 
found that chromium stimulated fatty acid oxidation in rats. The concentration of total 
SH groups was significantly decreased in kidney tissues from treated rats; the SH 
groups of the proteins and enzymes are probably altered. Thus, K2Cr207 administration 
results in depletion of total SH groups and also GSH, which is one of the defense 
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factors against peroxidases which produce free radicals. The depletion in SH groups 
indicates that chromium binds to, or can result in the oxidation of, protein or non-
protein (GSH or free cysteine) sulfhydryl groups. Thiol group is known to be very 
reactive with metals and several chemical compounds like alkylating agents. 
Administration of K2Cr207 also resulted is decline in the activities or Cu-Zn 
SOD and catalase, protective enzymes against lipid peroxidation. The decreased 
activities of these enzymes probably resulted in increased lipid peroxidation. The 
decrease in catalase and Cu-Zn SOD activity depresses the pathway of enzymic 
detoxification of reactive oxygen species. Thus, in order to maintain the stability of 
living organism it is necessary to reach a balance between the oxidative actions and the 
anti-oxidant defence. Enhanced free radical production with lipid peroxidation has been 
observed during K2Cr207 induced nephrotoxicity. The decreased activity of Cu-Zn SOD 
and catalase, as observed in the present study, may further aggravate this situation. 
It has been earlier reported that protection against chromium (VI) compounds 
can be achieved by ascorbate, and also by molecules containing SH groups, since they 
can easily reduce chromium (VI) (Samitz et ai, 1968, Weigand et al., 1984). It has has 
been reported that vitamin C (ascorbic acid) can effectively prevent K2Cr207 induced 
nephrotoxicity (Samitz et al., 1968; Weigand et al., 1984). Vitamin C is an effective 
anti-oxidant of major importance for protection against disease and degenerative 
processes. In the present study vitamin C was used to study the protective effect against 
K2Cr207 induced nephrotoxicity. Treatment with vitamin C, 6 hr prior to K2Cr207 
administration, resulted in significant recovery in Scr and BUN levels. The activity of 
BBM marker enzymes also showed significant recovery after vitamin C pre-treatment. 
Similarly, the reduction in ^^ Pi uptake by BBMV from K2Cr207 treated rats was also 
ameliorated by pre-treatment with vitamin C. This means that vitamin C can reduce the 
nephrotoxicity induced by K2Cr207 administration. Protective effect of vitamin C in 
K2Cr207 induced toxicity was also observed by earlier investigators (Ellis, 1982; 
Korallus e/a/., 1984). 
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Pre-treatment with vitamin C also resulted in significant recovery in lipid 
peroxidation, total SH groups and the activities of Cu-Zn SOD and catalase. Lipid 
peroxidation constitutes a complex chain reaction of free radicals, which leads to the 
oxidation of polyunsaturated fatty acids in cell membrane (Halliwel and Gutteridge, 
1989). There is evidence that vitamin C along with vitamin E functions in vivo as a 
chain breaking antioxidant that prevents the propagation of free radical damage in 
biological membranes (Burton et ai, 1983; Ingold et ai, 1987). Anti-oxidant enzymes 
protect cellular components with the help of endogenously derived anti-oxidants and 
also prevent the cell from lipid peroxidation. Significant recovery in the activities of 
Cu-Zn SOD and calatase after vitamin C pretreatment, therefore, led to reduction in 
lipid peroxidation. 
From the present study it is clear that vitamin C pretreatment resulted in very 
significant reduction in K2Cr207 induced nephrotoxicity. Vitamin C is inexpensive, 
easily available and can be used to reduce chromium-induced nephrotoxicity. Therefore, 
the administration of vitamin C to persons working in chemical, dye and leather tanning 
industries, where they are exposed to chromium compounds, has the potential of 
ameliorating the K2Cr207 induced nephrotoxicity. 
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SUMMARY 
Drugs with spectacularly effective means of treating disease themselves carry risks 
of adverse side effects. The growing list of drugs developed and released by 
pharmaceutical industry has been paralleled by an increased awareness of their capacity 
for acute and chronic renal adverse reactions. Drugs causing nephrotoxicity are a major 
cause of concern in clinical medicine. The most common cause of acute renal failure 
(ARF) in cancer patients at present time is the nephrotoxic effect of the antineoplastic 
agents. A review of contemporary scientific literature seems to suggest increasing 
controversy regarding experimental ARF as there is no consensus of fact or opinion 
concerning the primary mechanism responsible for the pathophysiologic manifestation 
of ARF. 
"Acute renal failure" is a process in which the kidneys stop their excretory 
function. The major cause of ARF has been identified as either toxic insult or ischemia, 
which is manifested by oligouria and increased blood urea nitrogen (BUN) and serum 
creatinine. The proximal tubule along the length of the nephron is considered to be the 
principal site of damage caused by drugs or ischemia, which results in acute tubular 
necrosis. During the early phase of ARF microvillar brush border membrane (BBM) is 
sloughed into the lumen which might be narrowed down by swelling. 
Cisplatin (CDDP), a widely used antineoplastic agent, also induces acute renal 
failure. Animal studies have shown a severe CDDP induced nephrotoxicity that is dose 
related. CDDP results in profound alterations in the morphology, structural integrity, 
metabolism and functions of proximal tubules. Brush border membrane, which is the 
major site of absorption in proximal tubule, is badly damaged by CDDP administration. 
The anatomical localization of the tubular injury caused by CDDP appears consistent 
with the distribution of the drug within the renal tissue. Measurement of platinum 
concentration in plasma and various tissues after CDDP administration showed that the 
drug accumulates in the kidney. CDDP concentrates in the outer stripe of outer medulla 
and particularly within the straight portion i.e. the S3 subsegment of the proximal tubule. 
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Potassium dichromate (KjCrjO?), a chromium (VI) compound, has been widely 
used as an experimental model of nephrotoxic ARF. The pathophysiologic manifestation of 
K2Cr207 induced ARF parallels that observed in clinical ARF. K2Cr207 administration 
resuhs in decreased GFR along with increased serum creatinine and BUN levels. Cr(VI) 
nephrotoxicity is accompanied by decreased renal glutathione (GSH) and GSH reductase 
levels and increased lipid peroxidation. Chromium (VI) compounds, including K2Cr207, 
induce acute tubular necrosis in episodes of industrial poisoning; long term exposure of 
workers to chromium compounds is associated with low molecular weight proteinuria. 
K2Cr207 induces site specific damage of proximal tubule causing morphological changes in 
the outer cortex i.e. Si subsegment of the proximal tubule. K2Cr207 administration results 
in excretion of BBM marker enzymes and lysosomal enzymes in urine suggesting damage 
to BBM and lysosomal membrane within kidney cells. However, despite extensive studies 
by conventional bioanalytical procedures, the mechanism of renal dysfunction and 
biochemical conditions causing ARF induced by K2Cr207 exposure remains poorly 
understood. 
Both CDDP and K2Cr207 generate reactive oxygen species. Therefore, much 
attention has been given to the possible role of anti-oxidants in protecting against CDDP 
and K2Cr207 induced nephrotoxicity. Vitamin C, an essential nutrient, strong anti-
oxidant and active reducing agent is involved in many biological processes. Since 
vitamin C has been shown to protect against various kinds of injuries and neoplasm 
involving oxidative stress, it is possible that pre-treatment of animals with vitamin C 
may attenuate CDDP and K2Cr207 induced nephrotoxicity. 
To gain an insight into the mechanism underlying drug and chemical induced 
nephrotoxicity, we have studied in parallel the ARF induced by known chemical toxins 
namely, K2Cr207 and CDDP. Since both CDDP and K2Cr207 appear to damage the renal 
BBM, several studies were carried out to characterize the changes in BBM induced by 
these nephrotoxins. Rats were given a single dose of CDDP (6mg/kg body weight) or 
K2Cr207 (15mg/kg body weight) in normal saline while control rats received normal 
saline only. The effect of vitamin C administration (250mg/kg body weight), 6 hr prior 
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to treatment with CDDP or K2Cr207, was also studied. Several biochemical parameters 
were studied to examine the effect of K2Cr207 and CDDP on rat kidney and the 
following results were obtained. 
l(a> Food intake, body weight and urine parmeters 
The food intake and body weight decreased significantly in CDDP treated rats. Rats 
treated with K2Cr207 also showed reduced food intake and body weight. Both CDDP 
and K2Cr207 caused significant polyuria, proteinuria and glucosuria. 
(b) GFR and serum parameters 
GFR as estimated by creatinine clearence was significantly reduced by CDDP as well as 
K2Cr207. Both agents caused significant increase in BUN, serum phospholipids and 
cholesterol levels while Pi levels were markedly decreased. All these parameters in 
CDDP treated rats showed maximum changes on day 4 and returned to normal values on 
day 16, while maximum changes after K2Cr207 treatment was observed on day 2 which 
returned to normal values on day 8 compared to their respective controls. 
2. Enzymes of carbohydrate metabolism 
The activities of enzymes belonging to various pathways of glucose metabolism e.g. 
glycolysis, TCA cycle, HMP shunt pathway and gluconeogenesis were differently 
affected by CDDP and K2Cr207, The activity of LDH increased significantly while 
MDH decreased both in cortex and medulla upon CDDP and K2Cr207 treatment. The 
activities of both G6Pase and FBPase (gluconeogenic enzymes) were lowered by CDDP 
as well as K2Cr207 treatment in cortical and medullary homogenates. However, CDDP 
and K2Cr207 showed differential effects on the activities of G6PDH and ME. The CDDP 
treatment decreased the G6PDH activity while the activity of ME was increased. 
K2Cr207 administration, however, showed the reverse effect; it increased the activity of 
G6PDH while the ME activity declined. CDDP induced maximum effect on these 
enzymes was on day 4, which returned to normal levels on day 16. K2Cr207 showed 
maximum effect on day 2 and on day 8 complete recovery in the activities of these 
enzymes was observed. The effect of CDDP was more pronounced on medulla while the 
cortex was more effected by K2Cr207 treatment. 
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3. Activities of marker enzymes of BLM and Ivsosomes 
K2Cr207 and CDDP administration caused a decrease in the activity of BLM marker 
enzyme Na -^K* ATPase in both cortex and medulla. AcidPase, the marker enzyme of 
lysosomes, was also affected by CDDP and K2Cr207 administration; its activity was 
increased both in cortex and medulla. K2Cr207 administration caused greater changes in 
the activities of these enzymes in cortex while CDDP in the medulla. 
4. Activities of BBM marker enzymes in; 
(a) Homogenates of cortex and medulla- The activities of BBM marker enzymes in 
homogenates of cortex and medulla declined significantly in both CDDP and K2Cr207 
treated rats. However, CDDP caused greater decrease in medulla while K2Cr207 in the 
cortex. 
(b) BBM- The activities of marker enzymes AP, GGTase, Mlt and LAP in BBM isolated 
from whole cortex were reduced by CDDP and K2Cr207 administration. CDDP 
treatment resuhed in maximum decline on day 4 and K2Cr207 on day 2, which returned 
to normal values after 16 and 8 days respectively. However, there was differential effect 
of CDDP and K2Cr207 on the various enzymes. CDDP showed greater effect on the 
activities of GGTase and LAP while K2Cr207 reduced the activities of AP and Mlt to a 
greater extent. Kinetic studies revealed that the enzyme activities were altered mainly 
due to changes in Vmax while the Km values were not significantly altered. 
5. Transport of ^ ^Pi in BBM vesicles 
The transport of ^^ Pi was decreased significantly by treatment with both CDDP and 
K2Cr207. Na*-gradient dependent uptake of ^^ Pi in CDDP or K2Cr207 treated groups 
declined sharply at all the time points (5s, 10s and 20s) but not at equilibrium (120 min). 
Na'^ -independent initial uptake of ^^ Pi (at 20s) was found to be even higher in CDDP or 
K2Cr207 treated groups compared to their respective control groups. However, the net 
Na'^ -gradient dependent uptake of ^^ Pi (Na-dependent minus Na-independent) declined 
significantly in both the treated groups compared to the corresponding control group. 
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6. Thiol groups, lipid peroxidation and anti-oxidant status 
CDDP or K2Cr207 administration resulted in reduction of total sulfhydryl groups and 
increase in lipid peroxidation, CDDP and KaCriO? treatment also resulted in a decrease 
in the activities of free radical scavenging enzymes, catalase and superoxide dismutase, 
in cortical and medullary homogenates. 
7. Effect of vitamin C pre-treatment 
The administration of vitamin C, 6 hr prior to treatment with CDDP and KjCraO?, 
resulted in significant attenuation of the changes introduced by these nephrotoxins. Thus 
ail the parameters studied (BUN, serum creatinine, BBM enzymes. Pi transport, thiol 
groups, lipid peroxidation, anti-oxidant enzymes) showed more extensive changes in 
rats treated with CDDP or K2Cr207 alone compared to vitamin C pre-treated groups. 
Treatment with vitamin C alone did not have any effect on these parameters. 
In conclusion, the results of the present study show that CDDP or K2Cr207 
administration to rats markedly damaged the structural integrity and altered metabolic 
and functional aspects of the proximal tubule. The damage was, however, reversible and 
the kidney regained normal function 8 and 16 days after administration of K2Cr207 and 
CDDP, respectively. The degeneration of BBM resulted in impaired transport flinction 
with a decrease in the activities of BBM marker enzymes. The marker enzyme 
components may either be inactivated or dissociated from the membrane as the results 
show decline in the marker enzyme activities. The activities of certain enzymes of 
carbohydrate metabolism were altered differentially by CDDP and K2Cr207 in different 
kidney tissue zones. It appears that reduced Pi transport and mitochondrial dysfunction 
may cause decline in ATP levels in the renal tissue. CDDP and K2Cr207 generate 
reactive oxygen species thus causing lipid peroxidation, loss of sulfhydryl groups and 
also inhibit the activity of anti-oxidant enzymes. It was found that CDDP had more 
profound effect on medulla while K2Cr207 on cortex. Pre-treatment with vitamin C 
resulted in significant recovery from CDDP and K2Cr207 induced renal damage. 
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